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Quality of life in patients receiving 
platinum based chemotherapy for 
advanced Non-small Cell Lung Cancer
1Quality of life in patients receiving platinum based chemotherapy  for advanced 
non-small cell lung cancer.
Lung cancer is the cause of 34,000 deaths in the UK each year, with a five year 
survival rate of only 7.5%. The current treatment for advanced Non Small Cell Lung 
Cancer is combination chemotherapy but this confers only a small survival advantage. 
Quality of Life is often proposed as a secondary outcome to most chemotherapy 
studies as chemotherapy remains palliative. Quality of life is measured using a series 
of tools, such as the EORTC QLQ 30 that although established and tested for validity 
are functionally based or focus on physical symptoms. The aim of this study is to 
explore the meaning of quality of life in this group of patients.
The study utilises use comparative methods (interview n=50, QLQ EORTC 30 data, 
clinical observation/field notes, medical notes, nursing notes and mapping) to 
examine the meaning of quality of life in this patient group. This is essentially a 
collaboration of medical and nursing practice with the aim of understanding what 
quality of life means to these patients, improving the experience of patients 
undergoing treatment and offering appropriate psycho-social support.
Content analysis has generated a core theme of patient experience as having an impact 
on quality of life (negotiation of the treatment calendar, value of treatment broker and 
interactions with professionals) the overlapping themes are Lens of diagnosis (viewed 
as atrocity stories), The worth of treatment (despite physical side effects and poor life 
expectancy, chemotherapy is a focus of hope and allows for adjustment to poor 
prognosis) and Suffering (psychological and social, for example exclusion from social 
activities and loss of independence). This study has impacted on the service to cancer 
patients at a central London NHS Foundation Trust.
2Chapter 1 
Introduction1  Introduction
“Malignant disease of  the lung is a rare condition. The Middlesex Hospital Reports 
show only 890 cases of  cancer of  the Lung, 317  found at post mortem examination
since records began.  As for prognosis a fatal termination is inevitable with
average duration of  the disease [life expectancy] to be 13.2 months.
From Fowler & Godlee 1898 
Diseases of the Lung.
“Lung cancer is currently the most common form of  cancer worldwide ...life 
expectancy is usually between three to seven months from diagnosis. ”
From Boyle et al 2000 
Textbook of Lung Cancer
From being a virtually unknown disease at the end of the 19th century, lung cancer 
has become the most common worldwide cancer. In just over one hundred years lung 
cancer has become a modem epidemic (Boyle et al 2000) thought to account for over 
3 million deaths each year worldwide and 33,400 in the UK (Cancer Research UK
2004), and with a five year survival rate of only 7-12% overall (Cancer Research UK
2005).
Survival from advanced lung cancer has barely improved in the last thirty years (Spiro 
and Silvestri 2005).  However there has been a decline in deaths in the male 
population and an increase in female deaths. This trend can be seen from the 
standardised cancer data registry data for the UK (Office of National Statistics 
accessed 2006).
4In contrast one-year survival has improved to some degree. In England and Wales, 
one year survival in men with advanced Non Small Cell Lung Cancer (NSCLC) has 
risen from 15% in the 1970’s to 25% in 2000/1 (Coleman et al 2004).
In this section, the biology, epidemiology, treatment and cancer as a psychosocial and 
socio-political phenomenon are examined with respect to laying the groundwork for 
the main body of this study.
The initial aim of this work was to compare two chemotherapy regimes, for use in the 
most common type of lung cancer. Non-small cell lung cancer (NSCLC) accounts for 
about 90% of all lung cancers (King 2000). It is rarely amenable to surgical 
techniques, because when patients become symptomatic and a diagnosis is made, the 
disease has usually reached an advanced stage. Despite having few symptoms, about 
70% of patients who are diagnosed with Non Small Cell Lung Cancer already have 
locally advanced or metastatic disease (Souhami and Tobias 2005). Systemic 
chemotherapy is then usually the treatment of choice.
However as this treatment is rarely curative and increases survival by only a few 
months, issues such as quality of life and the toxicity of the chemotherapy become 
paramount. This study examines the meaning of quality of life in patients receiving 
platinum based chemotherapy agents using a mixed method approach, quantitative 
health related quality of life data and the analysis of content of one to one interviews 
with patients who have undergone treatment in this context.
5For the quantitative arm this study uses as a vehicle the London Lung Cancer Group 
Study 11 which is a randomised controlled trial of Mitomycin, Ifosfomide, Cisplatin 
(standard treatment) Vs Gemcitabine/carboplatin (trial) chemotherapy. The endpoints 
for Study 11 study were survival, tumour response, toxicity and quality of life (LLCG 
1999).
The aim of this work is to focus on the quality of life and related issues in a group of 
patients receiving platinum based chemotherapies for advanced NSCLC.
61.1  The Pathology of Non-Small Cell Lung Cancer
Here the meaning of the word pathology is used in the context of the study of disease 
and the purpose of this section is to look at how the disease affects humans. This is 
from a medical/scientific perspective, but is necessary, as pathology is the main 
influencing factor on the chosen intervention in clinical practice. The chosen 
intervention then may have an implicit and explicit effect on the quality of life of a 
patient and significant group. This perspective is multidimensional in its own right 
however and not simply a reductionist view. It is therefore one that should be 
considered as an understanding of the disease and its effects will enhance 
understanding on a more holistic level.
There are various histological types of Non Small Cell Lung Cancer (NSCLC) the 
most common type being squamous cell which is classified on the basis of 
differentiation (approx. 40%), followed by adenocarcinoma and Large cell types 
(Souhami & Tobias 2005). In oncology practice patients with large cell, squamous 
and adenocarcinomas of the lung are usually grouped together because these cell 
types have similar treatment regimens and prognosis. They are termed Non Small Cell 
Lung Cancers (NSCLC).
In 1998 the World Health Organisation together with the International Association for 
the Study of Lung Cancer re-classified lung cancer types to ease diagnosis and 
understanding amongst clinicians (Shimosato 2000). The area of interest here is the 
invasive malignant epithelial tumours. Only the broad headings have been taken for 
the purpose of this study, as cell variants are often not reported by the clinical 
pathology services.
7The first of these is squamous cell carcinoma of  the lung It is thought to be the most 
common type diagnosed in the UK at present (Boyle et al 2000) tends to arise 
centrally in the chest and is very uncommon amongst non-smokers (Macbeth et al 
1996).
Adenocarcinomas have the typical neoplastic features when examined histologically 
and five variant types. They are often peripheral in site of origin (often invading the 
pleura). On occasion they can arise in fibrotic or scarred lung (Souhami and Tobias 
2005). Large Cell carcinomas are poorly differentiated cancers, which do not show 
either histological or cytological features of other cell types (Shimosato 2000). 
Although the cells are large and featureless for the most part, the tumour usually has 
well defined borders and usually arises from the distal or subsegmental bronchus. 
(Souhami and Tobias 2005).
Most of the patients who present with NSCLC do so as a result of progression of the 
tumour. Such progression can precipitate the symptoms of dyspnoea, cough, chronic 
bronchitic illness, haemoptysis and pain. Direct tumour invasion to the left laryngeal 
nerve may cause hoarseness of voice as a presenting symptom. Other presenting 
symptoms may be due to the spread of distant metastasis. For example, pain at the site 
of bone metastasis or Addisonian like symptoms from adrenal metastasis.
Diagnosis is usually made by imaging and then confirmed by histology/cytology often 
obtained by flexible bronchoscopy. In this way a diagnosis and staging of the cancer 
can be done with reasonable speed.
81.2  Clinical presentation and diagnosis
Few lung cancers are actually cancers of the lung parenchyma. Most of the tumours 
seen in clinical practice are found in the large or medium segments of the bronchial 
tree. Such cancers often present with chest symptoms such as haemoptysis, whereas 
peripheral cancers grow asymptomatically and quite often are found by chance, for 
example on a chest X-ray. Many clinicians feel the importance of a history cannot be 
emphasised enough (Bourke and Brewis 2000). Occupational exposure to 
carcinogens, family history, smoking history and previous chest disease are factors 
that need careful consideration. The presenting signs and symptoms of lung cancers
are shown in Figure 1.1.
Fig 1.1. The presentation of Lung Cancer (after Bourke and Brewis 2000)
Chest Symptoms
Haemoptysis
Cough
Wheeze
Stridor
Pain
Mediastinal
Superior vena cava 
obstruction 
Hoarse Voice 
Pericardial effusion 
Diaphragmatic palsy 
Arrhythmia
Chest X-ray
Lobar collapse 
Peripheral nodule 
Cavitating mass 
Enlarged hilar nodes 
Pleural effusion
Neuroendocrine
syndromes
Hypocalcaemia 
Inappropriate 
secretion of ADH.
PRESENTATION OF 
LUNG CANCER.
Physical Examination
Clubbing 
Lymph node 
enlargement 
Localised chest signs
Paraneoplastic
syndromes
Peripheral neuropathy 
Cerebellar degeneration 
Nephrotic syndrome 
Lambert-Eaton 
Syndrome
M etastases
Bone: Pain
Brain: Fits, hemiparesis 
Liver: Jaundice 
Skin: Nodules
General Symptoms
Weight Loss 
Anaemia 
Anorexia 
Lethargy
9Once imaging such as a chest X-ray or CT scan has taken place, a provisional 
diagnosis is made, as tumours are usually visible on imaging. Further investigation is 
usually needed to confirm the histology but it is usually at this point that a probable 
diagnosis is communicated to the patient.
101.3  Staging and Treatment for Non Small Cell Lung Cancer 
Staging is the process of medical investigations conducted to discover the extent of 
the disease. From a clinical perspective, the type of treatment offered, if any, is 
usually based on the outcome of these investigations. Commonly used investigations 
are the extended use of imaging, for example bone scanning for bone metastasis, and 
computerised tomography (CT scanning), bronchscopy to visualise a tumour and 
obtain a biological sample for histology or cytology, glomerular filtration rate 
estimation and estimation of bone marrow and renal or liver function by 
haematological and biochemical testing. These tests and investigations are also part of 
the patient journey and should be viewed as such (Cancer Services Collaborative 
2001, NICE 2005). The findings of these assessments can have as much impact on the 
patient journey as diagnosis (Parker et al 2001). This is particularly so if a patient is 
found to have, for example, poor renal function that would exclude the use of 
chemotherapy.
After such investigations the disease is then “staged”. The internationally recognised
system of staging is know as the TNM system evolved in the middle of the last
century and was developed by the Union Internationale Contre le Cancer in 1988
(Goldstraw 2000,2006). It stages the extent of disease by:
Tumour (primary site) size and invasion of nearby structure (T)
Lymph Node involvement (N)
Presence of Metastasis (M)
Depending on the TNM classification, the disease overall is often still given a stage 
between 0 and 4 by many clinicians. For example a tumour that invades the 
mediastinum would be T4, no lymph node involvement would be NO and a bone
11metastasis would be M l. This patient would have disease classified as T4 NO M l. 
This patient has stage 4 disease.
The optimum treatment for Non Small Cell Lung Cancer is removal of the tumour 
(resection) this usually involves removal of a lobe of the lung (lobectomy) or the 
whole lung (pneumonectomy). Unfortunately as the majority of patients 
(approximately 80%) present with extensive disease surgery is rarely an option 
(Souhami & Tobias 2005) This is because the tumour has either spread extensively 
locally (Stage 3b) or has distant metastasis (Stage 4). If a tumour is technically 
resectable, pre-existing co-morbidity such as chronic obstructive pulmonary disease 
may preclude safe and appropriate surgery (Karamanoukian et al 2001). Common 
sites of metastatic spread are the skeleton, adrenal glands and the brain. The 
symptoms from these distant sites of spread can cause the presenting symptoms, some 
of which are very distressing such as brain metastasis causing diplopia.
Treatment options in extensive or advanced Non Small Cell Lung Cancer include 
radiotherapy and chemotherapy or a combination of the two. Radiotherapy is the use 
of a precise beam of ionising radiation to induce cell death. This beam also passes 
through healthy tissue before reaching the tumour and so can also damage the non- 
cancerous tissue. This is where the unwanted side effects of radiotherapy can be 
apparent such as fatigue and difficulty swallowing. Much also depends on the 
intention of the radiotherapy, whether it is palliative or radical (Souhami and Tobias
2005).
12Chemotherapy is the term commonly in use to describe a range of cytotoxic drugs. 
The first chemotherapeutic agents were introduced after the Second World War and 
have been used for around fifty years (Neal and Hoskins 1994). Chemotherapy, unlike 
radiotherapy, is a systemic treatment. This means its cytotoxic effects are usually 
exerted on all fast growing cells in the body. This has implications in terms of side 
effects. Chemotherapy drugs work in various ways, but are largely cytotoxic because 
they interrupt the cell cycle causing the cell to arrest and become unable to divide and 
reproduce (Neal and Hoskin 1994). This happens as cancer cells divide faster than 
many other cell types in the body. However fast growing cells in the body can be 
affected such as hair follicles and the lining of the gut (Neal & Hoskins 1994).
In non-resectable, advanced NSCLC treatment options are limited. Any treatment is, 
at present (2005), unlikely to be curative. Present treatment options are systemic 
chemotherapy, local radical radiotherapy, surgery and active symptom control. 
Increasingly biological agents are being considered which target cancer at a molecular 
level but are in limited use at time of writing.
Due to the nature and stage on presentation, the options of chemotherapy and active 
symptom control (palliative care) are the most realistic options for patients with stage 
3b or 4 disease (Fitzpatrick et al 1998) and recent evidence supports this (Clegg et al 
2001, NICE 2005).
Systemic chemotherapy is of most interest here. As the aim of chemotherapy in 
NSCLC is to palliate symptoms rather than cure the disease, it is worth considering a 
few important points.
13Traditionally, the “success” of chemotherapy treatment has been measured in terms of 
response of the tumour and survival. Objective response in this context would show 
only a 30% response (based on World Health Organisation criteria) and modest 
survival benefits (Middleton et al 2000). However by looking at response in terms of 
palliation of symptoms the response is 70% (Cullen 1993, Ellis et al 1995)
141.4  The epidemiology of Lung Cancer
Many authors now comment that lung cancer is endemic in society (Boyle et al 2000). 
The increased incidence of lung cancer in the last one hundred years has certainly 
been recognised. One of the causes of this rise is the now axiomatic link with 
smoking, primarily tobacco. This has implications in terms of lay belief (Chappie et al 
2004), and is discussed in Chapter 2. Some authors cite factors in conjunction with 
direct tobacco use such as low socio-economic status (Ekberg-Aronsson et al 2006). 
However there has been a small decrease in smoking habits in the UK. Smoking is 
still prevalent in lower socio economic groups but has fallen by 5% in male unskilled 
manual groups. The General Household Survey generated by the census (ONS 
accessed 2006) shows the prevalence of tobacco use in different socio economic 
classes. This is shown in Table 1.1
Table 1.1 Prevalence of smoking by socio economic group
Prevalence of cigarette smoking: by sex and socio-economic 
group
Great Britain___________________________________________________ Percentages
Males Females
1998  2000 1998  2000
Professional 16 17 14 14
Employers and managers 22 23 21 20
Intermediate/junior non-manual 25 27 24 26
Skilled manual 34 33 30 26
Semi-skilled manual 39 36 33 32
Unskilled manual 44 39 31 35
All non-manual 22 23 22 22
All manual 36 34 31 29
All aged 16 and over 30 29 26 25
Socio-economic group of the household reference person (excluding those in the Armed 
Forces and full-time students.
Source: General Household Survey, Office for National Statistics
15Since the mid-1970s there has been a decline in the UK death rate for lung cancer 
among males. This can be closely linked to the proportion of the population who 
smoke. In 1974 the death rate among all males in the United Kingdom from lung 
cancer was 110 per 100,000. By 2002 it had declined to 58 per 100,000. In contrast, 
the lung cancer death rate among females reached its peak of 31 per 100,000 in 1988. 
Since then the rate has declined very little, and in 2002 it was half that of men. (Office 
of National Statistics accessed 2006)
As has been stated, the last one hundred years have seen little in improvement of 
survival but huge increases in lung cancer death rates worldwide. As one of the few 
authors taking an epidemiological and historical perspective, Boyle et al (2000) 
divides the century and epidemiology of lung cancer into four phases.
The first of these phases was the establishment of a causal link between smoking and 
lung cancer risk in the 1930-1950’s. The second phase (from the mid 50’s) was the 
increase in understanding of the aetiology of lung cancer and also the growing 
awareness that lung cancer was becoming more prevalent and reaffirming the causal 
link to smoking tobacco. This was, in part, due to the benchmark studies of Doll and 
Hill (Doll and Hill 1950,1952, 1954). The body of evidence was so strong that in the 
USA the Surgeon General was moved to produce an official statement on “Smoking 
and Health” which caused a worldwide reaction. Phase 3 saw a descriptive 
epidemiology of lung cancer and the publishing of larger cohort studies (for example 
the work of the National Cancer Institute in the USA). The fourth phase (from 1960’s 
onwards) charts the rise in smoking related disease (of which NSCLC is just one) and
16the present situation. It also charts the way in which smoking habits have changed. 
For example in the 1970’s consumers were made aware of “Tar Levels” and 
encouraged to smoke low tar products. This seems merely to have changed the 
histological subtype from squamous cell to adenocarcinoma. (Boyle et al 2000). The 
reason for the inclusion of Boyle’s work here however is to not only summarise the 
impact of the rise in incidence of NSCLC but also to establish the now almost 
axiomatic link with tobacco both from a epidemiological/academic perspective and as 
a perception of the public (UK Lung Cancer Coalition 2005)
The establishment of a link with tobacco is one that continues to be examined. 
Richard Peto and colleagues (Peto et al 2000) examine the link between lung cancer 
and smoking cessation. There is a clear increase in risk associated with continued 
tobacco use (Fig 1.2).
17(
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Figure 1.2 Continued tobacco use and risk (Peto et al 2000)
Men
Continuing cigarette smokers 
Stopped age €0 
Stopped age 50 
Stopped age 40 
Stopped age 30 
Lifelong non-smokers
45  55  65  75
Age
18In addition to socio economic group and tobacco use, NSCLC tends to affect adults in 
middle to older age and more cases still are recorded in men than women despite the 
downward trend shown in the death rate for men. Cancer Research UK’s figures for 
2004 show the incidence of lung caner by age and sex (Fig 1.3). The peak age in the 
UK is 6-7lh decade, however the distribution range is wide-the image of lung cancer 
as a disease of old age is shifting.
Fig 1.3 CRUK recorded incidence rates in lung cancer (CRUK 2004)
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191.5  The lung cancer patient journey
The format adopted for this section follows that of the lung cancer patient care 
pathway suggested by the NHS Cancer Plan (Department of Health 2000a) and the 
Cancer Services Collaborative (CSC) (2001). The rationale for this approach is to 
illustrate the biomedical, psychological and sociological dimensions of the patient 
journey and interaction and conflicts of service delivery and social policy. The 
approach taken here is therefore temporal as opposed to completely reductionist.
The Department of Health Lung Cancer Care Pathway (CSC 2001) consists of ten 
“milestones” that patients should reach on their individual “cancer journey”. This 
system was introduced so that practitioners could introduce flexible practice and 
initiate systems to ensure patients reach each milestone. In reality, patients do not 
need each milestone (for example surgery) or may “jump around” the pathway. The 
literature review in Chapter 2 aims to parallel this approach. The Lung Cancer Care 
Pathway is illustrated in Fig 1.4 below.
Fig 1.4 The Lung Cancer Care Pathway (CSC 2001). The Ten Milestones.
Pre-diagnosis Diagnosis Chemotherapy Pre-surgery Post-surgery
Discharge Radiotherapy Follow up Terminal Care Bereavement
20The impact of the NHS Modernisation agenda is also apparent throughout this study, 
which has a definite temporal dimension in terms of social policy. This work was 
initiated in 2000, the same year in which the NHS Cancer Plan (DoH 2000a) was 
introduced. Little direction in terms of treatment paradigms and management of 
patient pathways apart from academic collaborative research was available at the 
time. In contrast 2005 saw the publication of the National Institute for Clinical 
Excellence (NICE) 170 page guidance on Lung cancer care accompanied by 350 
pages of supporting evidence. This reflects the change in social policy intended to 
deal with the perceived inequalities in accessing specialist cancer care which was the 
aim of the NHS Cancer Plan.
211.6  The psychological, social and political implications of NSCLC 
Cancer has meaning in society, both as a word and disease. It is often thought to be 
uncontrollable and unpredictable resulting in a short life and painful death with pain 
being the primary concern of 70% of patients with cancer (Neal & Hoskin 1994). The 
perception of “cancer” as something to be feared is often based on anecdote or 
experience of many years ago in the experience of the author. Media such as 
television also use cancer (inextricably linked with death) for dramatic licence, often 
with little bearing in reality (Holland 1998). It could be said that cancer is as much 
socially constructed as it is pathological.
The link between lung cancer and smoking tobacco established by Doll and Hill in the 
1950’s (Doll and Hill 1954) and subsequent health promotion campaigns have 
influenced the public perception of lung cancer as a disease of smokers. In a recent 
survey the UK Lung Cancer Coalition found that 40% of the population considered 
lung cancer to be self inflicted, despite the fact that one in eight lung cancer patients 
are never smokers (UK Lung Cancer Coalition 2005). Because of the established 
epidemiological link with tobacco use, lung cancer patients often feel feelings of 
stigmatisation and guilt (Chappie et al 2004) which gives an added dimension to their 
suffering.
Poor five year survival in advanced lung cancer reflects the technical difficulty in 
developing agents to treat this disease but there is also evidence of influence by other 
socio-political factors. The Public Accounts Committee has recently issued a report 
confirming that there is still an identified a link between variations in the incidence of 
lung cancer and levels of socio-economic deprivation (Public Accounts Committee
222006). Poor five-year survival may also be a consequence of lack of investment in 
lung cancer research. Only 4% of UK cancer research funding goes towards lung 
cancer research (Roy Castle Foundation 2005).
Lung cancer has become the most common cancer in men in the world. Compared to 
other cancer types however, less seems to have been written about it. A search of the 
common databases covering the last thirty years such as CINHAL and OVID reveals 
a dearth of published work. This is discussed in Chapter 2.
There has been little published work in this area that is specific to the quality of life of 
patients with Non-Small Cell Lung Cancer outside of the clinical trials literature. This 
work hopes to contribute to the field by exploring the influences on quality of life in 
NSCLC in a more global sense, rather than concentrating exclusively on the impact of 
symptoms.
23Chapter 2
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242 A review of the literature- The dimensions of lung cancer and method of review.
This review begins by examining the literature around cancer and specifically lung 
cancer as a psychosocial and socio-political entity to provide background and context 
for the study. Over the lifetime of this study there have been radical changes in the 
way that cancer is managed in the NHS.
The review then examines the literature in quality of life in four topic areas. These 
are:
•  The understanding of quality of life as a concept-What is quality of life?
•  Issues in the context of health and the meaning of the term quality of life
•  Quality of life issues in cancer
•  Quality of life issues in the context of chemotherapy for advanced Non Small 
Cell Lung Cancer (NSCLC).
Whilst clinical trial data features heavily in the last topic in lieu of other work, this is 
not a systematic review of the trials literature as this has been done elsewhere (NICE 
2005).
One of the methods used in this study is also reviewed throughout this Chapter. The 
European Organisation for the Treatment of Cancer Quality of Life Questionnaire 
version 3 with Lung cancer module (EORTC QLQ-30+LC17) is reviewed along with 
comparable tools in the section dealing with Quality of Life Issues in Cancer. The 
second and principal method of this study uses content analysis of interviews with 
respondents who have recently undergone chemotherapy for advanced NSCLC. This 
is described more fully in Chapter 3(Methods). As there is very little literature and no
25comparable studies that use content analysis in chemotherapy for advanced non-small 
cell lung cancer and quality of life, a brief overview of content analysis is given here.
Content Analysis is approximately 60 years old but has intellectual roots that can be 
traced back into human history to the first conscious use of symbol and voice 
(Krippendorf 2004) Virtually all disciplines within the humanities are concerned with 
the meaning of symbols, meanings and messages. The use of content analysis in the 
UK can be traced back to the inquisitorial pursuits of the Church in the 17th century 
but the term “content analysis” was first used during the second world war by 
Berelson in 1941 (Berelson and Lazarsfield 1948)
Content analysis entails the systematic reading of a body of text, image or symbolic 
matter, tabulation and interpretation of that matter. It is an empirically grounded 
method that is exploratory in process and predictive or inferential in intent 
(Krippendorf 2004).
Content analysis is a research technique for making replicable and valid inferences 
from text or other materials. In the context of this study, the interviews with patients 
undergoing chemotherapy for advanced NSCLC were transcribed and underwent 
content analysis. According to Krippendorf, data are commonly thought of as 
representing observations or readings but they are always the products of chosen 
procedures (Krippendorf 2004). As a technique content analysis relies on several 
specialized procedures for handling text and these are described in the context of this 
study in the Methods chapter (Chapter 3). In content analysis data result from the
26procedures the researcher has chosen, for example to answer specific questions 
concerning phenomena.
A search of the databases of the last thirty five years (1970 to present) limiting to 
English language yield much in terms of literature with respect to lung cancer and 
quality of life, but little combining the two areas, particularly outside the context of a 
randomised clinical trials examining quality of life as an end point of a drug trial.
The search used various engines: CINHAL, Medline, Ingenta/EMBASE, SOSIG 
Psychlnfo, The Cochrane Library, OVID and the National Cancer Institute via the 
HILO portal and search engine for the initial search. As new engines became 
available in the course of the study, new literature was reviewed via portals such as 
Google Scholar and British Library ONLINE.
Using keywords and phrases such as “lung cancer” “lung carcinoma” “non small cell 
lung cancer” “ quality of life” “health related quality of life” “life satisfaction” “global 
quality of life” “NSCLC” and “chemotherapy related quality of life” and utilising 
Boolean search techniques and exploding specific phrases, papers were obtained from 
the databases and via Index Medicus using the search algorithm given in Fig 2.1. 
Additionally other material including unpublished studies were sought, this also 
includes “grey” literature as yet unpublished or personal correspondence.
Bibliographies were searched as a source of references and also contact made with 
experts in the health service, charitable organisations and in industry. Studies reported 
as posters/conference abstracts were excluded as these are only available in published
27form not via electronic portals or printed indices. However some of these led to 
sources of grey literature.
In addition to published peer reviewed work, a number of standard texts have been 
consulted to contribute to the medical and scientific strand of this work. Gathered 
largely from work based in the United Kingdom, Europe, USA and Canada, the 
following examines the knowledge as it stands in the context of NSCLC.
As the study progressed, both the author and library professionals made repeated 
searches as themes arose from the interview study which was analysed using content 
analysis. This is described in Chapters 6 and 7. The rationale for doing so is to elicit 
more data in which to examine emergent themes of quality of life in Non small cell 
lung cancer. The results of this process are integrated into the discussion chapters as 
themes from the qualitative strand emerged and this review is also used as a source of 
data.
28Fig 2.1 Literature review QoL in chemotherapy for NSCLC
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292.1  The cancer journey, the individual and society
There is an abundance of trial literature examining quality of life in lung cancer trials 
much of which is reviewed herein.  Nevertheless the experience of the lung cancer 
journey, including treatment, is something rarely examined. Cancer care and treatment 
cannot take place in a vacuum as individuals that experience disease are still 
individuals. This is expressed eloquently by Harvey Cushing :
“A physician is obligated to consider more than the diseased organ, more even than 
the whole man-he must view the man within his world” Harvey Cushing 1869-1939 
(Faull and Woof 2002).
There is much published work on cancer and its meaning. The literature reviewed 
here, whilst not exclusively examining the advanced NSCLC patient population, aims 
to place the rest of the review in context. As the aim is to place the quality of life 
literature in context, the enormous amount of cancer literature has not been fully 
reviewed here. Instead using the milestones from Fig 1.1 this section aims to illustrate 
the cancer journey by examining specific contemporary issues.
A study by Krishnasamy and Wilkie in 1999 (pre launch of the NHS Cancer Plan) 
examined the needs of lung cancer patients, their carers and professionals’ perceptions 
of such needs. This study remains one of very few which looks at these issues in any 
depth. There are many possible reasons for this, the possibility of nihilism in the 
treatment of lung cancer or the comparative funding issues (Roy Castle Foundation 
2005). It is interesting to note that when Krishnasamy and Wilkie (1999) performed 
their study, only 35 out of 107 hospital consultants agreed to take part (32.7%). Some
30consultants (n=25) did agree to disclose reasons for non participation and this is 
shown in Figure 2.2
Fig 2.2 Reasons for non-participation in Macmillan National Needs Assessment Study 
(Lung cancer)
Reason for declining Numbers reporting reason
Small numbers of lung cancer patients in practice 8
Pressure of work 15
Inadequate records to trace patients 4
Consultants felt study un-necessary/patients needs 
already known
19
Taking part would be too distressing for patients 13
Study would raise more problems than solutions 17
Needs of lung cancer patients no different to other 
cancer patients
9
As the consultants approached were those with specific clinical responsibility for lung 
cancer patients they might be considered the most powerful advocate group, and so 
the low response rate is surprising. This study is post Calman/Hine Report (CMO 
1995) but pre dates the majority of the cancer modernisation agenda. The cancer 
modernisation agenda in the UK at the turn of the century became a powerful 
influence for change.
312.1.1  Issues around suspected cancer and investigations-the modernisation agenda.
“Cancer is on of the biggest killers in this country, and we have made it one of the 
central priorities for the NHS”  Alan Milbum MP 2000
The NHS Cancer Plan (DoH 2000a).
The rationale for inclusion of this section in a work essentially aimed at examining
quality of life is illustrated by this quote from Alan Milbum, then Secretary of State
for Health (Department of Health 2000a). Cancer is as much a social and political
issue as it is a pathology. The NHS Cancer Plan (DoH 2000a) was the basis of the
cancer modernisation agenda in England and Wales at the turn of the 20th century.
The four aims of the Cancer Plan were cited as:
•  To save more lives
•  To ensure people with cancer get the right professional support and care as 
well as the best treatments
•  To tackle the inequalities in health that mean unskilled workers are twice as 
likely to die from cancer as professionals
•  To build for the future through investment in the cancer workforce, through 
strong research and through the preparation for the genetics revolution, so that 
the NHS never falls behind in cancer care again.  (DoH 2000a)
The ethos of the plan was to be a practical and empowering way of delivering a ten- 
year strategy and built on previous initiatives such as the Calman-Hine report (CMO 
Expert Advisory Group 1995).
32The NHS Cancer Plan saw the initiation of many service improvement targets in NHS 
cancer care and delivery. This investment and reform was part of the greater 
modernisation agenda within the health service (DoH 2000a).
For users of the service this means a more streamlined and confluent approach to care, 
particularly around the area of first presentation from primary care and into secondary 
or tertiary referral where many bottlenecks to patient movement had been identified. 
One such target demonstrates this. A person going to see a general practitioner in 
primary care with signs/symptoms of cancer can now expect to see a specialist in 
secondary care who will initiate investigation within two weeks of presentation to the 
GP. This allows patients to have equitable access to specialist multiprofessional care, 
no matter where they live. The Trust in which this study takes place in illustrates this. 
A patient coming from a primary or secondary centre for a diagnostic/curative 
thoracic procedure would have waited an average of 38 days in the last quarter of 
2001. The implementation of the modernisation agenda cut this time to a mean of 8 
days (last quarter 2003) by allowing local initiatives to unblock the pathway, and 
addressing unnecessary delays (Leary & Corrigan 2005).
The implementation of the modernisation agenda means that the cancer journey is 
now much faster with an initial target of diagnosis to definitive treatment of 31 days 
in 2001 (DoH 2000a) and currently a target of GP presentation to definitive treatment 
of 62 days (DoH 2003).
In a time of uncertainty this allows little time for the adaptation process which can 
cause increased psychological pain (Houldin 2000) and the “patient journey” along
33with the organisation of care for people with cancer can therefore become a much 
more negative experience than it already is (DoH 2000a).
Another significant area of change in the management of the cancer pathway is the 
much earlier (often pre-diagnosis) involvement of other healthcare professionals such 
as clinical nurse specialists and oncologists. Cancer care is now managed by teams 
rather than, for example, and individual surgeon or physician as was often the norm 
(CSC 2001).  Patients’ value having a contactable key professional at all stages of the 
journey (Schou and Hewisonl999, Krishnasamy and Wilkie 1999, DoH 2000b) and 
the multiprofessional team has made this a realistic possibility in practice.
2.1.2  Issues around diagnosis-communication
The aim of good communication at the diagnosis of cancer is to reduce uncertainty, 
enhance a therapeutic relationship and give the patient and their significant others a 
direction in which to move (Twycross 1997, Ellis and Tattersall 2001). Whilst little is 
apparent in the literature with regard to communicating a diagnosis of NSCLC, there 
is much on the communication of a cancer diagnosis and this is worth considering as 
many patients reflect on this time later in their journey and find that this 
communication of diagnosis has bearing on how they cope with “having cancer” and 
its treatment.
Problems around communication and diagnosis often arise from the fear of either 
party. Professionals do not wish to inflict suffering (Cassell 2004) and in the UK it is 
usually a non-cancer specialist who communicates a cancer diagnosis. This can be a 
problem as the communication of a cancer diagnosis has issues of prognosis and
34treatment embedded in it, which require specialist knowledge (Schou and Hewison 
1999).
There is a significant amount of literature in this area. For example a study from the 
USA used a 41 item questionnaire to ascertain patient preference for the 
communication of diagnosis in head and neck cancer. Although those patients 
questioned had been treated and free of disease for two years, and this is unlikely 
given the poor prognosis of patients with NSCLC, the paper still has relevance. Head 
and neck cancers are potentially life threatening and affect breathing and speaking. 
The study found that patients preferred physicians to communicate the diagnosis of 
cancer in simple and direct terms, without medical terminology and wanted 
physicians to be “truthful, caring and compassionate” (Kim and Alvi 1999).
Many doctors find the disclosure of a cancer diagnosis difficult or very difficult (Ellis 
and Tattersall 1999) coupled with the fact that often the most stressful time for the 
patient and significant group is the time immediately (first month) after diagnosis 
(Kruijver et al 2000) it can therefore be seen how this is a potentially very painful 
start to the journey. The paper by Ellis and Tattersall (1999) also reiterates the need 
for presenting bad news in an unhurried, honest and balanced way.
This theme continues throughout the literature. Parker et al (2001) found little in the 
literature about the actual communication of “bad cancer news”. This group from the 
USA conducted a literature search and found that from 300 papers from 1973-1993 
only 23.2% had any descriptive data at all and that 66% of the published work was in 
the form of letters, opinions, case reports and non-data based descriptive studies. The
35authors of this paper note few studies have assessed patient’s reactions as to how bad 
news was conveyed. A study was then conducted by this group examining this issue.
It is reviewed here as it is not only of a high methodological standard but the focus is 
on a patient’s rather than clinicians perspective and is one of the few papers available. 
It should be considered that such news might not only be a diagnosis of cancer but 
also news of treatment failure or recurrence of disease.
Working with a group of 351 patients with a cancer diagnosis, the authors asked 
patients to complete a questionnaire that was specifically designed for the project. The 
authors found that factor analysis indicated that patient preference for the breaking of 
bad news in oncology could be grouped into three categories. These are content (what 
and how much information is told) facilitation (setting and context) and support 
(emotional support during the interaction). The authors also found that women and 
patients with a higher level of education had higher scores on the content scale 
(Parker et al 2001).
Further work in this area was conducted on behalf of the Comptroller and Auditor 
General by the National Audit Office (NAO 2005a) which examined the progress of 
the Cancer Plan (DoH 2000a) after five years and the changing patient journey (NAO 
2005a). The NAO reports improvements overall in the level of services and 
experiences of patients with cancer. However in terms of communication the NAO 
reports that there has been only a 6% improvement in communication by medical staff 
of condition, treatments or tests which patients found easy to understand (62% in 
2000 to 68% in 2004) ( NAO 2005b).
36In literature originating from Europe or the USA in recent years the nature of 
disclosure of diagnosis of cancer is examined but not whether it is “right” to disclose. 
This is an ethical question and beyond the remit of this work as clinicians in the UK 
are socialised to embrace truth telling, however in other cultures this is not always so. 
This perspective should be recognized, as the UK is a multicultural society. In the 
context of diagnosis there is a small but significant amount of work on disclosure of 
cancer in other countries. A paper from Taiwan in the Peoples Republic of China 
states that older people and those “with lower education” (this term is not defined) are 
less likely to be told the diagnosis, although this paper also states that disclosure leads 
to lower intensity of pain (Lin 1999). Two papers from Japan suggest that patients 
should be told of the diagnosis and then the family should be told with the patient’s 
permission. This would seem to contrast with current practice whereby the family are 
told the diagnosis and then decide if the patient should know (Seo et al 2000).
A return to this practice in the UK seems unlikely as there are many issues around 
consent and such action would to contravene patient autonomy. A study from Portugal 
based on a questionnaire given to physicians in one city hospital showed that only 
71% of respondents would tell a patient a cancer diagnosis and yet 98% would tell the 
patient’s relatives (Foijaz and Guamaccia 2001). This paper helps to illustrate the 
different cultural attitudes to a cancer diagnosis disclosure. This is important in British 
multi-cultural practice.
Despite honesty being recognised as central to practice, it is essentially a two way 
process. The psychological adaptation to a cancer diagnosis can lead to illusion and 
misperception (Beadle et al 2004) and collusion with medical staff (The et al 2000).
372.1.3  “Having cancer”-the person with cancer and the concept of suffering.
Technological developments such as general anaesthesia and microscopy have 
allowed science and medicine to define cancer. By the early twentieth century, cancer 
became a disease state in it own right. Due to the limited availability of analgesia and 
the fact that surgery was not as technically advanced, the person with a tumour would 
typically have more visible symptoms. Non healing, fungating wounds, poorly 
controlled pain and debilitation would have been visible to those around the person. 
The fact that some of these visible signs may have been similar to those of Syphilis 
may have contributed to the common belief that cancer was contagious (Holland 
1998)
This may account for the stigma that is attached to cancer today and the stigmatising 
effect which Scambler has defined as “a condition which sets apart the possessor from 
‘normal’ people” (Scambler 1991). It is something of an axiom now that cancer is a 
stigmatising illness. Scambler’s classic work goes onto describe the perceived 
exclusion of those with rectal cancer as a result of labelling (Scambler 1991). The 
person becomes the person with cancer despite the previous role they held in society 
and may still hold. Repeated studies have shown this (Mathieson and Stam 1995).
Lung cancer seems to carry an extra stigma. That is one of blame of self or by society. 
A recent MORI poll for the Cancer Research Campaign found that 70% of people in 
the UK thought people who develop lung cancer had “brought it upon themselves” but 
77% thought they had as much right to treatment (CRC 2001) Reasons given for this 
reply by respondents cited tobacco use. The UK Lung Cancer Coalition
38commissioned a survey of 956 adults between the 30th September and the 2nd of 
October 2005 to canvas attitudes toward and understanding of lung cancer. Of those 
interviewed 40% believed lung cancer to be self-inflicted. There was variation across 
socio economic groups however. 50% of the AB group said that lung cancer was self- 
inflicted compared to only 35% in the lower socio economic groups (DE) (UKLCC 
2005).
The epidemiology of lung cancer and the link with smoking has already been 
discussed, but this link is almost ingrained into society and lay belief as a result of 
many health education initiatives. Tobacco use is recognised as a risk factor in lung 
cancer but there is limited information about how a smoking history impacts on the 
emotional distress of those diagnosed with lung cancer. There have been some 
studies, which examine causal attribution of lung cancer in populations who smoke or 
have used tobacco in the past. These have shown that past tobacco use correlates with 
greater emotional distress (Berckman and Austin 1993). It is also thought that anger 
and resentment may be exhibited by those who have no smoking history themselves 
but who may have been exposed to second hand smoke at home or work (Sama 
1998). A recent study by Chappie et al reports that participants (adults with lung 
cancer) felt stigmatised to the point in which they felt the interactions with family, 
friends and doctors was often affected, with some participants concealing their 
disease. This occurred in smokers and non smokers (Chappie et al 2004).
In addition, in terms of Parson’s classic work (Parsons 1951) of “the sick role” a 
person with advanced NSCLC cannot be realistically expected to fulfil the obligations 
of recovery and for the person with advanced NSCLC it is unlikely to be temporary
39state. The person with advanced NSCLC may also wish to fulfil the obligation of co­
operation with medical practice. This is likely to be chemotherapy that offers little 
survival benefit. Should persons with advanced NSCLC be exempted from these 
obligations? Would this obligation extend to prioritising quality of life above other 
medical treatment?
The person who has cancer as a pathological disease state will also experience the 
psychosocial dimension of “having cancer”. The benefits of having social ties (and as 
a corollary, lack of social ties) are illustrated by the model of pathways linking the 
social environment to Cancer (Helgeson, Cohen and Fritz 1998). The benefits of such 
social ties are shown in Fig 2.3
Fig 2.3  Pathway Linking Social Ties to Cancer after Helgeson et al 1998)
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40The nature of suffering is a concept that is gaining credence in oncology. The work of 
authors such as Eric Cassell (Cassell 2004) who explore suffering as a concept 
support this. Suffering is of interest as in the media the term is often imbued along 
with “quality of life” with multidimensional qualities. Like “quality of life” it resists a 
reductionist approach (see section 2.2).
The concept of suffering has roots as least as far back as the classical scholars, 
perhaps further, with explicit reference in the Hippocratic Corpus and the works of 
Cicero (Hippocrates trans Chadwick and Mann 1983, Cicero trans Grant 1971).
Suffering can represent physical injury to the person through accident or disease, 
often this is reacted to by health professionals with solutions borne from a 
deterministic perspective. In oncology there has been an implicit understanding that 
those without physical symptoms also suffer. This can be demonstrated by the 
recognition of other professional groups with a differing skills focus in the 
multiprofessional team (DoH 2000b).  As has been seen from the work of authors 
such as Scambler (Scambler 1991) “the person with cancer” may not be able to fulfil 
the roles expected by society. People can suffer from what is lost of themselves in 
relation to the world of objects, events and relationships. This is where intactness as a 
person comes from (Cassell 2004).
It is important for clinicians to recognise that the intensity of suffering amongst cancer 
patients varies widely (Houldin 2000). Recent work has described cancer patients’ 
needs whilst suffering. Patients wish for nurses to have the ability to see beyond the 
symptoms-to be affirmed as a person and understood, and to have their needs met
41beyond the level of physical problems (Fagerstrom et al 1998) and on a person-to- 
person level (Gregory 1994). This means offering patients understanding, empathy 
and compassion through meaningful communication (Gregory 1994, Byock 1994, 
Houldin 2000).
422.1.4  Issues around treatment-doing work
The majority of patients with advanced Non Small Cell Lung Cancer will die of their 
disease. In the USA around 178,000 people are diagnosed with lung cancer annually, 
of these 160,000 will die of their disease (Middleton et al 2000). If resected, there is a 
5 year survival rate of 60% (Warren & Faber 2000). Patients with locally advanced or 
extensive disease have a five-year survival rate (with treatment) of 10-13% (Souhami 
and Tobias 2005). The median survival for NSCLC that is advanced is four to six 
months with only 10-20% of patients alive at one year after diagnosis (Dark and 
O’Brien 2001).
Although palliative chemotherapy is used for many cancers, there is still a reluctance 
to prescribe this type of treatment for patients with NSCLC, perhaps because the 
earlier chemotherapies saw no survival benefit and many clinicians saw chemotherapy 
as unjustified for patients not in a clinical trial. There is also a lay belief that 
chemotherapy is very difficult to tolerate (Lindley et al 1999). In other types of cancer 
the ultimate goal of palliative chemotherapy is the palliation of symptoms, not 
necessarily an increase in survival and so why does this rationale not seem as 
acceptable in the management of NSCLC?
In the UK only a small number of patients (5%) diagnosed with NSCLC have been 
receiving chemotherapy (Clegg et al 2001). The principal reason for this seems to 
have been the still widespread belief that chemotherapy is unacceptable to patients 
because of toxicity, and clinicians view chemotherapy for advanced NSCLC as
43ineffective. A survey of clinicians pre cancer plan found little support for treating 
NSCLC with chemotherapy (Crook et al 1997).
It has been recognised for some time that NSCLC has been an under invested cancer, 
the Roy Castle Foundation reports that only 4% of UK cancer research funding is 
spent on lung cancer research Roy Castle Foundation 2006). An editorial from the 
mid nineties referred to NSCLC as the “Cinderella of cancer medicine” (Smith 1994). 
However even studies from around this time show small gains in survival and quality 
of life, such as the meta-analysis by Souquet et al (Souquet et al 1993). Studies from 
around this time do not demonstrate a clear advantage in survival but do begin to 
show a benefit in terms of symptom control such as pain, cough and breathlessness 
(Hardy et al 1989). Another review in 1994, concluded that using chemotherapy could 
give a small benefit in survival, but expressed doubts about the balance between extra 
time versus toxicity and effect on “quality of life”, this should be a powerful statement 
but the authors do not actually provide any evidence of quality of life (Marino et al 
1994).
In the last ten years, the introduction of platinum based chemotherapy drugs has 
changed this attitude to some degree because this group of drugs has been found to 
increase survival overall by small amounts (Spiro et al 2004). In some studies this has 
included the assessment of health related quality of life, which has also been shown to 
improve in terms of palliation of symptoms (Dark and O’Brien 2001). The quality of 
life issue is central to this work, for example is a reported improvement in quality of 
life a valid one? If the goal of this chemotherapy strategy is palliation of symptoms, it 
should be a central issue. For some patients the beginning of the “work” of cancer
44starts here-with the therapeutic nihilistic approach that is still prevalent toward 
NSCLC, some patients are required to seek out centres which offer treatment by 
themselves (Roy Castle Foundation 2003).
Apart from the physical effects of disease and side effects from treatment, the 
majority of work that has to be done by patients with cancer is around managing the 
treatment calendar (appointments with key professionals, investigations, infringement 
into everyday life) (Schou and Hewison 1999). Easier negotiation of the calendar or 
“cancer trajectory” by standardisation is one of the motivations of initiatives such as 
the modernisation agenda and the Cancer Plan (DoH 2000a). Many clinicians in 
practice will appreciate that the cancer trajectory is not always a straight line and this 
causes more work for patients, physically, organisationally or in terms of emotional 
labour. Many patients negotiate the calendar by accessing the key professional who 
has power or influence over the calendar (Schou and Hewison 1999, Leary and 
Corrigan 2005). This role has now been recognised and supported, usually by means 
of clinical nurse specialists (DOH 200b) and the recognition of the Key worker role 
(NICE 2005). It is now recognised that although medical care can reduce the impact 
of illness, inattentive care can increase the impact of disruption and therefore become 
a source of suffering (Cassell 2004).
452.1.5  Issues around completion of treatment-abandonment and uncertainty.
“When chronic illness intrudes, it separates the person of  the present  form the person 
of  the past and affects or even shatters any images of  the self  held in the future. 
Cancer with its often insidious, ambiguous presentation and unpredictable course, 
takes the experience of uncertainty to a higher level”.
Houldin 2000
Following on from the concept of suffering-or perhaps as a dimension of it-is the 
experience of uncertainty. Illness related uncertainty has been defined as the inability 
to determine the meaning of illness events, when these events are ambiguous, highly 
complex, lacking information or when outcomes cannot be predicted (Mishel 1990).
Advanced NSCLC as a disease certainly would engender uncertainty from a 
pathological aspect alone. Events in the disease course are ambiguous (for NSCLC 
may or may not respond to chemotherapy) and outcomes in terms of survival cannot 
realistically be predicted for the individual, it can only be loosely predicted for 
groups. Add to this is the increased need for and complexity of information required 
by those who have to negotiate the treatment calendar (Schou and Hewison 1999, 
NICE 2005) and it is therefore not surprising that patients express fear and have 
difficulty in adaptation from a psychological perspective.
Research examining illness and uncertainty has shown an association between 
uncertainty and adjustment (Oberst and Scott 1985), distress (Wineman et al 1996, 
Fifiel995, Wong and Bramwell 1992), spiritual well-being (Landis 1996, Cassell 
2004), coping (Schou and Hewison 1999, Christman 1988), and quality of life 
(Hawthorne and Hixon 1994). The literature offers more studies to support these 
findings, however nothing in the context of advanced NSCLC.
46Uncertainty is sometimes heightened by the end of treatment, when lessening regular 
contact with health professionals is normal in the UK after the more intense 
experience of chemotherapy attendances. The literature showed that uncertainty is a 
continuing stressor (Mast 1998) and may strongly influence adaptive behaviour 
(Houldin 2000). The feelings of uncertainty and fear produced by feelings of 
abandonment after treatment can produce the strong need for vigilant behaviour 
(Houldin 2000, Janis 1967). This is particularly so when patients perceive protective 
action is primarily dependent on their individual actions (Reutter and Northcott 1994). 
This is why it is important for patients to feel that they are not alone in the 
management of their illness. As access to key professionals in the treatment calendar 
(Schou and Hewison 1999) can be made easier by the key worker (DoH 200b), this 
may dissipate some of the uncertainty.
In conclusion, words such as “belief/4  “suffering” and “meaning,” have often been 
used to describe the cancer journey and the patient experience. This could be because 
fear of treatment, recurrence or death causes suffering (Cassell 2004) and is central to 
that experience. Working with the beliefs and meanings of people with cancer is an 
essential part of helping people on their own journey (Richer and Ezer 2000).
472.2  Toward A generic definition of quality of life
"Scientists may use rating scales and visual analogue scales to measure pain, and 
they may even invent scoring systems quantifying types of  handicap, but when they 
talk about measuring quality of  life they have gone too far. ” (Wulf 1999).
The statement given by Wulff (1999) above, was cited in a review and deconstruction 
of the concept of Quality of Life (quality of life) (Koller and Lorenz 2002) which 
demonstrates not only the difficulty of developing such a definition but also the 
apparent scepticism in the value of doing so.
Quality of life in the literature was apparent in two contexts, authors either seek to 
define quality of life or measure quality of life. This may seem a logical path to take 
but it means that the literature lacks integration. For example, this fragmentation 
makes it difficult for a clinician to introduce quality of life assessment into practice 
without in-depth exploration of the two areas, unless a formulaic approach is used. 
This is exactly the situation at present and explains the dominance of questionnaires 
and quality of life tools in practice, particularly in the context of health economics. 
Some authors (Hayry 1999) argue for integration of three key questions:
I.  What is quality of life?
II.  How can quality of life be measured?
III.  Why do we need quality of life measurements? (Hayry 1999).
The definition from the Oxford English Dictionary (1995) of quality of life as “.. ..a 
vague and ethereal entity” serves to illustrate the difficulty in attempting to define 
quality of life and illustrates the difficulty also faced by the researcher in this area in
48trying to find that definition. When quality of life has been discussed in the literature, 
it has usually been in terms that vary widely from the “need” based theories of authors 
such as Maslow (Maslow 1954) to expressions of the value or excellence of life and 
the word quality is being used in an evaluative sense (Meeberg 1993). Authors argue 
that this is such an enormous area of study that it is almost impossible to define 
quality of life (Stegbauer 1994). This was also true in application of the term quality 
of life.
Quality of life is a multi-level concept reflecting macro-societal and socio­
demographic influences and also the micro-concerns of individuals’ experiences, 
circumstances, health, social well-being, values, perceptions and psychology 
(Bowling et al 2003).
In a recent major undertaking, the Royal College of Nursing sought to define nursing. 
The consensus defined nursing as “The use of clinical judgement in the provision of 
care to enable people to improve, maintain or recover health problems, to achieve the 
best possible quality of life, whatever their disease or disability until death” (RCN 
2003). Although in this context, the term quality of life has been used to formulate an 
important concept, (i.e. defining a whole profession and body of knowledge) no 
attempt has been made to define the term.
Quality of life became a focus for nursing practice in the 1980’s and as more 
definitions emerged, the concept receded (Mast 1995). It is possible that as nursing 
has evolved with such rapidity, many terms have become ambiguous. Quality of life is 
of particular interest to nurses and nurse researchers, as much value is placed on the
49evaluation of nursing interventions and quality of life could be perceived as an 
outcome measure. This is demonstrated by the liberal use of the term “quality of life” 
in the nursing literature. The Oncology Nursing Society for example, cited “quality of 
life” as among its top three priorities without definition (Stetz et al 1995).
The question here is “What is quality of life?” and the aim is to attempt to examine 
what is meant by the term “Quality of life” in the literature. There have been many 
attempts to define quality of life and these are explored in more detail in the concept 
clarification offered in the context of advanced NSCLC later in this chapter. However 
in a broader sense, quality of life is likely to mean a range of things to different 
individuals, and so the concept and definitions of quality of life presented in the 
literature are examined in more detail here.
2.2.1  Quality of life and The good life-Historical perspectives 
The first examination of the quality of life in a broad sense has often been attributed 
to the Greek philosophers of antiquity, such as Aristotle, who valued happiness and a 
“good life” (McKenon 1947). Such a concept as a “good and useful” life (Plato trans 
Saunders 1970) can be found in many ancient texts.
The writings of antiquity may allude to quality of life but this has caused conceptual 
confusion in the literature (Bowling and Windsor 2001). These ideas have been 
expressed in a variety of ways, for example as a “good life” in the very physical 
context of “having food and shelter or the price of a horse when in battle, to the 
faithfulness of trusted friends” (Xenophon trans. Cawkwell 1972). Plato considered a 
good and happy life the product of a just society, “the good man, because he is
50temperate and just, enjoys good fortune and is happy, no matter whether he is big and 
strong, or small and weak, or rich or poor; and that even if he is richer then Midas or 
Cinyras’ and has not justice, he is a wretch and lives a life of misery.” (Plato trans 
Saunders 1970). Plato and his contemporaries have been cited in work that aims to 
define quality of life or happiness.
It is apparent from the classical texts that much of Plato’s work is heavily influenced 
by his relationship with Socrates. In the Socratic dialogues it can be seen that the idea 
of happiness and a good life, which Plato attributes to a just society, is influenced by 
the Socratic idea of knowledge having an impact on society and the individual. 
Socrates argued that knowledge possessed by the individual attracts trust in that 
individual “knowledge makes one useful and good” (Saunders 1970, Saunders 1987).
Socrates appears to make happiness and “the good life” entirely dependent on moral 
goodness (Cicero trans Grant 1971) but Cicero argued that it is not simply “moral 
goodness” that makes life good, but that a “good life” is not quantifiable. Cicero 
states, “Take for example strength, health, wealth, honour or glory. These are all 
spoken of by people in general, indefinite terms without reckoning up the exact 
quantity of each that may be present in any specific case. Now, the same applies to the 
happy life. Even if it may fall short of perfect happiness, nevertheless it is entitled to 
be called happy when happiness is the constituent which greatly exceeds all others” 
(Cicero trans Grant 1971). These themes are carried from antiquity to the present day.
Although it is rare to find the term quality of life in anything prior to the 19th century, 
there are certainly examples (Meeks and Meeks 1999) of what different individuals
51and societal groups have considered as happiness or more profoundly, giving value to 
life. One of the most obvious examples of this concept in history is the link of 
everyday life and religion or spirituality. This can be found as far back as pre-dynastic 
Egypt, and throughout the development of the ancient dynastic Egyptian societies, the 
reality of daily existence in such times and the happiness and “goodness of living” 
(Meeks and Meeks 1999) of the people revolved around daily religious ritual, directly 
to gods or via a mediator (Meeks and Meeks 1999). More recent examples in history 
are abundant such as the 12th century knights whose sole purpose in life was to protect 
pilgrims on the pilgrimage to Jerusalem (Burman 1986). The idea of belief giving 
meaning and value to life is an ideal that still exists today. Although they did not 
define what quality of life is, these ideas demonstrated the value of the concept and 
how the concept has engaged minds throughout time.
The use of the phrase in the modem world appears to have been in post war America, 
and it was used by sociologists and policy makers in reference to the perceived 
increase in material wealth and consequent improvement in “quality of life” (Carr et 
al. 1996). Lyndon Johnson, then President of the USA, used the term “quality of life” 
in his speech to the American public in 1964 to refer to the bounty the post war years 
brought in terms of material and financial security (Meeberg 1993). The 1960’s also 
saw the start of the scholarly pursuit of a definition through studies in happiness. The 
majority conducted by sociologists and psychologists in the USA, studies included 
examination of concepts such as life satisfaction and well-being with the aim of 
quantification (Bradbum 1969), and in concord with the ideas of antiquity, what was 
meant by “the good life” (Gurin et al 1960).
52The first proposed theoretical model of quality of life was presented by Lawton in 
1983 (Lawton 1983, Bowling 1995) but an early, if implicit, definition of quality of 
life was introduced after the Second World War by the World Health Organization 
(WHO).
The WHO defined health in 1948 to be “a state of physical, mental and social well­
being and not merely the absence of disease” (WHO 1948). This definition has 
evolved over time, in 1978 WHO stated that individuals have a right to an “adequate 
quality of life” in the definition (WHO 1978). More recently The WHO Quality of 
Life Group defined quality of life thus;
”Quality of  life is defined as an individual’ s perception of  their position in life in the 
context of  their culture end value systems in which they live and in relation to their 
goals. expectations. standards and concerns. It is a broad ranging concept affected in 
a complex way by the person’s physical health, psychological state, level of 
independence, social relationships and their relationships to salient  features of  their 
environment. ” (WHO 1993).
This definition has had a profound impact on the design of quality of life assessment 
and this impact is seen clearly in oncology, most of the reviewed studies herein refer 
to the WHO definition and it is clear to see how this definition informed quality of life 
assessment development, particularly throughout the 1990’s (Aaronson 1993, Schou 
and Hewison 1999).  The concept and measurement of quality of life are dependent on 
the expert rather than lay views of the important constituents (Bowling 2001).
53The term “health related quality of life” (HRQoL) as first used in the context of 
cancer by Aaronson (1990), who argued that factors such as happiness and life 
satisfaction are “distal to the to the goals and objectives of healthcare” and therefore 
do not adequately capture the effectiveness of interventions (Aaronson 1990). It could 
be interpreted from Aaronson’s argument that quality of life assessment is only a 
means to an end. This statement also seems to contradict much of Aaronson’s later 
work, which is reviewed here. It can be seen from the literature that health related 
quality of life is increasingly used as an outcome measure of healthcare in evaluative 
research and clinical trials (Montezari et al 1998).
2.2.2  Quality of Life in the literature
Quality of life is amorphous and subjective (Bowling 1997). Areas that are self - 
nominated as important to individual quality of life have not always correlated with 
what is considered important by researchers investigating quality of life (Bowling and 
Windsor 2001). This amorphous quality was recognised by the early scholars who 
sought to define quality of life, for example the comment by Campbell et al (1976) 
that “Quality of life is a vague and ethereal entity, something that many people talk 
about but which nobody very clearly knows what to do about”. It has been seen from 
the WHO definition alone that quality of life encompasses a vast range of areas and 
disciplines such as sociology, health, geography, philosophy and economics reflecting 
the multidimensional nature of quality of life (Bowling 1997).
54In the same way that the WHO definition of quality of life has evolved from one of 
health, the quality of life literature has been seen to reflect the way that much of the 
work undertaken in the pursuit of a definition of quality of life is in the health arena. 
This is perhaps because policy makers and others in the health professions 
increasingly sought ways in which to evaluate interventions. It has been argued by 
some authors (Fitzpatrick et al 1999) that the need for the assessment of interventions 
is one of the motivating forces for the development of the concept of health related 
quality of life (Cooley 1998).
The aforementioned assessment of quality of life has been traditionally based on a 
medical or pathological model, with a focus on disability, symptom or decline and 
focus on role function, such as work and family care (Bowling 2003). Functionalism 
is a theory, which is based on the interrelationships within the social system, and the 
consequences of change in such situations (Bowling 1997). Such changes in normal 
roles are explored by many quality of life outcome measures.
In contrast a search of the available databases cited above using the keywords 
“Quality of life” now elicit over ten thousand items, particularly from the 1990’s. 
Through the filtering process described in Fig 2.1 these items become more 
manageable. Most published work on quality of life seems to have originated in the 
1980’s. This work was conducted by sociologists and psychologists examining issues 
such as housing (Meeberg 1993) and from then onwards the term “quality of life” was 
found in many different studies from the working environment to health care. Opong 
et al (1987) stated that quality of life can be conceptualised either as conditions of life 
or as experiences of life (Opong et al. 1987).
55Other recent attempts to define quality of life focus on self-perception and self report 
in three domains: somatic, psychological and social (Koller and Lorentz 2002). 
Zebrack (2000) examined quality of life and cancer survivorship (commonly taken to 
mean progression/disease free survival of five years or more) and noted a focus on 
adaption to change as a principal construct of quality of life. Zebrack then went on to 
state that by the mid 1990’s the term “Quality of Life” appeared to supplant terms like 
“adaptation” and “psychoscocial adjustment” in studies examining outcomes in cancer 
survivors (Zebrack 2000). This illustrates the fluid nature and the almost erratic use of 
the term in the literature.
As stated earlier, quality of life has now come to be a prominent part of health care 
with the growing realisation that the well-being of patients is as important as treating 
disease or sustaining life which became much more emphatically stated in the 1980’s, 
perhaps because of the increased availability of life-sustaining technology (de Haes 
and van Knippenberg 1985). Johanna De Haes and Ferdinand Von Knippenberg 
sought to define Quality of life to some degree.
56In their 1985 review of quality of life in cancer patients (a general patient population) 
they offered six definitions (de Haes and Von Knippenberg 1985):
•  The ability of patients to manage their lives as they evaluate it.
•  The degree of need satisfaction within the physical, psychological, social, 
activity, material and structural areas.
•  A function of the patient’s own endowment, and the efforts made on the 
patient’s behalf by others.
•  The global evaluation of the good or satisfactory character of people’s life.
•  The totality of those goods, services and situations which are articulated as 
being needed and wanted.
•  The output of two aggregate factors: physical and spiritual.
These characterisations of quality of life are not clear or concise (I layry 1991), 
however they represent two diverse perspectives. These were those of self-fulfilment 
and met needs. Hayry also pointed out that philosophical discussions predate 
medicine (Hayry 1991) and  discussions such as those presented by de Haes and Von 
Knippenberg (1985) presented two facets of what quality of life is: Is quality of life 
achieving what an individual wants or what an individual needs?
Other investigators during the 1980’s sought to define quality of life in terms of well 
being (Packa 1989, Meeberg 1993). This was a continuation of the work by 
investigators during the 1960’s and 70’s. In contrast Tartar et al(1988) gave a very 
comprehensive definition of quality of life as “ a multi-faceted construct that
57encompasses the individuals behavioural and cognitive capacities, emotional well 
being, and abilities requiring the performance of domestic, vocational and social 
roles.” (Tartar et al.1988). This contrasts with an earlier, reductionist, attempt to 
quantify quality of life with the formula:
QL=NE x (H+S)
where QL represents quality of life, H represents the contribution of the individual to 
family/home, NE represents the patients “natural endowment” and S represents the 
individual’s contribution to society (Shaw 1977 in Meeberg 1993) It is difficult to 
accept this as a valid model, mathematically it does not offer mere manipulation of 
Constants  It is difficult tO SC C  any relationship hptwppn the far:tnr<i whir.h are all 
heavily derivative. It should however, be taken in its historical context.
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hterature. This formula does not seem to have been developed further in the context of 
quantification or as an empirical definition of quality of life. Meeberg used this 
formula to illustrate one end of a spectrum of definitions, and she went on to perform 
a concept analysis of quality of life that derived four defining attributes, which seem 
to be in concord with the rest of the literature reviewed here (Meeberg 1993) despite 
being from the early 1990’s.
58They are:
•  A feeling of satisfaction with one’s life in general.
•  The mental capacity to evaluate one’s own life as satisfactory or otherwise.
•  An acceptable state of physical social and emotional health as determined by 
the individual referred to.
•  An objective assessment by another that the person’s living conditions are 
adequate and not life threatening.
The definition of Shin and Johnson (1978) who suggested that quality of life consisted 
of “the possession of resources necessary to the satisfaction of individual needs, 
wants, desires. Participation in activities enabling personal development and self 
actualisation and the satisfactory comparison between oneself and others” contrasted 
with the earlier definitions  rwHmlarlv from antinuitv (Plato Trans Saunders 1970).
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The latter definition appears to imnlv that personal and financial resources are key to 
good quality of life.
Other attempts to define quality of life have included the subjective, such as Andrews 
& Withey’s concept that quality of life is an affective response to one’s role, situation 
and values (Andrews and Withey 1976). It would seem that the concept of quality of 
life in the literature that pre dates the 1980’s was still strongly connected with the 
“goodness of life” (Zautra and Goodhart 1979) concepts from antiquity (Plato Trans 
Saunders 1970).
59Definitions of quality of life range vastly from the holistic WHO definition (WHO 
1993) through social and physical well-being of patients to the ability to lead a 
fulfilling life (Bullinger et al.1993). Nursing and other health related literature yields 
the majority of quality of life references (Koller and Lorentz 2002) but there is little 
given in the way of definition of the term, quality of life has been viewed until 
recently, as a constant (Carr et al. 2001). There is recognition now in the literature that 
this is not so (Carr et al 2001).
Recent work does not try to define quality of life with one phrase and a trend can be 
seen from the late 1990’s of encompassing previous definitions whilst exploring the 
meaning nf the concept of quality of life in greater depth (Bowling 2003, Carr 2001, 
Addington-Hall and Kalra 2003). An example of this is the idea of quality of life as an 
individual and subjective concept and therefore countering the concept of quality of 
life as a constant or the gap between expectations and experience causing differing 
perceptions of quality of life (Carr 2001). Recent investigators have made explicit 
assertions that quality of life is not related to health, contrary to the current literature, 
but is related specifically to disease (Koller and Lorentz 2002).
There was no consensus in the literature as to what quality of life is, in particular with 
reference to health (Carr et al. 2001) or health related quality of life (HRQoL). Instead 
a variety of concepts and definitions have been presented. Despite many references to 
quality of life in the literature, the term was often used but few real attempts have 
been made to define it. It seems that quality of life resists definition, reflecting the 
amorphous nature of the concept. (Fitzpatrick et al 1998).
602.2.3  Measuring quality of life-quality of life as an outcome measure
“Like Humpty Dumpty, researchers and clinicians alike seem to think that quality of 
life can mean anything they want it to mean, regardless of  the concerns of  the patients 
themselves
Sonja M Hunt
Individual Quality of Life 1999 
There was much debate in the literature with regard to the measurement of quality of 
life (Zebrack 2000, Aaronson 1991, Fitzpatrick et al 1998). As quality of life has 
defied definition, is it possible to measure? Measuring the immeasurable is counter to 
positivist tradition.  In addition who should measure quality of life? (Fitzpatrick et al 
1998, Slevin et al 1988). The theme of doubt that quality of life could be measured 
was woven into the literature, for example:
“For a scale of  any kind to be meaningful there must be an agreed unit of 
measurement. In other words scientific measurement is inherently reductionisi- 
concerned with one type of  entity only-whereas quality of  life is multifactorial, and the 
factors a re   inherently incommensurable, no matter how complex the mathematics. 
Hence the attempt to produce  “quality of  life scales” is bound to fail. “
Downie 1999
Most of the literature pertaining to health interventions discussed functional status or 
health-related quality of life (HRQoL). Effectively these were patient outcome 
measures, used to assess interventions in patient populations (Byrne 1992, de Haes 
and von Knippenberg 1985). These outcome measures and instruments used in cancer 
populations are discussed in Section 2.2
Investigators agree that quality of life is multidimensional (Bowling 2003, Zebrack 
2000, Fitzpatrick et al 1998). As Testa and Simonson (1996) pointed out, different 
studies have focussed on different domains, for example physical, psychological and 
performance (Testa and Simonson 1996). The findings of Beretero and Ek (1993)
61demonstrated the need for multidimensional tools. In their study, Bereto and Ek 
(1993) found that patients verbalised their perceptions of quality of life and how it 
varied over time with regard to illness state, perspectives on survivorship and 
relationships. They found that the diagnosis of a serious or life threatening illness 
resulted in a higher priority being given to existential and psychological factors over 
other domains (for example physical) (Beretero and Ek 1993). These findings suggest 
that investigators need to assess the values that patients place on different dimensions 
of quality of life and evaluate those dimensions.
The literature offered a diverse range of outcome measures, and as a result of the 
process illustrated in Fig 2.1, patient based outcome measures were the only ones 
examined.
Seven major types of patient based outcome measure are available in the literature 
(Fitzpatrick et al 1998). These were:
Disease specific: Developed to provide patients’ perception of a disease or health 
problem. These instruments have a specific range and could detect changes in 
condition or disease state over time (Patrick and Deyo 1989). These instruments are 
limited in that they can only be used in the population with the disease (and not 
healthy control groups).
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body, for example the Oxford Hip score (Dawson et al 1996)
Dimension specific: These instruments assessed one aspect of health status, for 
example depression (Beck et al 1961)
Generic: These instruments are designed to capture a variety of aspects of health and 
illness states. They can therefore be used in a wide range of studies.
Summary item: These instruments are single items that invite respondents to verbalise 
health status by a small number of questions. The main disadvantage is brevity, 
however this also means less time demands on respondents.
Individualised : Individualised measures allow respondents to select issues which are 
of concern to them and not pre-selected by the investigators.
Utility: These instruments have been derived from economics and decision theory 
with the aim of estimating patient preference.
Fitzpatrick and colleagues (1998) also recommend eight criteria which investigators 
should apply to the selection of an instrument. These were appropriateness, reliability, 
validity, responsiveness, precision, interpretability, acceptability and feasibility 
(Fitzpatrick et al 1998)
63Validity in quality of life research has more facets than the reproducibility of a purely 
reductionist method. Bowling describes validity as: (Bowling 1997)
Content Validity: The components of the measure should cover the attributes that 
need to be measured.
Face Validity: A form of content validity, Is the measure the right one from an 
obvious standpoint?
Construct Validity: The validity of underlying factors (constructs). A more abstract 
approach for testing the development of hypothesis.
Criterion Validity: The closest comparison to validity in reductionist approaches. 
Criterion validity tests validity against a “gold standard” which is difficult to do in 
HRquality of life as this does not exist. Criterion validity is further divided:
Concurrent Validity: Defines how substantial the scale is, usually in comparison to a 
sucessessor.
Predictive Validity: Does the measure predict future differences?
These criteria should be considered in the selection of an instrument.
642.3 Quality of Life in Cancer
“Survival rates and side effects have become the dominant constructs of  cancer 
treatment and cancer care, to the detriment of  more supportive and patient  focussed 
approaches. The concept of  quality of  life introduced to address this has failed to 
temper the language of  oncology. ”  Jessica Comer
The Robert Tiffany Lecture 1996 
9th International Conference on 
Cancer Nursing
Incidence, survival and mortality have historically been used to map cancer pathology 
and treatment (Fraumen et al 1993) and this is reflected in Comer’s assertion (Comer
1997)  and confirmed by Alan Millbum’s statement at the launch of the NHS Cancer 
Plan (DoH 2000a). The oncology literature is dominated by studies in which five-year 
survival, prognosis and tumour response are the main themes. This is not surprising 
but as the primary language of cancer they reflect the fear ot the disease and suppoii 
uiw association of cancer with death. The introduction of quality of life and HRQoL 
has not tempered this language; however it is the criticism of the ovcr-emphasis on 
survival as the sole legitimate aim of treatment, which led to far greater consideration 
of factors such as quality of life (Comer 1997).
Oncology was one of the first areas of medicine to include the assessment of the 
impact of treatment on functioning as part of the treatment agenda. The work of 
Kamofsky and colleagues being an example of this (Kamofsky et al 1948, Schou & 
Hewison 1999). In general terms, cancer is difficult to cure and most types of 
treatment induce some kind of toxicity. In the late 1970’s and early 1980’s 
consideration of quality of life began to emerge in the oncology literature. Some 
authors have attributed this to technological progress and the increasingly complex
65treatment options that became available (de Haes and van Knippenberg 1985). 
Technology has increased lifespan in the western world and also meant that it is 
possible to keep humans alive for longer with chronic illness (Gerhardt 1990).
Chronic illness shifted the biomedical agenda in the latter part of the last century, 
through the changing population of acute care institutions, where some of the first 
qualitative studies of chronic illness took place (Gerhardt 1990). The first of these 
examined quality of life in patients with chronic illness (Strauss and Glaser 1975) and 
concluded that much of the work of acute care institutions is the management of the 
acute phases of chronic illness. Ten years later, Strauss and co-workers described how 
advances in medicine had now produced a group of chronically ill people who had to 
function in society (Strauss et al 1985).
This work set the foundations for quality of life to become a biomedical issue (Schou 
and Hewison 1999), and the biomedical model of acute illness is often criticised for 
its inability to deal with chronicity and the illness experience (Illich 1976, Levanthal 
et al 1982). A new model was called for, it needed to be multidimensional and holistic 
(Engel 1977, Cunningham 1986). One of the largest advocates of the importance of 
quality of life in the context of living with chronic illness, was the emergence of the 
hospice movement in the 1960’s and 1970’s.
As has been shown, definitions of quality of life vary widely (Bowling 1997, 
Fitzpatrick et al 1998).  The WHO (WHO 1993) definition is the one that seems to 
have informed the oncology literature to the greatest degree (Zebrack 2000), as this 
definition emphasised the multi-dimensional nature of health and well-being. Two
66themes emerged from the oncology literature in the context of quality of life. The first 
was that quality of life is a broad term, and this leads to difficulties when comparing 
studies. The second was that quality of life is multidimensional and included physical, 
psychological and social components (Aaronson et al 1991, Hopwood 1992, Testa and 
Simonson 1996. Fitzpatrick et al 1998).
It is the biomedical model that continues to dominate clinical practice. Physicians and 
other professionals set goals for cancer patients and then assess progress. Quality of 
life assessment is an extension of this process in the context of cancer treatment. 
Investigators (Schou and Hewison 1999) found that some clinicians considered 
including a patient’s own assessment of treatment in this form is in conflict with the 
to have clear and concise measures so as not to interrupt the flow of a time 
pressed clinic or clinician and an increased patient burden (Schou and Hewison 1999). 
This view re enforced the biomedical model and was in direct opposition to that of 
multidimensional and holistic care (Barkauskas 2002).
Generally quality of life in oncology is operationalized as functional status (Aaronson 
et al 1988, Holland 1992). The adoption of quality of life assessment in oncology has 
been influenced by the inclusion of quality of life assessment in clinical trials in the 
context of outcome measures (Byrne 1992) and so there has been a strong argument 
that quality of life in oncology essentially still has a biomedical focus through a 
dependence on a “functional living” perspective (Schipper 1984, Schou and Hewison 
1999, NICE 2005).
67This perspective has evolved from the early performance indicators, which were 
based on functional ability (Kamofsky et al 1948) and activities of daily living scales 
(MacDowell and Newell 1987). In many instances HRQoL is often extended to 
include other domains such as financial or global quality of life (Aaronson 1991) but 
essentially, non-function specific issues receive little consideration in the literature. In 
focusing on functioning, quality of life assessment developers have continued to focus 
on pathology and some authors argue, severely restricted the study of psychosocial 
aspects of cancer and it’s treatment to detecting psychopathology and the 
measurement of distress in patients (Schou and Hewison 1999, Holland 1992).
Catruvedi (1991) stated that the quality of life is not the same as the quality of 
function. What seems to Fe missing from quality of life assessment in cancer is a 
sense of meaning of the experience of cancer and treatment for an individual. The 
Icini meaning gives some depth to functionality, but is not merely an extension of 
functionality. Meaning can include issues of understanding and acknowledgement 
from professionals and ideas about support (or non-support) from professionals or 
others, the nature of choice in treatment and the different experiences of the treatment 
trajectory or even treatment cessation. There have been authors who supported a shift 
from the “distress” model of psycho-oncology toward a positive exploration of the 
meaning in the experience of cancer and treatment (Fife 1995).
The psychological aspects of quality of life have been heavily linked to function and 
coping strategies. Using this method has resulted in assessing stress or distress felt by 
the patient in respect to diagnosis, treatment or prognosis and not assessing quality of 
life (Schou and Hewison 1999). Again the influence of the biomedical model arising
68from pathology is clear and so is its origin in the Cartesian philosophy of the body as 
a machine (Bowling 1997). Studies available in the literature (Spiegal 1997, Schou 
and Hewison 1999) have examined various aspects of psychological response and 
“functionality” in this way.
In the cancer literature examined other than that for NSCLC (for example breast and 
gynaecological cancers) there was a wealth of literature examining reaction to 
treatment, to prognosis or diagnosis, self- esteem and sexuality but little literature on 
the healthcare context such as professional-patient relationships that have positively 
affected information giving in terms of optimism or pessimism (Spiegel 1997). 
McCorkle et al (1989) defined quality of life as “functional capacity, symptoms and
Dementinn<i nf health” i  i  '  "
It can be said then that quality of life in llic cancer iiieraiure is siiii based in terms of a 
functional approach that gives conventional biomedical perspectives priority. Such an 
approach would seem to fail to take account of the personal experience of people with 
cancer. Patients’ experience of treatment, of the health care system and of living with 
cancer are all aspects of the social experience of illness (Holland 1992, Somerfield 
and Curbow 1992, Testa and Simonson 1996, Schou and Hewison 1999) and require 
more attention than they have received in the oncology literature. There is a lack of 
empirical research in this area (Zebrack 2000).
It has become apparent that the effect of non-small cell lung cancer (NSCLC), and 
cancer in more general terms, cannot be considered only in terms of pathology. 
Holistic practice is based on a broad knowledge of many issues that affect people with
69cancer. In the last half of the twentieth century more has been understood of the 
psychological effects of health and illness and the context of health and disease in 
relationship to the rest of life. The teaching of these ideas certainly makes up a 
significant part of the clinical pre-qualification curricula of various disciplines in the 
UK. This work was clinically based and so it is appropriate to examine the issues 
around this area particularly in the oncology setting.
The exploration of issues such as the effect of cancer on the individual and the group 
is now often termed psycho-oncology or psycho-social oncology, a discipline which 
has developed as a sub speciality of oncology over the last thirty years as 
psychological factors were seen to influence the experience of people with cancer 
(Holland 1992).
There was a detectable pressure from with in the psycho-oncoiogy literature for the 
“scientific” measurement of quality of life using tools such as questionnaires (Schou 
and Hewison 1999, Holland 1992, Holland 1998, Bowling 2003). The tools thus 
developed and considered supported the idea of measuring pathology, not only 
physical but also psychological. This framework was assumptive and it has also been 
suggested that psychological morbidity in cancer patients has been overestimated 
(Meyerowitz 1993, Bowling 1997).
Two types of conceptual definition of quality of life have been used in psychosocial 
oncology, global quality of life and health related quality of life. The main differences 
noted were that globed quality of life sought to learn more about the character of life 
whereas health related quality of life sought to examine disease symptoms, side
70effects of treatment, psychological distress and functioning (Kaasa and Mastakaasa 
1988).
2.3.1  Quality of life and Psycho-oncology in the literature
Over the last thirty years investigators have written about the social construction of 
health and illness. This has formed the basis for much of the groundwork of 
psychosocial oncology. It is worth reviewing some of the work that made significant 
changes in the way that health and illness are viewed in a psychological and 
sociological context. This is because it is important to understand the psychological 
and sociological importance of illness so as to better understand the impact of cancer.
A study on the lav belief of illness was conducted by Herzlich in die laie twentieth 
century (Herzlich 1973). Herzlich found that the people she interviewed perceived 
illness as external, the result of a way of life. Health in contrast was perceived as 
internal to the individual. Three dimensions of health were identified. The absence of 
illness or “health in a vacuum”; an innate ability determined by constitution or 
temperament “a reserve of health” and a sense of equilibrium. The population that 
Herzlich interviewed consisted of eighty middle class French people but the results of 
her study have been confirmed.
A seminal study in the UK also illustrated these different dimensions of lay beliefs of 
what health is (Pill and Scott 1982). In the study by Blaxter and Paterson (Blaxter and 
Paterson 1982) some references were made to the absence of disease but for the 
majority of the mothers they interviewed from low social class backgrounds, defined 
health as functional, with many distinguishing between “normal” illness which could
71be accommodated and “serious” illness such as heart disease or cancer, which 
required a major shift in coping strategy. Central to psycho-oncology research are 
quality of life issues and the integration of this research into patient care (Holland
1998), but the issue arises once again of the domination of psychosocial oncology by 
psychopathology (Mathiesen and Stam 1995, Schou and Hewison 1999). Lay belief in 
lung cancer causes is reflected in the UKLCC study (UKLCC 2005) that has been 
discussed but reflects the findings of earlier authors such as Blaxter and Patterson 
(1982)
One of the most prominent influences of psychosocial oncology on quality of life in 
the literature was the concept of coping, and there were many studies in the literature 
devoted to the idea of cancer patients coping (Scmcrficld and Cuiuow 1992). Many of 
the self report quality of life tools that featured “coping” assumed that there is coping 
to be done. This is because quality uf life assessmeni research in oncology has been 
orientated to assessing coping with interventions. The model shown in Fig 2.4 
illustrates this (Holland 1998).
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Current quality of life assessment in cancer is still rooted in the need to assess 
interventions. This is reflected in the cancer literature on quality of life, the majority 
of which is based on chemotherapy/radiotherapy trials (Anderson et al 2001, Crino et 
al 1999, Geddes et al 1990). This is also a typically nomothetic style of the 
functionalist perspective. Bowling (1997) argued that quality of life is assessed from a 
nomothetic perspective and this approach was very apparent from the literature.
732.3.2  Influences on measuring quality of life in people with cancer 
Can quality of life be measured? How can one measure that which cannot be defined? 
Without an agreed upon definition, the concept of quality of life is difficult to measure 
(Molzahn 1990). A pragmatic approach was called for in oncology and some have 
abandoned the term because it is too general (Fitzpatrick et al 1998) whilst others 
have exploited it, as a marketing tool, because it lacks definition (Celia 1998).
The researcher is faced with a huge range of questionnaires, scales and tools designed 
in some way to quantify quality of life. The one thing that becomes apparent from the 
literature is that there is no agreed “gold standard” of quality of life or consequently, 
how to measure it. Most instruments in oncology reflect what could be described as a 
disuse model. The disease model is a “medical conception uf a paihoiogicai 
abnormality indicated by signs and symptoms” (Bowling 1997). Much of this 
quantitative rcseaich ia ua^cd un pre-conceivea ideas about what “quality of life” is 
and how it is measured. This would make an empirical measurement impractical, if 
not impossible. An obvious aspect of “measuring” but perhaps not such an explicit 
one in the literature, is the motivation for doing so. Most of the quality of life 
literature found in non-small cell lung cancer is in the form of assessments originating 
from clinical trials (Stephens and Hopwood 2000).
Some leading cancer nurses argue that quality of life measures “miss the point” 
(Comer 1997) as this type of assessment is too reductionist and has little to contribute 
to cancer nursing as therapy.
74There seems to exist a dualism in the quality of life literature between a philosophical- 
theoretical approach, and the literature, which could provide guidelines for methods 
for “real life clinical situations” (Hayry 1991). Hayry suggests three different motives 
for choosing methods (Hayry 1991):
•  Respect for the sanctity of life
•  Respect for scientific efficiency
•  Respect for human autonomy
This is rather confusing, particularly the first point, and would be difficult for 
clinicians to accept. This is because the inference given by the term sanctity of life is 
one of  prolonging life. Taking advanced non small cell lung cancer as an example, 
which is a severely life liiuiiing disease (Neai and Hoskin 1994, Souhami and Tobias 
2005) it is possible to prolong life in terms of quantity but at the cost of quality, this 
couia also apply to many palliative situations.
There was implicit and explicit opinion in the literature over the validity of attempting 
to measure quality of life (Carr 1991, Fitzpatrick et al 1998). This is not an allusion to 
Wulff (Wulff 1999), some of the doubt has arisen due to methodological issues of 
measuring the unmeasurable. This applies in oncology quality of life. An example of 
which is the view that instruments based on the WHO definition (WHO 1993) are 
fundamentally flawed. Authors such as Koller and Lorentz (2002) have cast doubt on 
the WHO definition of quality of life and put forward a three-component outcome 
model. Using the usual outcome measures to assess HRQoL in terms of disease and 
symptomology, only half of the picture is presented. The other half is composed of 
hermeneutic constructs and it is only when to two are combined that agreement on a
75successful outcome or endpoint can be reached (Koller and Lorentz 2002). This does 
concur with the growing opinion in the literature that quality of life, or satisfaction, 
can only be accurately assessed by the individual (Carr 2001, Cohen 1996).
Celia (1998) examined cancer specific quality of life/HRQoL instruments concluding 
that collectively thirty different domains or dimensions could be identified. Celia then 
went on to rationalise these and suggests seven distinct dimensions of quality of life in 
the instruments he reviewed. These were: (Celia 1998)
•  Physical concerns (symptoms and pain)
•  Functional ability (activity)
•  Emotional well-being
•  Treatment satisfaction (including financial concerns)
•  Sexuality/intimacy (including body image)
•  Social functioning
Celia’s review is thorough and useful in examining and rationalising the body of work 
that exists, however it does cover an enormous range and amount of quality of life 
work and to some degree over rationalises this work. Like many other similar works, 
it also fails to encompass one of the fundamental difficulties of quality of life 
research, that the reductionist and deterministic approach of medicine is most clearly 
expressed in symptom management (Benner and Wrubel 1989).  It is still a useful 
piece when considering the selection of a tool however.
76In people with cancer the value of the medical interventions offered has often been 
gauged in terms of quantity of life (Clegg et al 2001, Comer 1997). More recently, as 
can be seen from the following section, there has been a move towards evaluating 
interventions in terms of quality also. There have been a number of studies that have 
assessed quality of life in people with cancer. Much of the published work was 
however in the form of a secondary endpoint to a randomised clinical trial, usually 
using chemotherapy treatments (Clegg et al 2001, NICE 2005).
In a number of cancers, particularly breast cancer, there have been more studies with 
quality of life as a primary endpoint. The application of these data to NSCLC has 
b^n limited due to the much wider variation in prognosis and symptoms as well as 
the social context of the tumour site. As has been seen, people with breast cancci have 
been viewed by society as “victims” whereas people with NSCLC have been 
perceived as being in some way to blame for their disease (Cancer Research 
Campaign 2001, UKLCC 2005).
Much of the quality of life data that exists in the cancer literature originates from 
clinical trials, this has been particularly apparent in non-small cell lung cancer studies 
but the fact applies to cancer studies generally. Quality of life is usually a secondary 
outcome measure (Clegg et al 2001). It is common for quality of life data in studies to 
be presented separately from mortality and morbidity data. Although many quality of 
life tools examine symptoms by self-scoring, the data is rarely correlated with, for 
example, toxicity scores or other objective data (Clegg et al 2001). Quality of life 
scoring has reported the subjective experience of those symptoms. It has been seen 
that factors such as mood and anxiety influence scoring in quality of life in cancer
77patients (Jones et al 1989) and so it would seem a logical step to try to correlate 
subjective and objective data in some way. An interpretation of this linking is given 
by Michael Hyland in that quality of life is a causal sequence (Hyland 1999). This is 
shown graphically in Fig 2.5
Fig 2.5 Quality of life as a causal sequence
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The first stage of this causal sequence morbidity causes symptoms and whai is 
reported is the subjective experience of these symptoms. People with anxious or 
depressed mood may report more or intense symptoms (Hyland 1999). The second 
stage is for symptoms (or anticipated symptoms) to cause problems, however the 
symptoms may not cause problems or they may be minor ones. This is again 
dependent on psychological factors and coping strategies.  The final stage is for 
patients to evaluate. This is an important stage and one that is not commonly 
considered in quality of life as Hyland states (Hyland 1999) and anecdotally many 
people with cancer re-evaluate what quality of life means to them and this is a 
complex relationship, those with problems are not necessarily unhappy or 
experiencing what they would consider lower quality of life.
In conclusion, it has been shown that although a substantial amount of work exists, it 
does so with the aim of measuring HRQoL in clinical trials (Clegg 2001).  However
78assessment of quality of life can lead to a substantial level of intervention in the 
context of cancer care, particularly from a nursing perspective (Ryan 1996) and 
become an outcome measure, subsequently improving care (Lindley and Hirsch
1994).
2.3.3 Measuring Health related Quality of Life in patients with cancer 
A number of tools have been introduced over the last fifty years with the aim of 
quantifying or assessing HRQoL. To have reviewed all of these tools would have 
been an enormous task, and beyond the remit of this work.
Tv-  reviewed here were those used primarily for assessing HRQoL in
patients with cancer and were disease based. HRQoL became a factor in cancer 
management with the growing realisation that cancer therapies aimed at cure are often 
accompanied by side effects (McMillan 2000).  It can bee seen from the brief 
introduction above, that to even attempt to measure quality of life or HRQoL, any tool 
must have certain attributes. It has been shown that instruments need to 
multidimensional, (Bowling 1997) and need to measure all aspects of life that may be 
affected by a life limiting illness. Such instruments must also be sensitive to the area 
in which they are used and the client group (Patrick and Deyo 1989). They must also 
provide allowance for the collection of subjective data from the patient (McMillan
2000). It was stated earlier that instruments need to be valid and reliable (Schipper et 
al. 1984) although this seems axiomic, it does infer that quality of life is a constant.
The measures presented in this section are not exhaustive but represented the majority 
of studies from HRQoL literature for cancer. These measures were also represented in
79the HRQoL literature for the NSCLC studies, particularly clinical trials. This also 
included work, which used the palliative based scales (McMillan 1994). These papers 
have a focus on a hospice setting and patients receiving palliative care. The most 
commonly used measurement tools in cancer in the literature of the last thirty years 
are represented in Table 2.1. The palliative care setting was one of the first arenas in 
which quality of life was investigated in cancer care. A study of sixty people by 
Hinton (Hinton 1975) in the end stages of cancer examined issues such as “a sense of 
satisfaction with life” and concluded that greater satisfaction with life indicated that 
“dying was less troublesome”. The issue of the quality of time left to live having more 
importance than the quantity, is in direct opposition to Hayry’s “sanctity of life” 
motivation of quality of life (Hayry 1991).
Quality of time verses quantity of time is a concept entrenched in palliative care 
literature and education (Twycross 1997, Faull and Woof 2002) but the idea of 
maximising “quality of life” in education and clinical practice is virtually never 
defined or measured and yet many editorials and papers argue the importance of doing 
so (Tywcross 1987, Celia 1992, Ahmedzai 1993).
80Table 2.1 Quality of Life Outcome Measures for Cancer Populations
(After McMillan 2000, Bowling 1997)
Kamofsky Kamosky et al  1948 Physical/subjective
Performance functioning
Index
Quality of life Spitzeretal  1981 Outlook, support
index networks, Activity, health
Hospice QoL McMillan  1996 Physical/Functional
Index social/spiritual, Financial
Functional Schipperetal  1984 Physical, psychological,
Living Index family/social, somatic
(Cancer) sensation
Quality Of Padilla et al  1983 Ferrans et Symptom control,
Life Index al  1990 physical/psychological
(cancer) wellbeing
Functional Celia etal  1993 Physical/functional
Assessment of social/emotional
Cancer relationship with doctor
Therapy-
General
(FACT-G)
Quality of Life Aaronson et al  1993 Symptoms, Function
Questionnaire- (physical/emotional/soc ial)
cancer Finacial
EORTC QLQ
30.
No
Yes
Yes
Yes
Yes
Yes
Linear score Yes Not self reported, not 
specific QoL
IntJrview
Structured
questionnaire
2;5 rated items
Yes but
questioned in later 
years (Slevin 
1988)
Yes
2 2 Likert items  Yes
U  VAS items  Yes Has not 
undergone 
extensive testing 
1\\ Likert Items  Yes
Some confusion over 
dimensions
Content validity limited to 
hospice setting 
Difficult to complete, 
nubts over construct validity
Little used.
Functionally based
30 items  Yes  Function and HRQoL
additional  biased
nodules 
availableAn argument often given for not assessing quality of life in people who are receiving 
palliative care is that they are too vulnerable (Waldron and O’Boyle 1999) but this is 
an assumption that has not been tested, it also makes huge assumptions about a 
specific population. It is possible that because of this perceived vulnerability that 
measurement scales were developed.
The first of these measurement scales for use in the cancer population was the 
Kamofsky Performance Index. It is still in use today although the use of this measure 
has varied somewhat to become a measure of performance and as a proxy for 
functioning (Montezari et al 1998). One of the first health professionals to assess 
health related functioning in medicine, and the effect of one of the first palliative 
chemotherapeutic agents for lung cancer, was Kamofsky in the late l940's 
(Kamofsky et al. 1948). Kamofsky’s aims were to palliate symptoms from tumours 
and in particular “bronchogenic carcinomas”. With no means to measure symptom 
relief, Kamofsky and colleagues developed a system of objective and subjective 
improvement in the patient group. The subjective part of the assessment was a 
“subjective improvement” of “good, fair or none”.
It is difficult to ascertain from the original paper who measured or assessed the 
subjective aspect (doctor or patient) but over time the assessment has evolved into the 
Kamofsky Performance Index (KPI) which is usually an assessment by a practitioner. 
This is the most often criticised aspect of the KPI alongside its cmdeness and focus on 
physical functioning (Bowling 1997). However it should be taken in historical 
context. Kamofsky's group did not define or even use the term quality of life in the 
1948 paper, however it is used as a proxy for quality of life in the present day
82(Montezari et al 1998). This has been seen in the literature where the KPI has been 
used alongside other, more recently developed, tools such as the EORTC QLQ-30 
(Anderson et al. 2001, Burris et al. 1997). The limitations of the KPI centre on the fact 
that this is a practitioner, rather than self reported, measure.
The Functional Living Index-Cancer (FLIC) was developed in the 1980’s 
predominantly for use in clinical trials (Schipper et al 1984). It was a 22 item Likert 
style format on a scale of 1 to 7. It is a self-report measure and, from the literature, it 
was used predominantly in the 1980’s and early 1990’s.Validity was confirmed by 
comparative studies with other instruments (Schipper et al 1984, Finkelstein et al 
1988) however reliability was not assessed by the authors (Schipper et al 1984) and 
some authors state that the literature does not provide evidence ol reliability studies uf 
FLIC (McMillan 2001), and has been criticised for the method of scoring which may 
make the scale too crude to use clinically (Aaronson et al 1988) however there was 
limited evidence of reliability (Morrow 1992)
The Quality of  Life Index (QLI) was developed by Padilla and co-workers (Padilla et 
al 1983) as a self-report instrument designed to measure quality of life in cancer 
populations. It consisted of a 14 items that are rated using a visual analogue scale. The 
domains examined were symptom control, physical well-being and psychological 
well-being. The advantage of the Quality of Life index was ease of completion and 
simplicity (McMillan 2001). The validity of the QLI was examined in four groups of 
subjects (healthy volunteers n=43, outpatients receiving chemotherapy n=43, 
outpatients receiving radiotherapy n=39 and inpatients receiving chemotherapy n=48) 
and significant differences found between the groups, with the non-patient group
83scoring highest which the investigators claim supports construct validity (Padilla et al 
1983) but the details of the group (eg age, demographics and physical function) are 
not given. Subsequent studies confirmed reliability (Ryan 1985).
Quality of  life index (Cancer Version) QLI-CV This instrument was developed from 
the QLI by Ferrans and Powers (1985) who suggested that individuals values may 
have a variable impact on quality of life. This approach led to individuals weighting 
satisfaction items with importance. The QLI-CV is a thirty-five item instrument which 
aims to assess global quality of life (Ferrans et al 1990). The QLI-CV used domains 
such as health and functioning, socio-economic, psychological/spiritual and family. 
This instrument has been validated against the QLI and in general oncology use 
(Ferrans 1990).
Functional Assessment of  Cancer Therapy-General (FACT-G) is a self-report 
instrument that was designed to measure HRquality of life in cancer patients i vCciving 
therapy (Celia et al 1993). This 28 item instrument can also be augmented with site, 
disease or treatment specific adjuncts. The FACT series of instruments have been 
subject to validation and reliability studies (Celia et al 1993, McMillan 2001) and are 
in current usage.
European Organisation for the Treatment of Cancer Quality of  life Questionnaire 
(EORTC QLQ Version 3) This instrument has become one of the most apparent in the 
cancer literature. It was developed by the EORTC primarily for use in clinical trials 
(Aaronson et al 1993, EORTC 2005).  The EORTC QLQ addressed the domains of 
function, symptom control, financial, global health and global quality of life. It has
84been validated in 13 countries and translated into different languages (McMillan
2001). The QLQ also has disease specific modules such as the QLQ 30+L17 (Lung 
cancer module) and this is explored in more depth in Chapter 3.
852.4  Quality of life related to Non Small Cell Lung Cancer 
Lung cancer is an area where quality of life assessment has had an impact. As was 
seen earlier, many patients with lung cancer present in the advanced stages of the 
disease and there is little benefit from most treatments in terms of quantity of life and 
so advanced lung cancer is seen as disease that is treated in a palliative setting.
Despite the work of Kamofsky in the 1940’s (Kamofsky 1948), until recently very 
little was written about the Quality of Life of people with lung cancer of any type. In 
Splinter’s 1990 review of 142 clinical trials in NSCLC, only 10 had any form of 
quality of life measurement apart from a physician assessed recording of performance 
status (Splinter 1990). Splinter’s work has dated, generally the proliferation of quality 
of life assessment has been as a secondary endpoint to survival in chemotherapy drug 
trials.
From the mid 1990’s papers began to appear which reviewed and supported the idea 
that quality of life should be an endpoint in such studies (Kosmidis 1996, Hopwood 
and Thatcher 1990, Gralla 1994). These studies often employed a medical and 
pathological perspective.  It has been noted by authors (Stegbauer 1994, Cooley 1998) 
that there is a notable lack of theoretical quality of life work in the lung cancer patient 
population. The recent work in quality of life is driven by the cancer modernisation 
agenda, but still centres on clinical trials and HRQoL (NICE 2005).
862.4.1 Non small cell lung cancer-Health related quality of life (HRQoL) concept 
clarification.
This section serves as an exploration of the definition of terms for the rest of the work. 
The aim is to gain insight into areas such as the philosophical construction of the 
concept of quality of life in advanced NSCLC, particularly in the clinical context.
Many disciplines, such as philosophy, have placed value in concept development but 
as Rodgers and Knafl (1993) pointed out that as clinicians we “tend to know much 
more about how to tackle empirical concerns than we do about means to solve 
conceptual barriers to progress” (Rodgers and Knafi 1993). Certainly ii would 
that to investigate not only the empirical but also to go some way to resolving 
conceptual problems would add something to the understanding of the individual 
practitioner and the profession as a whole. This section introduces conceptual clarity 
by the use of concept development and analysis.
Concept analysis and development is a challenge to define. In the context of nursing, 
concept analysis entails synthesizing existing views of a concept and distinguishing 
such views from other concepts (Knafl and Deatrick in Rodgers and Knafl 1993). 
Concept clarification was the main focus of the various methods of achieving this. 
Concept analysis has gained popularity as a basis for much of the underpinning 
knowledge of clinical practice. This is perhaps much more so in nursing practice as 
much of the published work on the use and value of concept analysis has been from a 
nursing perspective. This could be due to the paradigm shift that has occurred in
87nursing in the last twenty years or so that has moved the fulcrum of nursing as an 
activity from ritual to evidence based practice for example the work of Binnie and 
Titchen (1999).
There was very little literature available on the conceptual analysis of quality of life in 
NSCLC. A search of the literature revealed only one explicit concept analysis of 
quality of life in NSCLC (Cooley 1998) and once a concept has been defined in such 
a way perhaps the question is “Is another concept analysis necessary?” It may not be 
necessary to re-define the concept but it could be argued that such a concept is not 
static. Most things change over time. This analysis was well researched and insightful 
and  i' unlikely that a new concept analysis would have contributed much to the 
body of knowledge. However there was a strong argument for a critique and 
expansion of Cooley’s work, which is focused very much on the population of North 
America and appeared culture specific (for example, references to a system of 
healthcare that has significant differences from those in the UK). Cooiey had to limit 
the amount of literature reviewed and analysed, reviewing fifty papers, published in 
English that used patient self-reports of quality of life. Phase one and two trials were 
excluded as they were deemed to have “limited applicability to persons with NSCLC” 
but no rationale for doing this is given. The strength of Cooley’s work was the focus 
on individuals with NSCLC.
Since the late1980’s and the work of those such as McCorkle et al (1989) the 
evolution of definition’s of quality of life in NSCLC became much more apparent. 
Upon reviewing the literature, a definite shift can be found to a more global approach 
and a broadening of health related quality of life. From the mid 1980’s (for example
88Bakker et al 1986) the focus of investigation shifted from functioning and physical 
symptoms to a more global approach. This is also reflected in the tools reviewed 
previously.
From the literature there has been an emerging consensus that there are at least four 
major dimensions of quality of life in NSCLC that relate to health including 
functional status, physical symptoms, emotional function and social function. 
functional status was defined by normal day to day living activities, and then further 
subdivisions of this with respect to performing the everyday activities of daily living 
such as bathing and dressing, and role responsibilities such shopping and working. 
Physical symptom an* the physical symptoms of the disease or treatment that is 
referred to. Emotional  Junction refers to the affect, which included positive and 
negative, for example depression and anxiety (Celia 1989).Social  Junction Schipper et 
al (1990) referred to the maintenance of relationships with family and friends. Some 
authors maintain that this dimension has been under-used (Schipper et ai i990).
As a result of this work a definition of quality of life in non-small cell lung cancer has 
been proposed:
“Quality of life in the context of NSCLC is the impact of th? disease and/or 
treatment on the functional status, physical symptoms, affective state and 
interpersonal relationships as evaluated by the person with cancer.”
(Cooley 1998)
Cooley argued that an obvious antecedent for self perceived quality of life is that an 
individual must have the ability “to make a cognitive appraisal of his or her life”
89although she offered no evidence, this seems somewhat axiomic and was rare to see 
such an explicit expression in the literature.
From the literature other antecedents became apparent:
•  Antecedents for  functional status: Chemotherapy, co morbidity, income, 
kilocalorie status, prior weight loss, time since surgery. (Bakker et al 1986, 
Sama et al 1993)
•  Antecedents for physical symptoms: Chemotherapy, co morbidity, gender, 
income, no surgical treatment, age, stage of disease, smoking. (Bakker et al 
1986, Sama 1993a)
-  Antecedent lb: •rrru^fiona!  function: age, spousal support, and time since 
diagnosis. (Sama 1993b, Quinn et al 1986)
•  Antecedents for social  function: age, marital status. (Sama 1993b)
This was clarified somewhat by the explanation that Cooley viewed health related 
quality of life as an antecedent to global quality of life (Fig 2.6) and also introduced 
the importance of physical health as perceived by many to be on of the most important 
self-disclosed factors in a cognitive appraisal of quality of life or predictor of life 
satisfaction (Girzadis et al 1993).
Fig 2.6 Relationships between physical health, health related quality of life and global 
quality of life. (Cooley 1998)
Physical Health ^Cognitive Appraisal => Health Related Quality of Life=> Global Quality of Life
This paper is difficult to critique. It is well researched examining sixty-five papers, 
and is the first of its kind. There is no real comparison to be made with other works as
90there is little written on the subject from this perspective. Cooley recognises this, 
particularly the lack of work on the emotional and social function.
The clear message from all the definitions reviewed in the literature demonstrated that 
there is still much ambiguity. However a useable definition of quality of life in 
NSCLC is at hand in the work of Cooley (1998). There was a virtual non-existence of 
any spiritual or existential dimension to the concept by the papers reviewed. Zebrack 
(2000) noted that this dimension was important to patients and certainly anecdotal 
experience would tell us this also. Spiritual care is also a mark of holistic practice 
(Barkauskas et al 2002). It is hard to see how spirituality could not influence the 
perception of global quality of life as “spiritual weii-beiug can have a positive impact 
on the individual’s ability to cope with the physical manifestations of the disease 
process” (Walsh, Crombie and Reveley 1999).
912.5  Quality of life in Non Small Cell Lung Cancer: Instruments in the literature
Since the 1970’s it has been common practice to use performance status as a 
prognostic indicator in lung cancer practice (Montezari et al. 1998). This arose from 
Carlens’ Vitagram (Carlens et al. 1970) used to plot survival against performance 
status. Studies over the next twenty years appeared to confirm this proxy relationship 
(Montezari et al 1998), demonstrating that performance status is a good predictor of 
quality of life, or rather an indicator of psychological, physical or symptom distress 
(Montezari et al. 1998). Although using performance status as a proxy for quality of 
life has been controversial, studies have shown correlation between performance 
status and global quaiiiy of life in some populations of lung cancer paucxits (Oscba el 
al. 1994). In practice performance status continues to be used as a proxy for more 
thorough quality of life assessment (Montezari et al. 1998, Tishelman et al 2000) and 
some authors caution against its continued use as a proxy for quality of life, having 
made direct comparisons in patient groups (Koller et al. 2000).
In the literature many instruments are used to assess quality of life outcomes in cancer 
patients (Table 2.1) and this statement applies equally to lung cancer. From 1990 
onwards however the assessment of quality of life has utilised a core of instruments 
that are examined in more detail here and illustrated in Table 2.2. The development of 
the majority of the instruments that are cancer and cancer site specific have been 
developed as a result of increased activity in clinical trials. Hopwood (1998) offers 
practical points to consider in this context that would serve as a guide to any
92researcher choosing an instrument specifically for quality of life assessment 
NSCLC and this has been shown in Table 2.3 (Hopwood 1998).Table 2.2 Quality of life in NSCLC: Common outcome measures shown in context as used in the reviewed literature.
Dimensions assesse Tool  Puipose  Year of  Dimensions assesse*
;  publication
KPS
ECOG
Sickness
impact
profile
DDC
Performance
status
Performance
status
Generic
Continuous 
Drug Trials
Kamofsky
1948
Zubrod
1960
Bergner et 
al 1981
Geddes et 
al.1990
RSCL  Generic/symptoms 
LCSS  Lung cancer 
specific 
FACT-L  Lung cancer 
f  specific
EORTC  QLQ-30 plus lung 
QLQ  cancer specific 
30+LC17  module
Bergman 
et al. 1994
Physical functioning  No
Physical functioning  No
Overall function and 
symptoms
Symptoms
Multidimensional 
physical wellbeing, 
relationship with 
carers
Global/physical/social 
and symptoms 
domains
Yes
Yes 
Yes + 
observer 
Yes
Paring  Yes
FLating  Yes
Yes
Daily  Yes
completion of 
self rated 
items
Questionnaire  Yes 
Questionnaire  Yes
44 item  Yes
questionnaire
Yes  Questionnaire  Yes
30+17
Not
multidimensional
Not
multidimensional
Length
Limited domain 
measurement
Aimed at 
assessing lung 
cancer
symptoms, not 
treatment effects 
Functional 
HRQoLTable 2.3 Issues and practical consideration on collecting QoL data in NSCLC trials.
Patient sample size 
QL Outcomes 
QL study design 
Measuring
palliation
QL data collection 
Clinical value of 
QL end points
Theoretical Perspective______
Large numbers of patients with 
NSCLC
Well defined domains, well 
constructed instruments 
available
Straightforward in theory, 
guidelines exist
Symptoms can be quantified by 
QoL measures and analysed 
Assumes patients attend per 
protocol
QL can be summarised 
numerically to show differences 
in treatment options
Practical consideration
Minority of patients with 
NSCLC treated in trials 
Clinicians reluctant to 
change traditional 
endpoint from survival 
Instrument selection, 
timing, sample size more 
difficult in clinical practice 
Definition of palliation not 
agreed
Compliance problematic in 
palliative centres 
Treatment options not 
always clear cut. Scores 
have limited value when 
discussing treatment 
options with patients
In the literature many different tools were utilised to assess quality of life in lung 
cancer. These ranged from generic performance status instruments (e.g. WHO 
Performance status) to cancer site-specific tools. There were three instruments in 
common usage in the context of thoracic oncology and they are examined here and 
examples of instruments of performance status are given in Appendix E.
Lung Cancer Symptom Scale (LCSS). This instrument was developed in the 1980’s at 
the Memorial Sloan-Kettering Cancer Center in the USA. It was based on an 
empirical conceptual model insofar as the LCSS attempts to depict to the quality of 
life dimensions or domains associated with the symptoms and, subsequently, the 
treatment and palliation of lung cancer (Hollen et al. 1994). Essentially the LCSS 
examined the physical and functional aspects of quality of life, focussing on the major 
lung cancer symptoms and the effect of the symptoms on function and performance
95status. It is somewhat unusual as it was made up of two reporting components, one for 
patients to self-report and one for professionals as assessors of the patient. The 
administration of this tool made it easy to use. The development team found that the 
patient scale took eight minutes to complete and the professional assessment two 
minutes on average (Hollen et al. 1993). The LCSS has been used in a number of 
chemotherapy trials, and in common with many other quality of life instruments, this 
was the motivation for its development.  This tool has been used and validated in a 
trial setting (Hollen et al 1993, Hollen et al. 1997, Lutz et al. 1997) and across age, 
gender and culture (Hollen et al 1999) but it is the least used of the three selected tools 
based on this review. There were no negative critiques of this tool, it seems merely to 
have been superceded by other instruments. Although there are no negative critiques 
of the LCSS found in the literature, the LCSS does focus very much on the physical 
and functional domains. It is not multidimensional. The development team cited its 
use as an assessment tool in therapeutic studies as the reason for its limited domains, 
such as the exclusion of spiritual/social/psychological aspects (Hollen et al. 1994) but 
perhaps this is the reason for the LCSS decreasing popularity with researchers.
The Functional Assessment of  Cancer Therapy-Lung version 3 (FACT-L v3) is a self- 
reported 44 item questionnaire which is divided into two parts. The first part is a 34 
item general/oncology based HRQoL and the second part, consisting of 10 items, is 
lung cancer specific. The focus of the items in part two is a measure of lung cancer 
related symptoms rather than HRQoL or QoL. The principal use of the FATCT-L, in 
common with many other instruments, was in clinical trials. Both the LCSS and 
FACT-L have been validated and are considered reliable tools (Hollen et al.1993, 
Celia et al. 1995, Hollen and Gralla 1996), however fast becoming the most popular
96instrument in the literature is the European Organisation for the Treatment of Cancer 
(EORTC) Quality of life questionnaire (QLQ).
The EORTC QLQ instrument evolved as a result of a desire by the EORTC to 
evaluate interventions in cancer therapies. A study group on Quality of Life was 
initiated by the EORTC in 1980 to develop a brief and practical quality of life 
measure (Aaronson 1991). The group developed the original 42-item questionnaire 
that used self-report. This was reduced to 36 items in the early 1990’s (Aaronson 
1991).The current thirty item (EORTC QLQ Version 3) is a multidimensional 
questionnaire encompassing five functional domains: physical, role, cognitive, 
emotional cuiu social. Three symptom domains: nausea & vomiting, pain and fatigue, 
and single items such as a self rating VAS of own quality of life. Patients rate each 
item using the terms “not at all” “a little” “quite a bit” and “very much”. It also 
includes a self rated global VAS (Aaronson et al. 1993). In recent years a 13 item lung 
cancer site specific module has been added (Aaronson et al. 1993, Bergman et al.
1994).
The EORTC QLQ-30+LC 17 was developed during the 1990’s primarily as a tool for 
assessing quality of life in lung cancer patients entered into clinical trials. Aside from 
the recommendations of the FDA, a growing realisation by researchers of the 
palliative nature of lung cancer treatment has contributed to the increased use of 
quality of life instruments in trials and particularly the QLQ 30+LC 17 (Krzaowski et 
al. 2002). The reason for the increased use of the QLQ 30+LC 17 could be the 
multidimensional nature of the instrument. The tumour specific module includes not 
only lung cancer symptom items (haemoptysis, dyspnoea, cough) but also items based
97on effect of treatment for lung cancer (trouble swallowing, hair loss, pain, parasthesia) 
which researchers have found useful in the evaluation of interventions (Montezari 
1998).
Some authors questioned the validity of the QLQ 30+LC 17, and the other site specific 
modules as being hybrid instruments (Celia et al. 2002) and yet these instruments 
continue to be adopted by large research groups, increasingly as the only quality of 
life outcome measure in clinical trials. This instrument has undergone extensive 
testing including in its original form and has been adapted into many different 
languages (Aaronson 1991, EORTC 2005) which makes it attractive to researchers. 
The EORTC QLQ 30: LCi 7 is included in Apperidiv A  The EORTC QLQ in various 
forms has also been tested across age, gender and disease (Celia et al 2002). The 
EORTC QLQ was also designed with clinical trials in mind. As trials are becoming 
more collaborative and taking on an international approach, the tested cross-cultural 
validity of EORTC QLQ means it is very appealing to research groups.
982.6  Quality of life in the context of treatment (chemotherapy) for advanced Non Small 
Cell Lung Cancer.
The following section is a review of the literature found which focused on the use of 
gemcitabine in trials in which quality of life is an endpoint, usually a secondary 
endpoint, to survival. Many of the following studies reviewed take the same approach, 
the comparison of two treatment modalities within a randomised controlled trial. 
Although the quality of life is a secondary endpoint in these trials and so is 
investigated to varying degrees, the absence of more descriptive data means that these 
studies me the major soui'ce of work available. The aim here was to review and 
critique the work that has been done.
The WHO definition of health (WHO 1947, WHO 1993) has been used to develop 
quality of life studies in cancer. In 1985 the Food and Drug Administration (USA) 
encouraged Quality of life to be an outcome measure in oncology clinical trials. This 
is a very salient point in that this work uses a clinical trial as a vehicle, and reflects the 
way that attitudes have changed in the UK with collaborative and commercial studies 
now also encouraging the use of quality of life as an outcome measure (for example 
the Medical Research Council 2000). This is supported by the fact that there was little 
dedicated literature prior to the mid 1980’s.
The impact of the FDA recommendations of the late 1980’s was apparent in the 
literature. Some form of quality of life measurement was included in most of the 
chemotherapy based clinical trials. It should also be considered that many of the
99published trials receive sponsorship or financial support from pharmaceutical 
companies although this is usually declared.
The meta-analysis performed on behalf of the Non Small Cell Lung Cancer 
Collaborative Group (NSCLCCG) concluded that pessimism in the treatment of 
NSCLC has turned to cautious optimism. This 1995 paper in the BMJ (NSCLCCG
1995)  was then updated as a Cochrane review in 2000. This review demonstrated the 
problem well as it showed that chemotherapeutic agents used in NSCLC have 
changed considerably since the 1980’s, from alkylating agents to platinum based 
therapies such as carhoplatin.
The most difficult problem with chemoiheiitpcutic agents is non-specificity. Most 
chemotherapeutic agents affect healthy tissue causing toxicity. Over the last eight 
years the introduction of the four “new generation” drugs may shift this outlook 
further. The new generation drugs, of which gemcitabine is one, use a novel approach. 
Gemcitabine is a pyrimidine antimetabolite rather than a true alkylating agent, and has 
a broad spectrum of anti tumour activity (Drabitsaris et al 2002). Theoretically this 
means that such compounds should be more tumour specific, have less side effects 
and more reversible toxicity. This has been further demonstrated by the UK 
Gemcitabine study that showed that although only 20% of patients had a response in 
tumour volume, it also showed 50% had improvement in symptoms (Anderson et al 
2000).
Based on the available evidence of the late 1980’s and 1990’s (up until 1998), the 
Clinical Oncology Information Network (COIN) published guidelines. These
100guidelines concluded that it was appropriate to offer chemotherapy to selected 
patients, usually in the context of clinical trials. The general consensus of most 
clinicians of the time can be summed up by the quote from the guidelines “strong 
evidence of only a modest effect on survival, with no clear evidence of benefit in 
terms of quality of life” (Macbeth 2000).
Subsequent authors commented on the “nilhism surrounding lung cancer in the United 
Kingdom” that such reports engender (O’Brien & Cullen 2000). In 1998 the so-called 
new generation drugs had not yet entered common usage in the UK, they were starting 
to ho used in clinical trials and so it could be argued that previous work supporting the 
nihilistic approach is even less valid.
In terms of patient preference, the Health Technology Assessment (Clegg et al 2001) 
of new generation drugs acknowledged that there was very little in the literature on 
which to anchor patient perception and attitudes to chemotherapy (Clegg et al 2001). 
This has resulted in seeking patient’s views from a patient support group, The Roy 
Castle Foundation. The Roy Castle Foundation operates a telephone support and 
information service, which receives approximately 100 calls per month. About 25- 
30% of these are from patients or carers seeking alternatives to best supportive care 
(Roy Castle Foundation personal communication with author 2003,2006).
101The opinions of those who contacted the helpline include the following:
•  If there is a possibility that chemotherapy could be beneficial, either by 
extending life or by maintaining quality of life, patients feel they should have 
the option of receiving this therapy
•  Patients are aware (from doctors, media, internet and others) that new drugs 
are available and may have activity against NSCLC and therefore offer hope 
in a condition in which outcomes are poor.
•  Faced with an incurable disease, worsening symptoms and a short life 
expectancy, sufferers do not feel that cost should be a factor in deciding 
treatment notions.
•  Inequality in access to therapies, which are available in ihc private sector and 
in other countries, is seen as unjust.
•  Patients often have the impression that their doctors believe that lung cancer 
has such a poor outlook that referral to a specialist oncology service is not 
worthwhile.
(Clegg et al 2001, Roy Castle Foundation personal communication with author 2003, 
2006).
One of the new generation drugs, Gemcitabine, is examined as part of this study. It is 
usually used in combination with another drug either Carboplatin or Cisplatin. These 
drugs are usually given as an intravenous infusion every three weeks (one cycle) four 
to six times on an out-patient basis. This is described in more detail in Chapter 3. This 
review identified several randomised controlled trials (RCT’s) which use gemcitabine 
in advanced non-small cell lung cancer but usually have survival and tumour response
102as a primary endpoint and quality of life assessment as a secondary endpoint. As seen 
previously, at present people with advanced (non operable) NSCLC have an 
extremely poor prognosis. Why then is quality of life only a secondary endpoint to 
these studies? Most trials offer poor survival benefits if any.
A number of these RCT’s are examined here but this is not a systematic review of the 
trials literature, excellent reviews have been performed both as Health Technology 
Assessments (Clegg et al 2001) and by the National Institute of Clinical Excellence 
(2005) from which guidance on the treatment of advanced NSCLC has been 
published. The trials included herein reflect die Ihwaturc at the  of the study, prior 
to the qualitative arm taking place.
In 1992 a study was published that set the tone for the use of chemotherapy in 
NSCLC. The use of cytotoxic chemotherapy in NSCLC has always been 
controversial, but the review identified a number of agents, such as Cisplatin, in use 
that were having a small impact of survival. Response rates to single agents were 
found to be approximately 20% and the authors felt unable to recommend single agent 
chemotherapy for NSCLC (Ihde 1992). As the 1990’s progressed more novel agents 
became available, such as Gemcitabine. In addition some clinicians were asking 
patients to become involved in combination chemotherapy (two or more cytotoxic 
agents). This change in culture has been slow, with many clinicians still reluctant to 
offer chemotherapy, often citing cost or side effects as the rationale.
103A study by the Joint Lung Cancer Study Group (Sweden) used the QLQ-30+LC17 
module as part of a RCT in advanced NSCLC examining best supportive care (BSC) 
Vs chemo (Carboplatin+Etoposide). Patients in the chemotherapy group reported 
better overall physical functioning and symptom control compared to the BSC group. 
Scoring in the psychosocial domains showed little difference. The chemotherapy 
group had a median survival of 29 weeks compared to the BSC group, which had a 
median survival of 11 weeks (one year survival 28% Vs 8%) (Helsing et al 1998).
The Joint Lung Cancer Study Group study was fairly typical in terms of methodology 
■ jil'A  findings. Such studies enrolled patients with advanced disease (Stage 3b or 4) 
who generally have a poor prognosis trom a medical pciapcciive. In a similar phase II 
study examining safety and efficacy ot a cispiaiiu-guucitabinc combination 
chemotherapy, the authors found little survival benefit but high efficacy in the 
palliation of symptoms reflected by the scoring of HRQL via the QLQ 30+LC 17 
(Krzakowski et al 2002).
Despite the FDA recommendations and the inclusion of some form of quality of life 
assessment in most trials, quality of life continues to have less relevance than the 
focus on survival or time to progression. A large review which pulled together much 
of the chemotherapy trials in NSCLC gives only brief reference to quality of life 
(Haura 2001), despite the fact that by definition all chemotherapy for advanced 
NSCLC is palliative (Spiro et al 2004).
Some studies in the literature focused on quality of life and treatment decision­
making. A recent study by Detmar et al (2002) examined the reasons for modifying or
104stopping chemotherapy in patients with advanced cancers. This study examined 
physicians self reported reasons for changes or cessation of chemotherapy using 
changes in health-related quality of life (HRQoL). Physicians reported that HRQoL 
was a major factor in decision making, The authors used audiotape to record the 
physician/patient interaction and found that although the physicians perceived that 
they used HRQoL as a guide to treatment decision making, in practice this was not so. 
In this study 70% of patients with no tumour progression or serious toxicity but with 
seriously impaired HRQoL continued on the original treatment plan (Detmar et al
2002). This disparity between perception/quality of life assessment by medical staff 
arid lived experience of patients undergoing palliative chemotherapy is not newly 
discovered (Hopwood and Thatcher 1990) however iiuic im* wliangcd in practice 
despite this knowledge.
This study used as a vehicle a chemotherapy trial and seeks to examine in greater 
depth the quality of life aspect of the study. The vehicle for this study was a 
randomised controlled trial and compares two combination chemotherapy regimens. 
The two regimens are the standard Mitomycin, Ifosfomide and Cisplatin and the 
experimental arm of Gemcitabine and Carboplatin and a full explanation can be found 
in the Methods chapter. The primary endpoint was survival and secondary endpoints 
were tumour response and quality of life.  This study was co-ordinated by the London 
Lung Cancer Group and funded by the Cancer Research Campaign (now Cancer 
Research UK). It has no commercial funding. In design it was comparable to many 
other studies which also use quality of life as a secondary endpoint however quality of 
life data was captured at more frequent intervals (daily) rather than periodically.
105With such a small survival benefit for such chemotherapy regimens this study was 
expanded to gain more insight by focusing on quality of life from a more qualitative 
perspective. It should also be considered when examining the trials based quality of 
life data and results, that methods of collecting quality of life data in this way has 
already been called into question, particularly the variability of data quality 
(Stephenson and Hopwood 2000). The FDA recommendations and available evidence 
(Clegg et al 2001) now require investigators to collect some form of quality of life 
data and, as some authors view it, at the cost of rigour (Stephenson and Hopwood 
2000) and some groups still choose not to collect HRQoL data (Georgoulias et al 
2091). In addition, the use of the most appropriate quality of life tool is paramount 
(Gunnars et al 1997).
In contrast to this perspective, some authors argued that assessing quality of life in the 
context of a study is an intervention in its own right with a therapeutic benefit as it 
offers an interaction to the patient that would not otherwise occur (Bernhard et al
1995). This issue was reflected in a study that compared self reported quality of life, 
using the EORTC QLQ 30, to compare quality of life to disease course and medical 
records (Velikova et al 2001). This study demonstrated that physical domain health 
related quality of life issued are noted in medical records but functional domain issues 
were recorded in between 1% and 25% of the notes and more often (20% and 76%) 
on use of the QLQ-30 (Velikova et al 2001).
Many of the past RCTs comparing combination chemotherapy in advanced NSCLC, 
including some assessment of quality of life have been subjected to review and meta­
analysis. A review that focused on the quality of life demonstrated the benefits of
106chemotherapy in terms of quality of life and asserts that there is no longer a 
convincing argument for not offering chemotherapy to patients with advanced 
NSCLC (Klatersky & Paesmans 2001). It should be noted that these studies once 
again focused on health-related quality of life using instruments such as the EORTC 
QLQ30+LC17 rather than global quality of life and this restricted the value of the 
perspective offered.
Among the numerous chemotherapy RCT’s where quality of life is a secondary 
endpoint were studies which examined the use of chemotherapy and the patients lived 
experience. These studies were few but as the emphasis towards global quality of life 
shifts, they may become more commonplace. Such siiuiicai vvcic Onvii boSCd Gil 2.  
patients own or projected experience of ciicmuibtiapy. This took the form of nfFpririo 
patients a number of scenarios, for example, x weeks survival against y degrees of 
toxicity. Asking patients to project what they would find acceptable or unacceptable 
seems counter intuitive in terms of methodology but in fact is the reality of clinical 
practice.
The choice between accepting and rejecting chemotherapy for patients with advanced 
NSCLC is an exceptionally difficult one. In the study by Tamburini (Tamburini et al 
2000) four groups were given three scenarios projecting survival and toxicity of 
receiving chemotherapy. The groups were made of patients with NSCLC (n=104), 
patients with benign respiratory disease (n=129), healthcare workers (n=140) and 
students (n=120).
107The scenarios presented were optimistic neutral or pessimistic Relative to the other 
groups the NSCLC patients showed a consistently higher degree of uncertainty about 
whether to accept or reject chemotherapy. The NSCLC group also had the lowest rate 
of acceptance of the optimistic and neutral scenarios and in contrast the highest rate of 
acceptance of the pessimistic scenario. The NSCLC group also had the highest 
percentage of constant answers, independent of the scenario presented, particularly 
the answer “I don’t know” (Tamburini et al 2000). An earlier study (Silvestri 1998) 
stands out in the literature as it uses scirpted interviews to determine to what extent 
patient's would “trade off” between survival and toxicity (n=81). In this study the 
authors found that patients varied in what they would be willing to accept in terms of 
toxicity (the usual outcome measure in HRQoL). Several patients would accepi 
chemotherapy for a survival benefit of one week while others cnose noi 10 acccpi 
chemotherapy for a survival benefit of 24 months. The median survival threshold for 
accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe 
toxicity. Most patients would not choose chemotherapy for the survival benefit of 
three months but would if it improved quality of life, however the authors did not say 
how or if they determined what an acceptable quality of life would be (e.g. possible 
gains of survival were measured in units of time, but potential quality of life not 
assessed, benefits in treatment were measured as benefits in survival) (Silvestri et al
1998).
Although the work of Silvestri et al (1998) does have limitations, assessment of 
quality of life in this setting would allow clinicians and patients to effectively discuss 
the trade offs when considering various treatment options, particularly those which
108are perceived to have little benefit in terms of survival such as chemotherapy 
(Hopwood 1996, Grilli et al. 1993, Silvestri et al. 1998).
As gemcitabine is a third generation drug, comparisons (usually as RCT’s) with older 
regimens or best supportive care contributed heavily to the literature. As third 
generation drugs have only been in use for about seven years in the UK, including on 
a trial basis, this has limited the amount of literature, examples of which are given in 
Table 2.4.
109Table 2.4 Specific RCTs using Gemcitabine in advanced (Stage Ilia inoperable, Stage 
Illb and IV)
Author (Year) and 
study details
Pemg et al 1997 
GEM Vs CIS+VP  open 
RCT n=53 No support 
declared
Adverse events 
•  -
Tumour response and survival 
Survival GEM 37 weeks 
CIS+VP 48 weeks 
No QoL data collected  _____
CIS+VP arm, higher 
toxicity for 
Haematology, nausea 
and vomiting_______
iiii
Bokkel-Huninik et al 
1999
GEM vs CIS+VP open 
RCT n=147 Supported 
by Eli Lilly & Co
Tumour response and survival 
Survival (median) GEM 6.6 
months, CIS+VP 7.6 months 
QoL (QLQ-30+LC13) no 
significant change from baseline 
in either arm
Grade 3-4 toxicity 
recorded 
in both arms
Cardenal et al 1999
GEM+CIS Vs VP+CIS 
n— 135 Supported by Eli
T illv  Xr Or*
Tumour response and survival  Grade 3-4
Survival (median) GEM 8.7 
months, VP 7.2 months 
rvii  rm n  in+T r i 'n kr»th
V .   v  • ''* - *   '  *  v '  /   * ’*'v
groups saw improvement in
nain  rmioh  haem nntvsR  Nn
improvement in dyspnoea in 
either arm
haemato  logical toxicity,
oraHr A r.pirtrfwvmis
O- - - - - - - - - - - - -       J T
twirv* 35 ViiaVim  VP arm
Crino et al 1999 
GEM+GIS Vs MIC 
n=307 No support 
declared
fumour response and survival 
Survival GEM+CIS 8.6 months 
MIC 9.6 months 
QoL (QLQ-30+LC13) worse 
alopecia in MIC arm less pain in 
GEM+CIS. Both arms record 
improvement in insomnia and 
cough. Not significant difference 
in arms
Haematological toxicity 
in both arms. Grade 3-4 
nausea and vomiting in 
MIC 
Arm
Anderson et al 2000 
GEM + BSC Vs BSC 
Open RCT n=300 
Supported by Eli Lilly 
& Co
Tumour response and survival 
Survival (median) GEM + BSC 
= 5.7 months
BSC alone 5.9 months QoL
(QLQ-30+LC17) at 4mths >10%
improvement
in many domains for GEM
group
Low 3-4 toxicity 
Nausea & vomiting 
Lethargy, 
myelosuppression 
Flu like symptoms in 
GEM arm
Continues overleaf
111Sandler et al 2000 
GEM+CIS Vs CIS open 
RCT n=522 Supported 
by Eli Lilly & Co
Tumour response and survival 
Survival (median) GEM+CIS 
9.1 months CIS 7.6 months 
QoL (FACT-L) Both arms noted 
decrease in HRQoL
Higher rate of 
haematological toxicity 
in
GEM+CIS arm
Georgoulias 2001 
Docetaxel+Gemcitabine 
Vs Docetaxel+Cisplatin 
n-=406 Supported by 
Aventis
Tumour response and survival 
Survival (median) 
Docetaxel+CISlO months 
Docetaxel+GEM 9.5 months 
No Q oL assessment
Increased toxicity 
associated with 
Docetaxel arm
Jassem et al 2002 
Gem+Cis 
phase II n=80
Tumour response and survival 
(Complete response in 7%) 
Survival median 11 months 
QoL QLQ-30+LC17 
improvements in many physical 
domains
Grade 3-4
haematological
malignancy
Danson et al 7003 
MIC Vs GEM CARBO 
N=372 sunnorted 
Eli Lilly & Co
Tnmrmr resnnnce anH cnrvival
Survival (median) MIC/MVP 
248 days  GF.M+CARRO 736 
days
QoL QLQ 30+LC 17/13 High 
attrition rate
Grade 3-4
Haematological toxicity
Greater aloneeia in MTG 
arm
Rudd et al (2005) 
MIC Vs GC 
N=422
Tumour response and survival 
Median survival MIC 7.6 
months GEM+C ARBO 10 
months
QoL QLQ 30+LC 17 as 
discussed herein
Grade 3-4
Haematological toxicity 
Greater alopecia in MIC 
arm
Table 2.4 Specific RCTs using Gemcitabine in advanced (Stage Ilia inoperable, Stage 
Illb and IV) (continued)
The quality of life assessment is a secondary or tertiary endpoint and even omitted in 
some studies.
112In recent randomised controlled trials from the last fifteen years quality of life has 
been recognised as being a factor, and in at least one trial, the primary endpoint. The 
study by Anderson (Anderson et 2 d 2000) compared gemcitabine to best supportive 
care (BSC). This RCT used the EORTC QLQ-30+LC17 and also the SSI4 symptom 
scale. The QLQ 30 was used at two and four months to test 25 variables (QLQ used at 
every cycle, e.g. every four weeks). Of these 25 variables, six showed improved 
scores of > 10% at two months. Five of these were in the gemc;tabine arm and one in 
the BSC arm. Five of the twenty-five variables showed a 10% or greater decrease in 
quality of life, three of these were from the BSC arm and two m the gemcitabine arm. 
After four months six variables showed a 10% or greater increase in quality of life 
scores, all in the gemcitabine arm. Four variables showed a decrease in quality of life 
of 10% or more and three of these were in the BSC group (with alopecia being the
r t A t Y ^ O l f o K l r > P   i r o n o K I a )   A n   i m n m i r A m A n t   n r o o   W ,r  T O O /.
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and 24% BSC patients at two months, followed by 44% of gemcitabine group and 
25% BSC group at four months. At six months overall improvement was seen by 31% 
gemcitabine patients and 22% of the BSC group. (Anderson et al 2000).
This study By Anderson et al (2000) is encouraging in that quality of life is an 
endpoint and the breadth of the assessment undertaken, but the study lacks detail as to 
what exactly BSC consists of. Best supportive care by its nature is palliation of 
symptoms and some of these techniques such as analgesia using opiates and palliative 
radiotherapy are very effective in terms of symptom control (LASLC 2000). The use 
of BSC usually applies to the experimental group as well as the control (to do 
otherwise would be unethical), however the use and type of BSC used is not included 
in the paper. Another RCT compared gemcitabine vs cisplatin+etoposide reporting
113quality of life with the EORTC QLQ-30+LC17, and demonstrated no significant 
difference in the two groups after six cycles (approx five months) of treatment, only in 
one domain (alopecia) in the cisplatin group showed a reduction (Bokkel-Huninik et 
al 1999). A similar study using gemcitabine+cisplatin Vs cisplatin+etoposide also 
using the QLQ-30+LC17, found no change from baseline in functional or global 
domains, but improved symptom scores such as cough, pain, insomnia and 
haemoptysis. There was no change in dyspnoea and there was an expected decrease in 
the symptom domain for alopecia in the etoposide group (an expected side effect of 
the drug) fCardenal et al 1999).
In a siudy similar to the one that is the vehicle for this study, Crino et al compared 
sviiiwiauuicTciapiiuiii vs. IvilC ^miiomycin, itostomide and cisplatin). quality of life 
was reported using the OLO-30+LC175  and once again, no significant dixjLviwuw 
found between the two groups, apart from alopecia in the MIC group (Crino et al
1999). However, there was some decrease in physical functioning and worsening of 
nausea but improvement in pain, insomnia and cough. Sandler’s group compared 
gemcitabine+cisplatin vs. cisplatin using FACT-L to measure quality of life. They 
found no significant changes at all from baseline (Sandler et al 2000) but this could be 
because the FACT-L tends to focus on symptoms rather than global or HRQoL.
In a later phase II study, Jassem and co-workers (Jassem et al 2002) used quality of 
life as an endpoint using the QLQ-30+LC17 in combination therapy, 
gemcitabine+cisplatin, in a group of 80 patients with NSCLC. In common with most 
of the chemotherapy regimens Jassem’s group found common toxicity of grade 3-4 in 
myelosupression, but improved domains in global (22%), functional (19-37%),
114dyspnoea (36%), fatigue (45%), chest pain (38%) haemoptysis (77%) and cough 
(44%). It is unclear if there is any decrease from baseline in this study however as this 
data is not included and also as it is a phase II open trial, there is no control group for 
comparison (e.g. BSC).
An important point to consider when evaluating these studies in the context of quality 
of life is the amount of detailed information on the elements of BSC given. It is 
standard practice (IASLC 2000) to palliate symptoms with drug therapy and 
radiotherapy (eg, pain, breathlessness etc) in lung cancer but little information, if any, 
is given on the method and frequency of use, or non use. in any of the studies 
mentioned above,  i his must be considered when assessing the perceived benefit of 
palliation by chemotherapy. The aim ot the studies examined was to bring better 
therapeutics into practice. As a range of quality of life assessments are used this 
makes direct comparisons between studies difficult
The main criticism of oncology quality of life assessment in the context of trials in 
particular, is the firm grasp of the functional that dominates these studies. QOL in 
cancer is still rooted in functionalism and biomedicine prevails. The vast majority of 
studies use nomothetic measurements of quality of life (Bowling 1997). This 
approach may be dismissive of what is important to patients and its continuance to the 
expense of other methods will be at great cost to clinicians, researchers and patients.
115Chapter 3 
Methods3 Aims and methods of the study
The aim of this study was to examine quality of life, and the meaning of “quality of 
life” in patients receiving platinum (Cisplatin/Carboplatin) combination chemotherapy 
for advanced Non small cell lung cancer (NSCLC).
The original aim of the study was to collect quantative and qualitative data and to 
perform a comparison. As this study has evolved a revised methodology was required 
to analyse the data generated. The review in Chapter 2 demonstrates the difficulty in 
defining quality of life and a direct comparison in the light of this would be 
unrealistic. The futility of direct comparisons of the data in a purely empirical context 
is also demonstrated in the results chapters 4, 5 and 6.
In order to examine the meaning and interpretation of the term “quality of life” in 
patients receiving platinum based chemotherapies for advanced NSCLC two principle 
methods of data collection were employed.  Data collection consisted of HRQoL data 
in the form of the EORTC QLQ 30+LC 17 and in addition interview data with 40 
patients undergoing palliative chemotherapy for advanced NSCLC. Data from the 
EORTC QLQ 30+LC 17 was analysed using the EROTC CD ROM package. In 
addition a manual mathematical operation was performed on the HRQoL data. Data 
from the interviews was analysed using content analysis. Both of these methods are 
described herein.
117Content analysis is a quantification of qualitative data (Silverman 2001) and so the 
data generated from both components of the study is ultimately quantative. After 
communication with experts in the field, a revised methodology of grounded theory 
was considered but as most of the work, such as the literature review, had already 
been done this was considered inappropriate. However elements of grounded theory 
and positivism are comparable in terms of theory generation. This is considered in the 
concluding chapters and the philosophy of grounded theory and empirical positivism 
are considered here.
Fieldwork began approximately 18 months before the start of the interviews, and three 
months prior to registration for a higher degree. Participant observation and reflection 
in practice of the decision making process in the Lung Cancer Multidisciplinary Team 
(MDT) Meetings across several North London Hospitals occurred. Such meetings are 
the cornerstone of care delivery in the cancer modernisation agenda but many teams 
already used the format prior to 2000.
The clinic fieldwork coincided with this. It was an observation by the researcher prior 
to the commencement of the study that patients in clinical trials were required to fill in 
EORTC QLQ 30 questionnaires, but that in different tumour/prognosis groups 
different concerns were vocalised.
118The researcher worked in practice with three patient groups at the time of this 
observation-approximately 120 patients per year. The three patient groups were those 
with ovarian, colorectal or lung cancer. Patients with ovarian or colorectal cancers 
were receiving adjuvant chemotherapy regimens and had a good prognosis. These 
patients expressed concerns or wished to discuss topics in practice that were reflected 
in the functional nature of EORTC QLQ 30, such as working, symptoms, side effects 
of treatment and meeting the deficit of activities of daily living.
Lung cancer patients who were receiving chemotherapy with a stated palliative intent 
appeared to express a much wider variety of concerns in practice that were not 
reflected in the quality of life instrument such as issues around death and dying, 
serious and sudden impairment of social function, psychological distress including 
suicidal ideation, trust issues with staff or issues around collusion.
These observations lead to an initial review of the literature, which yielded little in 
NSCLC populations apart from the drug-based studies reviewed herein. Continued 
observation of the MDT meetings as a participant in practice and as part of on-going 
audit process along with further review of the literature revealed a lack of study into 
this aspect of quality of life. The omnipresence of HRQoL in lung cancer in the 
literature was not supported with any qualitative data, and the sensitivity/validity data 
offered for the HRQoL measures were normothetic as has been seen (Bowling 1996).
119What is apparent from the cancer literature, including the lung cancer literature 
reviewed in Chapter 2, is the exclusivity of qualitative or quantitative data presented 
in studies. This can be for many reasons but the growing recognition of cancer care as 
a multiprofessional activity (DoH 2000a) requires a multifaceted approach to enquiry 
in an area as subjective as quality of life.
The research problem is lack of knowledge reflected in the literature and therefore in 
clinical practice and this can be addressed as two specific research questions; in this 
case “What do patients receiving chemotherapy for NSCLC consider to be factors 
affecting quality of life?” and “What is the meaning of quality of life to these 
individuals?”
Outcomes based research as opposed to purely experimental design is now becoming 
more prominent in the study of palliative oncology in order to learn about the social 
construction and subjective experience of cancer-for the seriously ill person there is 
unlikely to be one objective “truth”. This kind of work can facilitate the understanding 
of a social phenomenon (such as the lived experience of having chemotherapy for 
advanced NSCLC) in natural rather than experimental settings (Strang 2000).
1203.1  The comparative nature of grounded theory and relationships with scientific 
positivist tradition.
The construction of a theory, which is grounded in data from various sources, has 
been an established method in social science research since the 1960’s. In addition to 
the interview studies, observational field notes and reflections in practice were also 
influences in the data collection and synthesis process.
The literature offers two approaches to what is termed “grounded theory” as the two 
founders (Barney Glaser and Anselm Strauss) diversified the application and use of 
the theory (McCann and Clarke 2003). The approach adopted here is sympathetic to 
the one developed by Strauss and Corbin (1998) which favours an active approach by 
the researcher. It was not possible to adopt Glaser’s independent approach in this 
study due to the researchers own experience with the patient group and professional 
relationships have already been established, hence the influence of being a participant 
and actively involved in audit of the service.
Comparison is at the heart of the process of grounded theory. The interview data is 
compared as per the methods, and this in turn is compared to the literature and the 
field notes. In addition the coding of the interviews produces many margin notes and 
all of these are used, in comparison, to locate an emergent theory. In positivist 
traditions, theories unify, they go “beyond, beneath and behind” phenomena that 
empirical study reports (Rosenberg 2000). Both grounded theory and positivist 
tradition rely on emergent theory generated by synthesis and examination of
121phenomena, despite the utilisation of different methods. From the literature there is an 
almost tangible sense of incompatibility between science and the humanities.
However the examination of phenomena tolerates the philosophy of either 
perspective. Many of the social science texts seem to equate scientific rigour with the 
reproducibility of controlled experimentation.  Science is much broader concept than 
this- science is the acquisition of knowledge about the world (Diamond 2005). The 
nature of grounded theory and positivist traditional and determinism are actually 
closely linked in this way-the generation of theory (by different rigorous techniques) 
that examines phenomena.
Unlike the reductionist principles employed by science and medicine, which are 
prescriptive about the presentation of data, the presentation of data which is gained 
from a mixed method study with a large qualitative input which is then subject to 
quantitative analysis can tolerate a more flexible approach. It is for this reason that the 
rest of this work is formatted thus. This is not at the cost of rigour but simply because 
the huge amounts of data generated support a theory and the difference in collection 
methods mean that each study will have unique aspects of presentation, particularly in 
terms of narratives which are used to illustrate experience (Silverman  2003).
By using a mixed method approach the aim was capture data that was not available to 
QOL researchers previously in this area. As Strauss and Corbin note (Strauss and 
Corbin 1998) much of what is termed “qualitative research” is qualitative techniques 
such as observation and interview, which is then quantified. This study is no 
exception to that. Content analysis of the interview data is the primary form of data
122analysis in this study; this is a reflection of the inexperience of sociological research 
methodology and training in scientific method of the researcher.
The author’s initial observations of different patient groups using the available tools to 
“measure” quality of life generated an inconsistency within clinical practice- 
empiricism apparently had failed in this situation but this does not mean the failure of 
positivistic approach. In grounded theory, the researcher begins with an area of study 
and allows the theory to emerge from the data. As grounded theory has developed it 
has attained an increasingly rigorous approach and this can be seen from the literature. 
It would have been a useful method to use in the context of this study-the exploration 
of the comparative data collection techniques and the resulting data would add 
dimension. The approach taken in this study has elements of the philosophy of 
grounded theory and positivism embedded in it.
Objectivity from the materials is required for fair representation of the data. The 
intention of the study was to interview participants using the topic guide (Fig 3.1) 
until saturation.
Unlike reductionist methods, objectivity does not mean controlling variables, but 
being open, a willingness to listen and the ability to “give voice” to the respondents 
(Strauss and Corbin 1998). In addition the use of both the technical and non-technical 
literature is required to give an overall perspective. Narratives from respondents were 
subjected to content analysis. This was done manually due to budgetary constraints 
and a coding strategy was developed and applied to the verbatim transcriptions. The
123addition of the qualitative data allows some shift of focus (Bowling 1997). The 
quantified, qualitative data will add another dimension in this way.
3.2 Selection and treatment
This study primarily uses as a vehicle, a multicentre randomised controlled trial 
(Study 11 London Lung Cancer Group, since published as Rudd et al 2005) that 
compared two chemotherapy regimens in NSCLC. The sample size of patients chosen 
by the investigators (the London Lung Cancer Group) was 387. This was judged to be 
the minimum size for measuring toxicity and quality of life and for detecting any 
significant shortfall in terms of survival for the trial group.
The regimens were Mitomycin/ Ifosphomide/ Cisplatin (MIC) as a standard treatment 
arm versus Gemcitabine (diflurodeoxycytidine)/Carboplatin (GC) as trial therapy. At 
the time of the study, Carboplatin was not licensed for use in NSCLC and therefore a 
DDX licence was applied for and granted. The treatment was as follows: (London 
Lung Cancer Group 1999)
GC 21 day cycle:
Gemcitabine 1200mg/m2  IV day 1  and day 8 
Carboplatin (AUC 5) in mg IV day 1
MIC 21 day cycle:
Mitomycin 6mg/m2 IV day 1  
Ifosfomide 3g/m2 IV day 1  
Cisplatin 50mg/m2 IV day 1
124In addition: Pre-medication with 3mg IV Granisetron and 8mg IV Dexamethasone day 
1  with Metaclopramide 20mg 8 hourly pm (as required) post chemotherapy anti­
emetic regimen was administered. This was altered depending on clinical 
indication/patient preference. Prophylactic antibiotics (oral) were also give day 8 to 
day 21 of each cycle to minimise risk of neutropenic sepsis and respiratory infection. 
The choice of antibiotic was left to the discretion of the clinician. Four treatment 
cycles are given in total.
Eligibility Criteria
Patients were eligible to enter the study if they were over eighteen years of age, able to 
give informed consent for both the chemotherapy study and the extended quality of 
life study, had adequate bone marrow function as assessed by full blood count 
including white cell differential, adequate renal function allowing the administration 
of platinum based chemotherapy by biochemical investigation and creatinine 
clearance or glomerular filtration rate. Patients were excluded if life expectancy was 
less than eight weeks, not fit for chemotherapy because of concurrent medical 
conditions or had symptomatic brain metastasis which required immediate 
radiotherapy or raised issues around consent. All patients had a confirmed histological 
or cytological diagnosis of NSCLC.
Both male and female patients were eligible. Each patient received a written 
information sheet prior to consenting (Appendix B). The local regional ethics 
committee for University College Hospitals London (NHS Trust) approved each part 
of the study. As the group was extended past the original Study 11 group, the 
sampling emphasis became more qualitative (Chapters 5 and 6).
125In order to assess quality of life in patients with NSCLC, two methods of data 
collection were utilised: Self completed questionnaires and open-ended interviews. 
Each patient was asked to self-complete the EORTC QLQ-30 V ersion 3 with the 
attached LC 17 lung module (EORTC 1995)(Appendix A) before randomisation and 
at the first follow-up visit. The first follow up visit is at the end of cycle four. The 
timing of this visit is dependent on chemotherapy toxicity but was scheduled to be 4- 
5months from randomisation. This tool was chosen as it has been validated (Bergman 
et al 1994, ibid).
Patients were monitored by pre-chemotherapy assessment of toxicity (of the previous 
cycle) using the Common Toxicity Criteria (CTC Appendix C) (LLCG 1999), 
including haematological and biochemical, and haematological toxicity at nadir (day 
10 of each cycle). Supportive care was given if required, to treat toxicity or for the 
palliation of symptoms, for example blood transfusion for the treatment of 
chemotherapy induced anaemia. Disease assessment in the form of chest x-ray was 
also performed prior to each cycle and CT scanning and/or assessment of metastatic 
sites as clinically indicated. Patients were also given palliative radiotherapy if 
clinically indicated at any point in time, for example the treatment of haemoptysis or 
pain control. Serious adverse events such as febrile neutropaenia, which requires 
intravenous antibiotics, were reported to the investigators.
Basic demographic data was collected such as sex, age and occupation or previous 
occupation if retired, educational level, changes in occupational pattern since
126diagnosis and self selected ethic-grouping data. The length and location of the 
interviews was also recorded.
In addition to the QLQ 30+LC17, semi-structured face-to-face interviews were used. 
Interviews were the chosen methodology as they allow flexibility in response and 
allow for probing and follow up questioning (Bell 1999). The aim of the interview 
was to elicit information and to examine issues that arose which were not evident 
from quality of life outcome measures.
Sampling for the interview study was performed via a cross sectional approach 
(Baruch 1981). However after interviewing 10 participants saturation was becoming 
apparent. The themes from the patient narratives indicated that some contamination 
may have occurred as the researcher had clinical responsibility for these patients. To 
increase objectivity patients were interviewed (n=40) for whom the researcher had no 
clinical responsibility. As the study of the phenomena is the aim, sampling is 
conducted to a different methodology. In outcomes based research the aim is often not 
to draw a representative sample at random from a population, but to identify certain 
groups or individuals who experience circumstances relevant to the phenomenon 
being studied (Mays and Pope 1996).
Approaching the area of qualitative research entails defining some parameters to 
ensure rigour. It has been seen in Chapter 2 that quality of life is a subjective, complex
127and an empirically difficult phenomenon. This means that unlike the reductionist 
methodology of measuring the objective, concepts must also be considered in 
consideration of the subjective.
Interviews are a the most common way of collecting talk (Payne 1997) and qualitative 
research method is concisely, if simply, summarised by Peter Strang in Fig 3.0 (Strang 
2000)
Fig 3.0 The steps included in an interview study (Strang 2000)
1. Thematizing
2. Designing
3. Tape recorded interviewing
4. Transcription (plus field notes)
5. Naive reading to gain an overall picture
6. Preliminary themes and coding (decontextualisation)
7. Comparison of codes and categorisation of data
8. Detailed analysis of data
9. Condensation of data
10. Recontextualisation
The interview is a recognised methodology in eliciting information (Moser and Kalton 
1971). The framework of questions used to guide the interview was based on 
preliminary data gathered in clinical practice, where the disparity between the topics 
of patient led therapeutic conversation and the items used by outcome measures first 
became apparent. This constituted pre-test.
The interviews for this study used five questions as a guide. These are shown in Fig
3.1
Fig 3.1 Five questions used to facilitate the face-to-face interview.
128What do you consider to be a good quality of life? (expand/paraphrase to “What 
makes life good?)
What do think affects your quality of life most? (expand/paraphrase to “What things 
affect your life?”)
How has having lung cancer affected you?
How has chemotherapy affected your quality of life? (expand/paraphrase to “How has 
chemotherapy affected how you feel/what you do?)
Do you think having chemotherapy was worthwhile?____________________________
This was to allow for greater flexibility in response, and also to allow for variations in 
literacy ability and allowed for the inclusion of patients who would be excluded from 
the questionnaire study due to inability to read English.
Open questions were used and those given in Fig 3.1 served to facilitate the interview. 
However deviation from the format was permitted to capture a wide range of 
responses and allow for focus in the interviews at the indication of the respondent.
The interviewer aimed for a neutral approach however interaction by the interviewer 
was also permitted if appropriate, for example areas of sensitivity such as expressed 
anger or anticipatory grief.
The aim of the interview was to elicit subjective responses such as perception of 
quality of life and narratives of the experience of undergoing chemotherapy for 
advanced lung cancer-essential ly how do people undergoing treatment for advanced 
lung cancer construct quality of life? (Silverman 2003).
The interviews were tape-recorded with the permission of the respondents and took 
place in the patient’s own home or that of the patient’s relative/carer. This allowed for 
a question and answer format to transform in to a more conversational style.
129Patients taking part were assured of their anonymity that and no data gathered via the 
interview would be passed on to the clinical team except with the explicit wish of the 
respondent.
The interviews were transcribed verbatim and underwent content analysis (Silverman 
2003, Krippendorf 2004)). These data were then analysed using manually using Excel 
and coded by the author alone due to limited resources. These themes were elicited 
using key words and phrases (for example worry/worried/worrying) and for narratives 
(Strang 2000)
1303.3 Content Analysis of the interview data
Content analysis, sometimes referred to as textual analysis, is a standard methodology 
in the social sciences on the subject of communication content. Lasswell (1965) 
formulated the core questions of content analysis: "Who says what, to whom, why, to 
what extent and with what effect?". Holsti (1969) offers a broad definition of content 
analysis as "any technique for making inferences by objectively and systematically 
identifying specified characteristics of messages".
Content analysis enables the researcher to include large amounts of textual 
information and identify systematically its properties such as the frequencies of most 
used keywords and phrases by detecting important structures (Silverman 2001). Such 
amounts of textual information must be categorised according to a certain theoretical 
framework, providing at the end a meaningful reading of content. The creation of 
coding frames is inseperable to a creative approach to variables that exert an influence 
over the content of the text
Lasswell propses that every content analysis should depart from a hypothesis 
(Lasswell 1965). As an evaluation approach, content analysis is considered to be 
quasi-evaluation because content analysis judgments need not be based on value 
statements. Instead, they can be based on knowledge. Such content analyses are not 
evaluations. On the other hand, when content analysis judgments are based on values,
131such studies are evaluations (Frisbie, 1986). There is certaily an element of evaluation 
in this study as the narratives are also examined in the context of the textual content.
The responses from the semi-structured interviews were open coded. Collecting data 
in this way can give a great deal of insight (Bowling 1997) Coding was done by using 
key words in context (KWIC) and key phrases (Krippendorf 2004) and subjected to 
tabulation.
Root codes elicited from analysis and tabulation of interview data are given below:
Preliminary root codes:
•  Communication
•  Psychological wellbeing
•  Physical wellbeing
•  Family and significant others
•  Health behaviours
•  Spirituality
•  Patient experience
•  Lifestyle changes
Repeated tabulation is a method of achieving validity in content analysis and was used 
in this study. Data was repeatedly tabulated by the researcher to elicit and then 
validate root and eventually, branch codes.
1323.4  Method of analysis-HRQoL EORTC QLQ 30+LC 17 data 
The EORTC QLQ 30 is composed of both multi item scales and single item measures. 
These are grouped as domains and include three symptom scales, a global health 
status question, five functional scales, and six single items. High scores represent high 
levels of response and so a high score for function indicates a high level/healthy 
function, however a high symptom score represents a high level of that symptom.
The principle for scoring is the same in all-estimate the average of items that 
contribute to the scale (this is the raw score) as: (if for example items 1,2,3)
RawScore RS = (Ii+l2+l3....I„)/n
and then use a linear transformation to standardise the raw score (0-100).
Functional scales:
s = ri-(Rs-ni ioo
[  range  ]
Symptom scales and Global status:
S = [(RS-l)/range] 100
Range is the difference between the maximum and minimum possible value of RS
The scoring table for the EORTC QLQ 30 Version 3 is shown in Fig 3.2 as shown in 
the EORTC Scoring Manual (Fayers et al 2001).
133The linear transformation performed on the raw score as described above was 
performed within a scalar range (this data represents scalar permutations).  A linear 
transformation is a function between two-vector spaces-it preserves linear 
combinations (Boas 1983). In the language of abstract algebra a linear transformation 
is a homomorphism of vector spaces.
Taking as definition and first consequences (in this proof only the homogeneous 
linear transformation is shown-other transformations are possible but not of relevance 
in this study):
/(x+y) = /(x) + /(y)  (additivity)
/(ax)=  a/(x)  (homogeneity)
=/ preserves a linear transformation, that is for any vectors xi„..xm  and any scalars 
aj... .mi the equality:
/(ai Xi+...,+am xm )= ai /(x,)+.. .+am /(xm )
holds. Thus a scalar linear transformation within a scalar range-it indicates one point. 
(Boas 1981). This means that multiple data can be expressed as one integer.
134Figure 3.2 The EORTC QLQ 30 Version 3 range and corresponding item domains.
Scale Number 
of items
Item
range*
Version 3,0 
Item numbers
Function
scales
Global health status / QoL
Global heahh status QoL (revved/ QL2 2 6 29, 30
Functional scales
Physical functioning (revised/ PF2 5 3 I to 5 F
Role functioning (revised/ RF2 2 3 6,7 F
Emotional functioning EF 4 3 21 10 24 F
Cognitive functioning CF 2 3 20, 25 F
Social functioning SF 2 3 26, 27 F
Symptom scales / items
Fatigue FA 3 3 10, 12, 18
Nausea and vomiting NV 2 3 14, 15
Pam PA 2 3 9, 19
Dyspnoea DY 1 3 8
Insomnia SL 1 3 11
Appetite loss AP 1 3 13
Constipation CO 1 3 16
Diarrhoea DI 1 3 17
Financial difficulties FI 1 3 28
*Item range is the difference between possible maximum and minimum vales or 
response to items (most take values ffom 1-4 hence range is 3)
Revised ffom Version 1.
The Lung Cancer Module consists of 13 items specific to that disease. Scoring the 
Lung Cancer Module (LC13 or 17) is done using the same mathematical operation 
and the module is shown in Fig 3.3.
135Figure 3.3 The Lung Cancer module used in conjunction with the QLQ 30 for the
Scoring Manual (note the LC 13 and 17 are identical modules)
Scale name Scale Number 
of items
Item
range*
QLQ-LC13  . 
Item numbers
Symptom scales / items
Dyspnoea’ LCDY 3f 3 3,4,5  X
Coughing LOCO 1 3 I
Haemoptysis LCHA 1 3 2
Sore mouth LCSM 1 3 6
Dysphagia LCDS 1 3 7
Peripheral neuropathy LCPN 1 3 B
Alopecia LCHR 1 3 9
Pam in chest LCPC 1 3 10
Pain in arm or shoulder LCPA 1 3 11
Pain in other parts LCPO 1 3 12
*  “hjsn range'' is the difference between the possible maximum and the minimum response to individual items, 
t  The dyspnoea scale should only be used if all three items have been answered  Some respondents ignore question S 
because they never climb stairs; in this case, the score for the dyspnoea scale would be biased if it were based upon
the other two items  Hence if item 5 is missing then items 3 and 4 should be used as single-ilem measure*.
This data can be handled using various statistical packages that are commercially 
available. This study utilised the data handling package designed by the EORTC to 
manipulate and analyse these data. Much of this analysis was verified manually to 
ensure no systematic errors were in place and to explore the possibility of comparison 
with the interview data..
In addition, to elicit any possible comparisons the linear transformations were 
repeated on the raw scores at the most basic level. Initially the researcher intended to 
obtain a raw score from each respondent by administering the EORTC QLQ-30 at 
time of interview due the change in study group (i.e. interviewing outside of the 
Study 11 group) but 40 exclusive questionnaires did confer enough power for the
136required mathematical operation. This meant a return to the original Study 11 data 
raw scores, which were then re-examined and were robust enough for the required 
serial linear transformation as described.
3.5  Summary
As a mixed method is used in this study it is important not to loose sight of the aims. 
This study is a clinical study and primarily based on the experiences, feelings and 
social context of the patients who undergo treatment for advanced NSCLC. The aim 
of the study is not to generalise to an entire population with these data, but to 
understand the experience this group. As has been seen in Chapter 2, patients 
experience cancer as a joumey-this cannot be measured purely in terms of tumour 
response or survival but it is hoped that the findings of this study in context will 
influence the researcher in practice:
“Although we do not create data, we create theory out of data. If we do it correctly 
then we are not speaking for our participants but rather we are enabling them to speak 
in voices that are clearly understood and representative. Our theories, no matter how 
incomplete, provide a common language, a set of concepts, through which research 
participants, professionals and others can come together to discuss ideas and find 
solutions to problems. Yes we are naive if we think we can “know it all”. But even a 
small amount of understanding can make a difference”  Strauss and Corbin 1998
The methods described herein have generated enormous amounts of data, which are
discussed in the following chapters.
137Chapter 4 
Results4 Results
The results presented in this chapter consist of the two streams of data central to this 
study. The interview study data and the QLQ 30+LC 17 data were subjected to the 
mathematical operations described in Chapter 3 to elicit comparative factors. As the 
content analysis of the interviews also includes the use of narratives, much of the data 
generated by the interview study is examined in Chapters 5 and 6.
Data collected from the EORTC QoL Questionnaire with LC-17 module for lung 
cancer is presented below. The EORTC QLQ 30+LC 17 is included in Appendix A. 
EORTC QLQ-C30 + LC17 Raw data collected by the London Lung Cancer Group is 
shown here as it was subsequently subjected to the mathematical operations described 
in Chapter 3 to elicit any comparable factors between the QLQ 30+LC 17 and content 
analysis of the interviews.
The demographics from both the LLCG Study 11 group (source of HRQoL data) and 
the interview study (source of content analysis data) are given here.
1404.1  Patient demographics for both data sources 
Patient demographics of  the interview study
The nature of  this study and the theoretical approach taken means that  full results are 
given in context within the Discussion (Chapters 5 and 6)
Respondent demographics of the interview study are as follows:
28 males and 12 females interviewed 5 EFL (Greek, Turkish, Spanish and 
Portuguese) 8 considered themselves as from a BME origin 
Mean age was 54 years (range 35-81)
Working Pattern 
25 already retired
8 changed working pattern because of cancer/treatment
7 continued in full or part time employment as previously i.e. no change in work 
pattern.
Smoking History
2 Lifetime non-smokers, 15 current smokers, 23 ex smokers 
Educational background
28 had no post-compulsory education, 8 had A level/NVQ/Apprenticeships, 4 had 
higher education qualifications (professional/technical/graduates)
Performance status 
ECOG performance status:
0  for 12, 1  for 15, 2 for 11 and 3 for 2 in the period three to six weeks after 
completion of last cycle of chemotherapy.
Chemotherapy received
8 MIC 32 Gem/Carbo. Only 12 of those in this group took part in the LLCG Study 11.
141Table 4.1 Patient demographics of the LLCG study (Rudd et al 2005) *and the
interview study for com parison.(CA)
G em Carbo M IC C A*
N=212 N=210 N=40
Age (Years)
Median 62 63 54
Range 40-81 34-81 35-81
Sex
Male 147 (69%) 149 (71%) 28 (70%)
Female 65 (31%) 61 (29%) 12 (30%)
ECOG Status+
0 64 (30%) 44 (21%) 12 (30%)
1 124 (58%) 133 (63%) 15(37.5)
2 9 (19%) 29 (14%) 11(27.5%)
3 5 (2%) 4 (2%) 2 (8%)
Stage
IIIB 95 (45%) 105 (50%) NA
IV 117(55%) 105 (50%) NA
Pathology
Squamous 85 (40%) 89 (42%) NA
Adenocarcinoma 79 (37%) 70 (33%) NA
Other NSCLC 48 (23%) 51 (24%) NA
+ECOG performance status: A description of performance status and the use of such 
scales is given in Chapter 2.
The number of forms received by the LLCG for analysis compared to the number 
expected is shown in Figure 4.1
Figure 4.1 Compliance (number, received / number, expected) of QoL form received 
centrally by London Lung Cancer Group
GC MIC
Within 7 days
Pre-treatment / cycle 1 193/212 (91%) 192/210 (91%)
Cycle2 154/184 (84%) 157/189 (84%)
Cycle3 142/165 (86%) 134/152 (88%)
Cycle4 118/143 (83%) 108/134 (81%)
<
Within 14 days
6 weeks from randomisation 158/199 (79%) 159/192 (83%)
12 weeks from randomisation 96/180 (5 3 % ) 99/175 (57%)
6 months from randomisation 10/153 (   7%) 11/119 (  9%)
142Note from Figure 4.1 at howl2 weeks from randomisation the attrition rate for QLQ 
30+LC module has risen. Only 53% and 57% respectively in each chemotherapy 
group completed questionnaires. 12 weeks from randomisation is the approximate 
time at which respondents are interviewed.
Possible reasons for this attrition rate include death of respondent and increasingly 
poor performance status. As these questionnaires are commonly given out at clinic 
visits and patients with poor performance status are more likely to be cared for by 
community teams with few or no visits to the clinic. Interviews took place in 
respondent’s home allowing capture of low performance/high ECOG score patients. 
In comparison a higher percentage of respondents had poorer performance status in 
the interview study than in Study 11. This is shown in Table 4.1.
1434.2 The Domains of the QLQ 30+LC 17 by question.
The domains measured by the QLQ-30 are presented below-data from each domain 
represents a group of questions from the questionnaire.
Outcome measures-the domains of QLQ-30 have been coded for ease of presentation:
EORTC QLQ-C30 Domain Question Number
Functional scales PF: physical functioning Q1-Q5
RF: role functioning Q6-Q7
EF: emotional functioning Q21-Q24
CF: cognitive functioning Q20, Q25
SF: social functioning Q26, Q27
Global health status QL Q29, Q30
Symptom scales/itemsFA: fatigue Q10, Q12, Q18
NV: nausea and vomiting Q14-Q15
PA: pain Q9, Q19
DY: dyspnoea Q8
SL: insomnia Qll
AP: appetite loss Q13
CO: constipation Q16
DI: diarrhoea Q17
FI: financial difficulties Q28
QLQ-LC17 (Lung Cancer Specific Module)
Symptom scales/items LCCO: coughing Q31, Q32
LCFLA: haemoptysis Q33
LCDY: dyspnoea Q34-Q37
LCSM: sore mouth Q40
LCDS: dysphagia Q41
LCHO: hoarseness Q39
LCPN: peripheral neuropath) Q42-Q44
LCPC: pain in chest Q38
LCHL: hair loss Q45
LCHU: upset by hair loss Q46
LCFE: fever Q47
Range of scales/items
All scales/items except QL are from 1  to 4 with the smaller the value the better. QL 
ranges from 1  to 7 with the larger the value the better. The rationale for this method 
and background of content is given in Chapters 2 and 3.
144Analysis dataset parameters set by the LLCG but as standard practice.
Forms with less than 80% items completed were excluded 
Scales with less than 50% items completed were excluded.
Data from QLQ analysed using the EORTC CD Package ratified by the London Lung 
Cancer Group findings. Figure 4.2 below illustrates the pre-treatment (baseline) 
HRQoL scores for the Study 11 (Rudd et al 2005) group. As described below the real 
numbers shown in this and the accompanying figures/tables are ranges.
Ranges are the comparable factors in many HRQoL tools including the QLQ 30. 
Subjecting the data to the mathematical operations described in Chapter 3 gives a 
series of values as real numbers which can then be compared to corresponding values 
as those in Figure 4.3 (values at 12 weeks-approximate time of interview).
Figure 4.3 also shows comparison of the two scores (baseline Figure 4.2 and 12 
weeks). Figure 4.4 also includes the cumulative SD and p values. These should be 
noted-in the comparison data the p values for some domains (such as social function 
0.85) are very high. This is probably due to the attrition rate within the groups 
however should be considered in the interpretation of these data. This is because these 
data seek to represent a facet of quality of life in the global sense. Given the low 
confidence of these data can it do this?
145Figure 4.2 QoL at pre-treatment (before chemotherapy for NSCLC)
Scale GC MIC Total
n mean median sd n mean m edian sd n m ean median
EORTC QLQ-C30
Functional scales
PF 189 1.87 1.80 0.65 189 1.84 1.60 0.66 378 1.85 1.80
RF 188 2.18 2.00 1.03 189 2.28 2.00 1.03 377 2.23 2.00
EF 190 1.91 1.75 0.76 190 1.93 1.75 0.73 380 1.92 1.75
CF 190 1.52 1.50 0.68 190 1.51 1.50 0.64 380 1.51 1.50
SF 189 1.89 2.00 0.90 190 1.96 2.00 0.92 379 1.92 2.00
Global health status
QL 190 4.41 4.50 1.45 190 4.58 4.75 1.32 380 4.49 4.50
Symptom
scales/items  FA 190 2.14 2.00 0.75 190 2.18 2.00 0.77 380 2.16 2.00
NV 190 1.31 1.00 0.59 190 1.31 1.00 0.58 380 1.31 1.00
PA 190 1.83 1.50 0.89 190 1.78 1.50 0.85 380 1.80 1.50
189 2.30 2.00 0.89 190 2.33 2.00 0.97 379 2.31 2.00
DY 189 1.98 2.00 0.99 190 2.11 200 0.97 379 2.04 2.00
SL 189 1.89 1.00 1.06 189 1.96 2.00 1.04 378 1.93 2.00
AP 189 1.66 1.00 0.94 190 1.53 1.00 0.81 379 1.59 1.00
CO 189 1.20 1.00 0.55 188 1.09 1.00 0.31 377 1.14 1.00
DI 187 1.63 1.00 0.95 189 1.65 1.00 0.91 376 1.64 1.00
FI
QLQ-LC 17
Symptom
scales/items
192 2.28 2.00 0.78 192 2.30 2.00 0.84 384 2.29 2.00
LCCO 192 1.23 1.00 0.53 192 1.27 1.00 0.63 384 1.25 1.00
LCHA 192 1.95 1.75 0.71 192 1.95 1.75 0.77 384 1.95 1.75
LCDY 192 1.23 1.00 0.58 192 1.19 1.00 0.57 384 1.21 1.00
LCSM 191 1.28 1.00 0.69 192 1.31 1.00 0.72 383 1.30 1.00
LCDS 191 1.64 1.00 0.95 191 1.60 1.00 0.91 382 1.62 1.00
LCHO 192 1.36 1.00 0.52 192 1.39 1.33 0.55 384 1.37 1.33
LCPN 191 1.64 1.00 0.84 192 1.66 1.00 0.84 383 1.65 1.00
LCPC 191 1.03 1.00 0.16 188 1.04 1.00 0.27 379 1.03 1.00
LCHL 131 1.11 1.00 0.47 127 1.16 1.00 0.56 258 1.14 1.00
LCHU 192 1.15 1.00 0.47 186 1.13 1.00 0.47 378 1.14 1.00
LCFE
* % of patients with score >2 (quite a bit / very much) for all scales except for QL 
which was % of patients with score <4 (below average health status).
All scales/items measured by EORTC QLQ-C30 and QLQ-LC17 questionnaires 
were balanced across the two treatment groups at the pre-treatment. The majority 
of patients did not experience or experienced a little difficulty in QoL.
146Figure 4.3 Comparison at 12 weeks (± 2 weeks) from randomisation
Scale GC MIC Total
n mean median sd %* n mean median sd %* Diff/sd
**
P
EORTC QLQ-C30 
Functional scales
PF 95 1.82 1.80 0.61 32 97 1.88 1.80 0.67 33 0.06/0.64 0.63
RF 95 2.13 2.00 0.93 37 98 2.26 2.00 0.96 44 0.13/0.95 0.35
EF 95 1.72 1.75 0.61 22 98 1.65 1.63 0.66 12 -0.07/0.64 0.20
CF 95 1.49 1.00 0.61 12 98 1.51 1.50 0.65 9 0.01/0.63 0.87
SF 95 1.86 2.00 0.82 27 98 1.93 2.00 0.93 26 0.07/0.88 0.85
Global health status
QL 94 4.82 5.00 1.31 21 98 4.66 5.00 1.22 16 0.18/1.26 0.25
Symptom scales/items
FA 95 2.10 2.00 0.74 38 98 2.25 2.00 0.79 40 0.15/0.77 0.22
NV 95 1.23 1.00 0.43 4 98 1.39 1.00 0.58 9 0.16/0.52 0.04
PA 95 1.51 1.50 0.59 12 98 1.49 1.25 0.66 9 -0.02/0.62 0.64
DY 95 2.11 2.00 0.86 29 96 2.11 2.00 0.93 30 0/0.89 0.94
SL 95 1.74 2.00 0.88 16 98 1.65 1.00 0.79 15 -0.09/0.83 0.61
AP 95 1.54 1.00 0.81 14 97 1.70 1.00 0.89 16 0.16/0.85 0.16
CO 95 1.34 1.00 0.66 6 98 1.50 1.00 0.84 14 0.16/0.76 0.23
DI 95 1.17 1.00 0.48 2 98 1.16 1.00 0.53 3 -0.01/0.50 0.64
FI 95 1.47 1.00 0.77 11 98 1.71 1.00 0.97 18 0.24/0.89 0.10
QLQ-LC 17 
Symptom scales/items
LCCO 95 1.86 2.00 0.64 19 93 1.89 2.00 0.71 24 0.03/0.67 0.87
LCHA 95 1.05 1.00 0.22 0 93 1.05 1.00 0.34 1 0/0.29 0.51
LCDY 95 1.80 1.75 0.61 27 93 1.72 1.50 0.67 25 -0.08/0.64 0.19
LCSM 95 1.24 1.00 0.54 5 93 1.26 1.00 0.57 6 0.02/0.55 0.92
LCDS 95 1.07 LOO 0.26 0 92 1.17 1.00 0.51 3 0.1/0.40 0.18
LCHO 95 1.44 1.00 0.68 6 93 1.42 1.00 0.73 8 -0.02/0.70 0.59
LCPN 95 1.39 1.33 0.40 5 93 1.44 1.33 0.58 10 0.06/0.49 0.73
LCPC 95 1.46 1.00 0.67 9 93 1.34 1.00 0.60 2 -0.12/0.63 0.22
LCHL 95 1.56 1.00 0.66 7 92 2.65 3.00 1.08 53 1/1.05 0.000
LCHU 70 1.39 1.00 0.75 10 88 1.63 1.00 0.97 17 0.24/0.89 0.12
LCFE 94 1.07 1.00 0.30 1 93 1.03 1.00 0.18 0 -0.04/0.25 0.31
* % of patients with score >2 (quite a bit / very much) for all scales except for QL 
which was % of patients with score <4 (below average health status).
**diff= mean of MIC -  mean of GC
P values calculated using % 2 apart from age, in which t-test was used. All statistics 
performed on the advice of trials centre statistician.
1474.3  Toxicities
All Toxicities were recorded using the Common Toxicity Criteria described in 
Chapter 3. Toxicity has been included here as along with performance status it is used 
as both a foundation for health related QoL scales. Occasionally it is also a proxy for, 
quality of life. The rationale and literature for this has been described in Chapter 2.
It is both toxicity and overall QoL domain scoring that will be compared with the 
interview study.
Figure 4.4. Haematological Toxicity for patients who received at least one cycle of 
chemotherapy
Reported worst GemCarbo MIC
toxicity by grade N=200/202* % N=201/202*%
Anaemia
0 2 4
1 26 32
2 61 24
3 7 8
4 2 1
Leucopenia
0 27 24
1 23 26
2 28 22
3 19 22
4 3 6
Neutropenia
0 28 34
1 13 12
2 24 21
3 21 18
4 13 15
Thrombocytopenia
0 45 48
1 28 38
2 3 6
3 11 4
4 13 3
*206 patients received at least one course. Data Unavailable for 6 patients on 
GemCarbo
148Figure 4.5 Non Haematological Toxicity for patients who have received at least one 
cycle of chemotherapy.
Reported worst toxicity grade GemCarbo 
N=197 (% >)
MIC
N=202 (%)
Allergy
0 93 91
1 5 2
2 1 1
3 1 0
4 0 0
Nausea
0 36 23
1 37 35
2 22 29
3 5 12
4 0 1
Vomiting
0 64 45
1 20 26
2 12 19
3 3 8
4 1 2
Alopecia
0 58 17
1 36 26
2 6 48
3 1 9
4 0 0
Rash
0 79 94
1 14 3
2 7 2
3 1 0
4 0 0
Constipation
0 52 39
1 30 36
2 16 17
3 2 7
4 0 0
Infection
0 70 72
1 6 8
2 16 12
3 7 6
4 1 1
Stomatitis
0 71 66
1491 18 27
2 10 5
3 1 2
4 0 0
Diarrhoea
0 82 83
1 12 12
2 4 3
3 2 2
4 1 1
Anorexia
0 51 51
1 32 23
2 12 19
3 5 6
4 1 1
Toxicity data is included here as part of the original comparative study was to 
determine if the reason cited by some clinicians as a limiting factor in quality of life is 
a valid one.
1504.4 The Interview Study
Interviews were transcribed verbatim and subsequently subjected to content analysis. 
Content analysis of the transcribed scripts was performed manually and managed on 
an Excel spreadsheet. As Krippendorff suggests (Krippendorff 2004) such texts 
generate huge amounts of data and this study is no exception to that. A total of 3,802 
responses were coded by content. Initial analysis was performed for structure and 
elicited narratives (e.g. atrocity stories) and a second was then undertaken to elicit 
themes (Mishler 1996, Benit et al 2005).
These transcribed responses were tabulated. Repeated tabulation lends reliability to 
the method and data. In addition such tabulation enables the creation of representation 
of frequency, illustrated by histograms.  The histograms generated from these data 
can be found in Chapters 5 and 6, which deal with the interpretation of the content 
analysis data.
On examination of these data there was apparent clustering of coded responses.
These are presented below and using a dendrogram to summarise in Figure 4.6. These 
data are further examined in context in the following chapters.
1511 Root code Communication HP and Patient
1.1 How diagnosis was communicated (positive or negative)
1.2 Attitude of those communicating diagnosis (positive or negative)
1.3 Willingness/reluctance of health professionals to discuss life expectancy
1.4 Willingness/reluctance of health professionals to discuss information needs
1.5 Willingness/reluctance of health professionals to discuss fear/emotional distress
1.6 Atrocity stories of pre diagnosis (communication)
1.7 Atrocity stories of diagnosis (communication)
1.8 Nor being able to discuss with HP
1.9 Feelings of shock, numbness or distance
2 Root code Psychological well-being
2.1 Ability to adjust to diagnosis/prognosis
2.2 Ability of significant others to adjust to diagnosis/prognosis
2.3 Suffering-Inability to adjust to diagnosis/prognosis
2.4 Suffering-Inability of significant others to adjust to diagnosis/prognosis
2.5 Feeling independent
2.6 Feeling Isolated (psychological)
2.7 Suicidal ideation
2.8 Emotional distress*
2.9 Labile mood*
2.10 Depression*
2.11 Feeling fear of unknown (eg suffering “what happens when you die?)
2.12 Feeling well (psychological)
2.13 Feeling relief
2.14 Experiencing other mental health problems
2.15 Change in body image
2.16 Suffering caused by uncertainty
2.17 Feeling guilty (smoking)
2.18 Feeling guilty (other)
2.19 Feeling determined/not giving up
2.20 Feeling disbelief
2.21 Feelings of failure
2.22 Feelings of Anger
* As defined by patient affecting QoL-not always confirmed as a pathology
3 Root code Physical well-being
3.1 Experiencing symptoms (e.g. dyspnoea, haemoptysis, orthopnea) associated with 
lung cancer
3.2 Experiencing symptoms not associated with lung cancer (eg other chronic 
conditions)
3.3 Experiencing side effects of treatment considered to have detriment to quality of 
hfeA
3.4 Experiencing side effects of treatment considered not to have detriment to quality 
of lifeA
1523.5 Feeling well
3.6 Experiencing improvements in symptoms
3.7 Physical effort of treatment (eg hospital visits) fatigue
A Side effects of treatment on QoL as defined by patient-not by CTC
4 Root code Relationships with significant others
4.1 Willingness of family/others to discuss diagnosis/prognosis
4.2 Reluctance of family/others to discuss diagnosis/prognosis
4.3 Concerns about future of family (children, partner)
4.4 Experiencing difficult reactions of family and others (eg anger, denial, exclusion 
from social activities)
4.5 Refusal to discuss with others
4.6 Support from family/others
4.7 Planning for the future
5 Root code Health behaviours
5. 1  Giving up smoking
5.2 Not giving up smoking/smoking more
5.3 Eating healthier
5.4 New belief in alternative (complimentary) therapy
6 Root code Spirituality
6.1 Affirmation of religious belief
6.2 Interest in spirituality
6.3 Interest in “afterlife”
6.4 Rejection of previous religious beliefs
7. Root code Patient experience
7.1 Level of service (eg waiting time) prior to oncology positive
7.2 Level of service (eg waiting time) prior to oncology negative
7.3 Level of service (eg waiting time) within oncology positive
7.4 Level of service (eg waiting time) within oncology negative
7.5 Scheduling of investigations prior to chemotherapy positive
7.6 Scheduling of investigations prior to chemotherapy negative
7.7 Options and alternatives presented prior to oncology positive
7.8 Options and alternatives presented prior to oncology negative
7.9 Options and alternatives presented within oncology positive
7.10 Options and alternatives presented within oncology negative
7.11 Feeling of trust in medicine/medical team prior to treatment
7.12 Feeling of mistrust in medicine/medical team prior to treatment
7.13 Feeling of trust in medicine/medical team on treatment (oncology)
7.14 Feeling of mistrust in medicine/medical team on treatment (oncology)
7.15 Control of treatment decisions/choices
7.16 Perception of control issues around circumstances of own death
7.17 Experience of therapies as positive (eg context of hope, access to experts)
1537.18 Experience of therapies as negative (side effect or useless)
7.19 Access to specialist nurse (eg lung CNS, chemo nurses) positive/negative
7.20 Access to doctors positive/negative
7.21 Access to others positive/negative
7.22 Community support positive/negative
7.23 Flexibility/negotiation of treatment calendar and support services (eg OPA 
booking/transport) positive
7.24 Flexibility/negotiation of treatment calendar and support services (eg OPA 
booking/transport) negative
7.25 Abandonment
7.26 Persistence (in accessing services)
7.27 Information needs prior to treatment positive/negative
7.28 Fear of treatment/what to expect
(positive and negative as defined by patient perceived effect on QoL)
8 Root code Atrocity stories non communication
8.1 Pre diagnosis (eg >2 visits to GP with herald symptoms before action)
8.2 Diagnosis
8.3 Post diagnosis/pre treatment
8.4 On treatment
9. Root code changes in role/social
9.1 Changes in working patterns/giving up work
9.2 Change in financial circumstances positive
9.3 Changes in financial circumstances negative
9.4 Change in social activities and interaction positive
9.5 Change in social activities interaction negative
9.6 Changes in independence/mobility negative
9.7 Feeling isolated (mobility/socially)
9.8 Leading a “normal” life
9.9 Suffering-not leading a “normal” life
10 Root Code Miscellaneous
154Figure 4.6 Examples of clustering of codes using a dendrogram of the tabulated interview results to the first level. Root codes are shown with 
numbers of branch codes in parenthesis show responses.
Branch codes
Positive------------------------------------1   Root codes
Communication Health professional and patient (9)
Negative----------------------------------- 1
Positive  —   I
Psychological well being (22)---------------------------------------------------------------------   Quality of Life in advanced NSCLC
Negative.
Positive
Patient experience (28)
Negative'
Negative Atrocity stories (4)
Negative. Changes in role/social (9)
155The two streams of data gathered by HRQoL and content analysis will be compared 
and contrasted to examine the meaning of quality of life in this patient group.
The findings of these data are used to elicit meaning of what quality of life means to 
patients who have advanced NSCLC in the following chapters.
156Chapter 5
Quality of life 
The work of cancer 
and
The lens of diagnosis5.Introduction
The result of coding produced root codes and a wide distribution of branch codes.
At a high level, from the content analysis of the interview data four themes were 
identified. These were compared across the scripts and with the published literature. 
In addition comparisons were sought with the EORTC QLQ-30 data. There is much 
overlap but two of them hnve such synergistic properties they are presented in one 
chapter
The four themes are:
•  Doing work
•  Suffering
•  The lens of diagnosis
•  The worth of treatment
The themes of Doing work and The lens of diagnosis appeared to have overlap and so 
are considered in this Chapter. The worth of treatment an Suffering are considered in 
the next.
1585.1 The Lung Cancer Journey-doing work
Using line-by-line analysis of content, this was the dominant theme. The dominance 
of this theme was the reason for sampling outside of the study group. In the initial 
sample of ten for which the researcher could not attain clinical isolation, saturation in 
this category was reached very quickly. Comparison of scripts of this initial group 
showed saturation and possible influence (originally thought to be contamination) of 
the respondent group by the therapeutic relationship shared between the researcher 
and the respondent. Subsequent interviews for which the researcher had no clinical 
responsibility yielded a similar result-fast saturation of this topic and possible data 
redundancy.
From the coded, tabulated responses, 29%  (1,101) described aspects of the patient 
journey. The importance of this journey was explained in Chapter 2 and is also 
recognised in the UK by the various guidance published by the Department of Health, 
such as the NHS Cancer Plan (2000) and the subsequent initiatives.
Comparisons of the EORTC QLQ data, the literature and the current Department of 
Health initiates are part of the comparison process with the interviews and patients 
own realities to explore the meaning of quality of life in the context of the patient 
journey.
159This is an area that is not covered by the functional status questionnaires such as the 
QLQ 30 + LC 17, although such tools do contain items such as assessment of physical 
function, emotion and social/role which may affect ability to negotiate the journey; it 
is not possible to extract information about specific influences on these domains. The 
responses from the lung cancer patients covered a wide variety of topics that have 
been coded into 28 branch codes:
Twenty-eight branch codes by open coding and content analysis for the root code 
patient experience.
1 Level of service (eg waiting time) prior to oncology positive
2 Level of service (eg waiting time) prior to oncology negative
3 Level of service (eg waiting time) within oncology positive
4 Level of service (eg waiting time) within oncology negative
5 Scheduling of investigations prior to chemotherapy positive
6 Scheduling of investigations prior to chemotherapy negative
7 Options and alternatives presented prior to oncology positive
8 Options and alternatives presented prior to oncology negative
9 Options and alternatives presented within oncology positive
10 Options and alternatives presented within oncology negative 
I i Feeling of irusl in medicine/medical Learn pnor to treatment
12 Feeling of mistrust in medicine/medical team prior to treatment
13 Feeling of trust in medicine/medical team on treatment (oncology)
14 Feeling of mistrust in medicine/medical team on treatment (oncology)
15 Control of treatment decisions/choices
16 Perception of control issues around circumstances of own death
17 Experience of therapies as positive (eg context of hope, access to experts)
18 Experience of therapies (negative)
19 Access to specialist rurse
20 Access to doctors
21 Access to others
22 Community support
23 Flexibility/negotiation of treatment calendar and support services (eg OPA 
booking, transport) positive
24  Flexibility/negotiation of treatment calendar and support services (eg OPA 
booking, transport) negative
25 Abandonment by service
26 Persistence
27 Information needs prior to treatment
28 Fear of treatment
160The distribution of these responses is shown below in Fig 5.1, however this is not 
usual practice in medical sociological research. The decision to include distribution is 
that it is valid data, which can be used for comparison and quantification of such data 
is common practice in content analysis (Krippendorf 2004).
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Patient experience was given as a basis for many quality of life issues in advanced 
NSCLC. This root code reached saturation quickly in the first ten respondents. As the 
researcher was initially part of the Study 11 research team and had a clinical 
responsibility for these respondents as patients, the researcher then interviewed 
patients outside of Study 11. This decision was made for two reasons. In addition to 
the reason just given-a possible bias toward the interviewer, another reason was the 
adoption by the National Institute of Clinical Excellence of the 
Gemcitabine/Carboplatin chemotherapy combination as best practice in advanced 
NSCLC. This meant that patients no longer received one of the chemotherapy 
regimens (MIC). It would have been unethical to continue the study in such a way.
Fig 5.1  Root code Patient Experience
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161The cancer patient experience or journey is a complex one to which the considerable 
investment by the current government attests (DoH 2003). Many of the sources of 
frustration or stress for cancer patients arise from access problems or bottlenecks 
(Leary and Corrigan 2005) even when a clear path based on clinical evidence is 
apparent. Mapping of the lung cancer pathway at one central London NHS Trust 
revealed 72 actions between GP referral and definitive treatment, which in real terms, 
represents a lot of work both physically and emotionally (Schou and Hewison 1999). 
This has been illustrated in Fig 5.2a and b. Fig 5.2.a is from an appointment diary 
volunteered by a respondent. Fig 5.2.b demonstrates the mapped lung cancer journey 
within the researchers own cancer network as part of the modernisation agenda work. 
In addition to this many respondents experienced difficulties negotiating this journey 
that then led to trust issues with professional groups.
The remaining figures of this section demonstrate lower level mapping of aspects of 
the patient journey, particularly the aspect of communication between professionals, 
patients and organisations. The various complexities of communication are shown in 
Fig 5.2.c. Two points of the journey have been selected to illustrate the complexity of 
the process and the negotiation the patient has to deal with. These are shown at 
outpatient diagnosis (Fig 5.2d) and the process of receiving a dose of chemotherapy 
(Fig 5.2e)
162Fig 5.2a Offered by a respondent 54, female during interview. An appointment diary. 
This diary was primarily for recording appointments but demonstrates the work of a 
lung cancer patient.
It starts with visit to chest clinic in a large district general hospital that is also a cancer 
unit after abnormal x-ray findings by GP.
21/10 AM chest clinic (diis identified the need for investigation)
28/10 AM Bronchoscopy
5/11 AM Chest clinic (rn results from bronchoscopy available-retum next week- 
should have had CT already but appointment not until 11/11)
11/11  AM CT Scan
12/11 AM Chest clinic results show lung cancer-might be operable refer to surgeon.
The respondent then waited a month for an appointment to see the surgeon in 
outpatients at a surgical clinic. The surgeon told her she was not operable and would 
refer back to the chest clinic. After waiting two weeks  for an appointment she rang the 
chest clinic to find no re-referral had been received. The chest team had to liase with 
the surgical team to confirm the findings and the respondent was seen in the chest 
clinic two weeks later.
5/1 AM Chest clinic referral made to oncology team and Macmillan nurse
The respondent finally received her first course of chemotherapy almost three months 
after her first visit to the chest clinic. Given the prognosis of NSCLC and the 
Department of Health guidelines for the treatment of cancer wait times, waiting three 
months exceeds all targets and represents work for the respondent.
1635.2b Lung cancer pathway-the work of having cancer (abridged-assumes GP initial visit) the actual pathway as mapped in one 
central London trust consists of 72 steps.
Referring Hospital
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Chest Team
1645.2c The different communication routes required for the journey (mapped by SE and North Central CN) 
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1575.2e The process or work, of having first chemotherapy dose (Gem< itabine and Carboplatin) and professionals involved in Chemo Daycare 
(2004)
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158The codes generated which relate to the patient experience are varied. A recurring 
issue was the importance of patients to have some control and be actively involved in 
the decision making process:
. .well I never felt, forced into having any treatment I didn’t want everyone explained 
what could or couldn’t be done.. .that’s important in my quality of life as I feel I know 
where I stand”  61 year old female
“I liked him, [chest physician], he just told me what it was and that I would see a 
cancer doctor next.but there was no.. .mucking about..y’know? He told me the pro’s 
and con’s and all that, but I always felt it was up to me.. .looking back that’s 
important to me cos its such a big decision.. .and its always been like that at 
[hospital].. .1 always felt I was able to make my own mind up”
5S year old male
It is interesting to note that the control (perceived or real) over treatment and the 
decision making process is so prevalent. The locus of control is something that many 
try to hold onto when faced with a change in circumstance, particularly in serious 
illness. fRuruess et a!  19RR1 and althounh no literature could be found to suooort this 
specifically in advanced lung cancer, it is not a surprising finding in its own right. The 
examination of the complexities of diagnostic and treatment pathways, even after the 
inception and progress of the cancer modernisation agenda (Fig 5.2a-e) show that 
accessing treatment or expert care is still a challenge.
What is interesting is that not only is the code of control/decision making a strong 
one, it is also usually justified by the respondent with an issue of trust or 
communication in previous experience with the medical profession.
168This can be seen by the amount of atrocity stories that were presented.
The narratives elicited included a number of “atrocity stories” which are situational 
accounts of encounters with medical professionals and were first identified in the 
1970’s (Webb and Stimson 1976, Dingwall 1977).
Atrocity stories usually appear at the inventory stage of interviews with patients 
(Baruch 1981) and portray a situational encounter in which the parties’ involved 
display different perceived characteristics. The patient is portrayed as an emotional, 
feeling person whereas the medical professional is depicted as cold and emotionless. 
In total 47 atrocity storks were elicited from the narratives of forty patients. In this
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throughout the course of the interview. Similar to the findings of Baruch (1981), 
patients paid close attention to the realities in which they locate themselves and 
members of the health professions as two separate realities.
Thirty-eight were narratives around diagnosis and communication with the 
respondent’s general practitioner. The most common topic that was subsequently 
coded was repeated visits to the GP before investigation or referral (35) where the GP 
acts as gatekeeper to acute services. This example demonstrates not only the 
interruption and work o 'the journey but also the breakdown in trust:
“I went to my doctor [GP] and he said I had an infection... .um... a chest infection, the 
antibiotics were not much help, I kept going back and after about three months.. .1 
think I saw him about five times.... I went to the (ref hosp) for the X ray, that’s when 
they found it.. .1 try to see the lady doctor since then or the young one.. .he [GP] 
doesn’t know what he is doing”  58 year old man.
169There were three narratives in which the probable diagnosis was delivered by the GP 
told as an atrocity story as the respondents expressed that they were not able to meet 
the complex information needs expressed by the respondent which is a recognised 
facet of cancer care (NICE 2005) although the respondents referred to the GP as 
“caring”, “kind” and “wonderful”.  An example from a 46 year old man:
“Well I asked....you know how long.. .he said probably....about six months.. .he [GP] 
didn’t know about any treatment.. .Mentally and emotionally I was down, I was just 
waiting for the six months to come around....even when Dr X [oncologist] said you 
can’t tell...1 had it in mv head.. .six months”
Another example was given by a 68 year old woman, who had a likely diagnosis 
communicated by her GP, after which she did not appear to have been referred to a
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causing anxiety
“.. .but any time I had spare time I was in the depth of despair... .1 was very conscious 
of walking around with this cancer inside me.. .it felt like a time-bomb waiting to go 
off, I’ve become very intolerant and impatient”
Six stories were around the diagnosis milestone within the acute sector and encounters 
with chest physicians. These stories were all centred on communication. The 
respondents had been diagnosed in different acute hospitals and all had told atrocity 
stories as gate keeping encounters.
A 78 year old woman told of her experience of communication of diagnosis by a chest 
physician:
“  I knew something was wrong before.. .1 knew it was serious so I was expecting it
to be cancer... well, he told me what it was and I wanted to know the ins and outs and 
what comes next.. .but that was it, next patient! He was alreadv at the door! And he 
wouldn’t look me in the eye, as if he were embarrassed or something.”
170Two stories were around an unexpected treatment plan change and change in 
prognosis, these stories depicted the circumstance and perceived realities of the 
patient and the healthcare professionals involved. An example of this is shown below. 
This story was told by a 54 year old woman who was thought to have operable lung 
cancer. On admission for surgery she complained of diplopia and consequently 
underwent a CT scan ol the head. The CT revealed brain metastasis, making the 
patient inoperable, and this news was communicated to her at 9pm the evening prior 
to surgery by the anaesthetist, an encounter which she recalls:
“he said.. .sorry to tell you, you won’t be having an operation tomorrow, you’ve got 
cancer on your brain.. .here I am left on my own.. .and not only that, I sat there,
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like, hang on, have I just been told I’m dying or have I dreamt it?”
One story was told by a 62 year old male respondent who was originally diagnosed
and treated for Non Small Cell Lung Cancer and histology re-review revealed a
Lymphoma. This narrative was around the communication of *he change of diagnosis
and consequent expressions of lack of trust with the medical team.
“..well at (ref hosp) they got the type of cancer wrong didn’t they.. .first I had this 
then I had that-they don’t have a clue, I was angry”
Many of the stories told were of GP encounters, which still featured despite patients 
being some six months from initial visit. The story of repeated visit to the GP before 
diagnosis/investigation was the most common. Non Small Cell Lung Cancer is 
difficult to diagnose an i it is not surprising that repeated visits may have been 
necessary. Respondents often made personal, professional or moral judgements about 
the GP.
171Change of  emphasis/professionalisation of  patient
Studies such as clinical trials and quality of life studies in which treatment is depicted 
as anonymous and asocial process-taking place independently of individual agents 
(Schou and Hewison 1999) demonstrates well the point Cassell (Cassell 2004) makes 
about the ontology of medicine. The human body as an organism with a disease to be 
cured or measured-but no concept of that state occurring within a dynamic system-this 
is where cancer treatment in the reductionist sense begins to fail for people with 
cancer.
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to “work the system”. This was important for maintaining control and independence
*9
which was often referred to in terms of quality of life:
. .after what happened at [hospital] we really learnt.. .you have to work the system, 
otherwise you loose out”  62 year old male
.. .1 usually organised my chemo for when I had no work or work when I knew I 
would be OK to work.. .that made a big difference.. .I’m self employed so it was good 
for me and the family...that I could organise the times I had the chemo and at the start, 
some of the tests as well”  42 year old male
“.. .you can’t just accept the first thing you are told, press for more information, more 
things that may be available to help you”  70 year old female
Hospital and community staff were cited as an important factor in managing or mis­
managing the treatment calendar and there is evidence of the value of what The et al 
(2000) refer to as the treatment broker.
172The negotiation of the treatment calendar and the work of having cancer is the basis 
for much of the cancer patient experience and consists of attitudes of staff, willingness 
and helpfulness, interactions at crisis points, flexibility, trust, professional credibility 
and a sense of fairness. It is important to note that the majority of respondents came 
from units and centres around southeast England. Twelve had specifically sought a 
second opinion of the team at the centre in which this study is based after receiving a 
first opinion at the referring unit which was not to their, or their family’s, own 
personal satisfaction.
. .the thing about going to (cancer centre) I just feel they know what they are doing, 
not like at {ref hosp] I think they will do their best for me, our quality of life is
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. .basically they told me to go home and die at [ref hospital], I thought [expletive] 
that, I’m only 59. My son went on the internet and saw [cancer centre] so I went back 
to [ref hospital] and said I wanted to go there. It was no trouble, they wrote me a letter 
and did it really quick and Dr [consultant] said I could have chemo.”
59 year old male
This needs to be considered as an element of the group are therefore self selected and 
had already presented strong opinions on what constituents the “good” patient- 
professional interaction  This has been explored in the context of atrocity stories but 
comparisons of these data will be made in the next section which also examines the 
lens of diagnosis-how respondents repeatedly returned to the initial stages of the 
journey.
The linear and temporal mode of structure is prominent in western society (Knudston 
& Suzuki 1992) and so illness is experienced in the context of the individual’s
173calendar. Calendars have the role of embodying goals, motivations and limitations; 
these can be social norms for some groups for example having children by a certain 
age or the expected length of one’s own life, what Schutz and Luckman refer to as 
social structures of relevance (Schtuz and Luckman 1974) Humans in western society 
have personal or private calendars, and these incorporate tasks of daily life, goals and 
responsibilities. Authors such as Sacks (Sacks 1989) believe these personal calendars 
operate at much deeper levels. In this deeper way, individuals locate specific close 
relationships, for example marriage, within them.
A diagnosis of cancer will have an impact on the personal calendar, and the diagnosis
ui an auvaiiV/GU  iui  winwii ucauuciii, n  uncicu, is 1 1   *xny  tO  uc |jaiiiauvt,  Win
have a significant impact-for if no other reason but as an indication that the lifespan of 
the personal calendar is likely to come to an end much sooner than anticipated.
A cancer diagnosis also introduces a new calendar an illness or treatment calendar 
(Schou and Hewison 1999).
The dominance of functionalism in quality of life neglects this social dimension. The 
social dimension of quality of life is shown in the context of illness and of treatment 
calendars. Professionals have power over the treatment calendar because they manage 
it within a patient-professional relationship that is unequal. Professionals hold 
knowledge and choose when patients have access to that knowledge.  The 
professional management of the calendar is bound up in the traditions of biomedicine 
(Schou and Hewison 1999). This may equally not be the desire of the professional 
group but is directed by institutional culture or political agenda or limited resources.
174The treatment calendar seems largely ignored in the quality of life literature and yet 
seems to have impact on patients’ quality of life as the topics for discussion, which 
explicitly asked respondents about quality of life, elicited so many experience 
narratives which allude to the treatment calendar.
The impact of the treatment manager or agent is profound (or treatment broker as 
referred to by Anna Marie The et al 2000) as when this job is done well, a better 
quality of life is provided for the respondent.
The issue of calendar negotiation and the treatment broker was a recurring code. The
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the consultant medical staff, staff in the chemotherapy unit and the lung cancer nurse 
specialist who were all referred to in the context of agent or broker. The respondents 
also emulated the role that these professionals played to some degree as a means of 
gaining control. The establishment of a therapeutic relationship in hand with patient 
professionalisation was important to quality of life. Consultant medical staff offered 
consistency throughout treatment, particularly in terms of prognosis:
“  well after the GP. that really unsettled me... .Dr [consultant] was more, I
dunno.. .reliable I suppose.. .the business with the y’know six months.. .he never said 
that...he was honest....he'd say.. .’’we don’t know-it depends on how you react to 
treatment” and well.. .he is a cancer doctor so that made me feel better in a way...not 
like a death sentence... .that made life better”  67 year old male
“.. .when I go to [cancer centre] I usually see [consultant] and that’s great because you 
don’t usually see the consultant with other things, you see a junior doctor and it’s a 
different one every time....you have to go through the whole thing again and again 
and sometimes you just don’t feel like it”
59 year old female
175The staff in the chemotherapy unit were valued by respondents particularly in terms of 
information giving, dealing with the practicalities of chemotherapy such as managing 
side effects, lifestyle changes and accurate information giving:
“the girls in the chemo suite, they were brilliant. I was so nervous about having the 
chemo, I was sick before 1 even went. If it hadn’t been for [CNS] I wouldn’t have 
even come back to hospital after they told me, I was so scared* ’
62 year old male
“..its good to have someone you can call, no appointment.. .just ring... .At one point I 
wanted to stay with my sister for a couple of days, and it was nice to be able to ring 
and ask..”do you think that would be OK?”..its reassurance.. .when so much changes 
in one’s life.. .even simple decisions become difficult.. .its very reassuring to know
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The introduction of the “key worker” a pivotal role in the multidisciplinary team
which acts as a navigator of the journey has recently been introduced as part of the
latest stage of modernisation (NICE 2005) but this role has been fulfilled by the
clinical nurse specialist in lung cancer. The narratives from the respondents
demonstrate how this role is viewed and valued as the principal one for negotiation of
the cancer patient joumey-the principal treatment broker.
“...we found it all very confusing, particularly at first but [CNS] was very good, I 
remember she rang us the next day to see how we were”
74 year old male
“.. .oh and [CNS] she was so good, I know I kept asking the same things over and 
over again. [CNS] helps me a lot, if I cant get there [clinic] she will help me change 
the appointment-if you just ring up yourself you can’t get an appointment for weeks- 
its always full. The time I was too ill, she rang to see why I didn’t come and got me an 
appointment for the ne: _t week. I can just ring her if I am not v/ell-my own doctor 
[GP] he is not a cancer specialist it takes a lot of worry out of it”
68 year old male
176Common codes which emerged from this data do not appear to support the view of the 
therapeutic nihilists. From an experience perspective few respondents commented  on 
chemotherapy as a negative experience and this can be compared with and confirmed 
by, the physical experience data which is presented in context In the next section..
The patient experience is characterised as hard work and yet work that will have a 
positive outcome:
“I think its important to try  Dr [consultant] was pretty straight I knew it was not
gonna make the cancer go away but at least I was trying.. .for me and the kids.. .at least 
we gave it a go and I dunno if I would have felt bad if I hadn’t tiled it”
48 year old male
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from Study 11. There are not common domains for patient experience and so any 
comparative data analysis in the statistical sense (for example a rank-spearman) would 
not yield helpful or reliable data data.
In summary the emergent coded responses of the negotiation of the treatment calendar 
are given in Fig 5.3
Fig 5.3-Emergent codes
•  Negotiating the treatment calendar and its complexities
•  Gaining control
•  Sharing decision making
•  Access to a treatment broker
•  Being supported by Health Professional and/or family
•  Negotiation of the pathway difficult but seen as a positive action
177Who makes the decisions? The dynamic of the Multidisciplinary Team.
The Cancer Plan (DH 2000) is explicit about the nature of clinical decision making in 
cancer care. Decisions should be patient centred and multidisciplinary in nature. For 
each type of cancer there should exist a core and extended multidisciplinary team to 
ensure equitable decision-making. This is explored here, as a number of respondents 
were self-selected. Twelve actively sought chemotherapy or other treatment at the 
centre after being either refused chemotherapy or offered best supportive care at the 
referring hospital. These narratives and the other gatekeeper atrocity stories have 
become a core theme of this data. The existence of these narratives prompts
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modernisation agenda.
The multidisciplinary team is directed by the work of the modernisation agenda to 
review and audit their work (Department of Health 2000a). This includes activity such 
as peer review and publication of tumour board minutes in the public domain. 
Transparency is encouraged and review is required to ensure equity of care 
(Department of Health 2000a).
The decisions made for this group of patients do not seem to have followed the 
standard MDT format as proscribed by the Department of Health Cancer Plan (2000a) 
and modernisation agenda. The MDT field notes of the researcher were re-examined 
in the context of this data for comparison. How are these decisions made and who 
makes these decisions?
178The observed work of the MDT meetings from the fieldwork across one cancer 
network produces an interesting power dynamic. The MDT functions as a group 
rather than a team, with personality, positional authority and established relationships 
influencing power. There is an alpha decision maker in each group who is a chest 
physician. The decision making process is altered when the alpha decision maker is 
not present and a beta decision maker becomes apparent. The beta decision maker is 
also influential when the alpha decision maker is present generally by affirming the 
decisions of the alpha decision maker.  If the characteristics of group Vs team 
behaviour are considered (Belbin 2003):
i C C iifi rV yj:  Group working
Mutual Trust  Trust is measured
Freedom to express views  People negotiate
Process issues part of the  work  Process issues worked on
The observed behaviour of the core and extended MDT’s reflect functioning as 
groups rather than as teams as there is little consensual decision making, instead 
opinions are elicited from the group with perceived positional authority being the 
determinant factor to the hierarchy of the group and subsequent influence on the 
decision making process. The hierarchy of the group is reflected by attitudes, 
willingness to contribute to discussions and even seating patterns within the meeting,
Work through conflict 
Common objectives 
Open
Decisions are made by consensus
High level of commitment 
People work together
covertly
High level of commitment 
People co-operate to get the job 
done
Conflict is accommodated 
Politics are at play 
Feelings not part of work 
Information passes on a need to 
know basis
179these patterns were consistent over months or in some cases the five years of the 
study. Some positions are fixed by external influence for example the pathologists 
have an assigned position at the microscope and the radiologists near the projector 
however in one meeting the radiologist/nuclear medicine physician was the beta 
decision maker:
Fig 5.4 The hierarchy of position in the MDT meetings
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From this dynamic it is possible to consider the decision making process. The 
evidence presented in Chapter 2 informs that performance status is the best predictor 
of coping with chemotherapy and yet the majority of the observed decisions in the
180MDT meeting utilised chronological age and occasional social factors to make 
treatment decisions. It is not surprising that this method could result in variations of 
equity. As the work of cancer and the patient pathway appear to impact directly on 
quality of life, the function of the MDT as originator of decision-making is of 
paramount importance. A process of peer review is the method of quality assurance 
used by cancer services across England and Wales that originated from the Cancer 
Plan (DH 2000). Teams are encouraged to look at their own practice and regularly 
audit their own service. In this way a dynamic system of improvements can be 
facilitated. In addition teams from Networks out with the cancer centre appraise and 
observe the MDT in a formal system of analysis.
1815.3 Lens of diagnosis and quality of life
“Illnesses become narratives very rapidly. Some sense is sought of time and sequence, 
for one’s self and others. The past confusion is explained, the present situation 
requires a story, and the future presents the possibility of terrifying resolutions.”
Jackie Stacey (1997)
Teratologies-a cultural study of cancer.
It is interesting to note how often the time of diagnosis is part of the narrative. The 
author quoted above is a sociologist who has written about her own experience of 
ovarian cancer. Stacey (1997) asserts that narratives offer a way of ordering events 
and assigning roles, it gives a temporal continuity and spatial coherence. The 
diacriosis of cancer is likely to be s neostive life ( “xnpripnrp  nnH the r»atholoov of non 
small lung cancer and probable prognosis and life expectancy is one that is recounted 
as negative by the respondents, but the manner and communication of diagnosis, 
particularly the frequency of atrocity stories, is surprising.
Observational fieldwork of the multidisciplinary team meetings across one cancer 
network was undertaken prior to the study and at various convenience points within 
the study lifetime. Refection and audit are encouraged as peer review by the DoH ( 
DoH 2000). The observation of behaviour and attitudes of staff in these meetings does 
not match the perception of the patients. Yet narratives of the time of diagnosis are 
seen not only as negative in the patient-clinician relationship, but almost as amoral.
182A possible reason for this is the groups observed in fieldwork.  No respondent 
received a diagnosis from an oncologist of any grade or a clinical nurse specialist. 
Chest physicians were the object of some of the negative diagnosis narratives but 
these individual physicians were not observed by the researcher in the MDT setting as 
they were from outside the cancer network in which this study is set.
This is significant in terms of the modernisation agenda as it demonstrates that those 
who receive training, guidance and are the followers of best practice do not deliver the 
diagnosis. The implication is thai oesi practice is nut being followed because the 
modernisation agenda is not being correctly targeted (Fig 5.5).
Fig 5.5 The observed discrepancy between target groups when delivering the cancer 
modernisation agenda. A potential for the source of atrocitv stories?
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DoH good practice
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183For those with serious illness there is seldom one objective truth and the patient 
experience may change over time (Strang 2000). Respondents seemed to be consistent 
historians. Examination of the medical notes shows consistency for example of 
histories given in clerking.
The coded responses around the communication of diagnosis represent approximately 
10% of the responses by content analysis with codes as follows:
1  How diagnosis was communicated,
2 Attitude of HP,
3 willingness/reluctance of HP to discuss life expectancy,
4 Information needs not met,
5 Reluctance to discuss emotional distress,
6 & 7 Atrocity stories,
8 NA
9Feelings of shock numbness or distance at diagnosis 
Fig 5.6 Distribution within this root code:
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Communication of diagnosis and communication of cancer bad news is still rarely 
examined although a process of change does seem to be underway. Some scholars 
such as Robert Buckman assert that the less than optimal delivery of bad news is part
184of the socialisation of medicine. Buckman (1996) suggests that part of the culture of 
medicine for many years was to avoid the truth, as the writings of de Sorbiere (1672) 
who thought that truth telling would jeopardise practice.
In 1961 Oken’s seminal study into disclosure of cancer diagnosis by American 
surgeons showed that 90% of surgeons in the USA would not routinely discuss a 
diagnosis of cancer with the patient. Novack (Novack et al 1979) repeated the study to 
find a shift in attitude. Less than twenty years later, Novack et al found that 90% of 
physicians now would speak to patients about a cancer diagnosis. In the twenty-five 
years since Novack’s work there have been many social, political and legal arguments 
to support truth telling. The legal argument has prevailed ir* the USA, however in the 
UK and Europe, there ir*  still a reluctance to discuss such issues. This is an issue in 
UK healthcare because of social, economic and educational migration. EU working 
practice and free trade agreements make working in the UK an attractive educational 
experience for doctors from countries where a reticence to share information may be 
socially acceptable.
In 1993 Thomsen et al found that 60% of European gastroenterologists did not tell 
patients a of a cancer diagnosis unless the patient asked. In Italy Grassi et al (2000) 
found that of 675 physicians about 45% agreed a patient should always be told of a 
cancer diagnosis, however only 25% would routinely do this.
Buckman also points out that it is not only the content but the delivery of what is said 
to patients. He points out that there are many reasons for not wanting to do this part of 
the job such as the ongoing need to provide support, but also makes clear that it is a
185responsibility that is not optional and that “if breaking bad news is done badly, 
patients and their families (or often their lawyers) may never forgive us”. Perhaps this 
is why patients with advanced NSCLC used diagnosis as a lens through which to view 
the rest of their journey.
Respondents narratives often referred back to the time of diagnosis throughout the 
interviews, not just at the inventory stage.
“I have been going through it from the day I was told... .when he first told me my first
thought was about death and then in a split second it was for my children  ”
49-year-old male
R: “that day keeps coming back, when I got the x-ray results, mostly a night or when I 
am on my own, I go over it again and again in my mind. That has affected my quality
Vi  liiV  i  U iiiliV
I “in what way?”
R “it comes back when don’t expect it, it stops you doing normal things.”
54-year-old woman
This lens of diagnosis seems to overlap with the atrocity story. The respondents view 
the rest of their journey through this lens:
“I keep going back to it...it seems so unfeeling...like he was embarrassed or 
something”
Cassell (2004) remarks on the wholeness of the past tense, to a time before illness. 
This is also offered by others such as Scarry (1985) who remarks:  “What is 
remembered in the body is remembered well”
186This was a recurring narrative. Respondents often referred to themselves in such a 
way. Common phrases such as “before I was ill” or “before tfo; cancer” often prefixed 
narratives about a good quality of life:
“before I found out abo^t the cancer we had just been to New York, we had a good 
quality of life then”  68 year old woman
If the concept of the treatment calendar is considered at this point, the early illness 
and then treatment calendar has influence. At the diagnosis and pre-diagnosis 
milestones the life calendar undergoes disruption. Newly diagnosed patients are 
threatened with disruption and probably cessation of their life calendar. In addition the
r*olSTldZ”  +K r» i11rsr‘« ’c/+r,r“ Qfmr*«t r'alr'nrlctr-'fiit’irp nlfltic  oivp wnv tn
medical commitments and the sick role. This may be why respondents used the past 
tense to describe the person without cancer as themselves.
Information needs bein.5 or not being met were also cited as having an effect on 
quality of life at diagnosis. This has been shown previously in the context of the GP 
and atrocity story-particularly in the context of life expectancy. This fulfilment of this 
need was often met at the cancer centre and in particular by the specialist nurse, chest 
physician or oncologist:
“I just felt finally someone knew what they were talking about and what to do next, 
things were a lot better after that”
54-year-old woman
“Don’t tell me to go away and don’t worry about it, I need to know that its, that I can 
continue on my own.. .1 mean maybe other people don’t want that.. .they need to be 
told fibs”  69 year old woman
187These issues around information reiterate the issues around trust. If incorrect or 
inconsistent information is given that is later contradicted, the patient-health 
professional relationship is damaged. This has been recognised for many years, 
particularly in nursing and has been verified by a recent National Audit Office report 
(NAO 2005). Much of the transfer of information is at the pre diagnosis or diagnosis 
milestone when information needs are high:
R “after the bronchoscope I had at [referring hospital] he [?chest physician] said “well 
I did see something down there but its probably nothing to worry about, it doesn’t 
look too nasty, but you know, we’ll wait for the thing to come back” and I thought 
what a thing to say....and then it came back cancer”
I “do you think he should have said something different?”
R “C [daughter in iawj worked m tiic department and slic said ne was opuimsuc, until 
he knew I feel actually It’ed be better not to say anything at all, you know take a few 
samples but not tell you it looks OK and then a week later you get a smack in the gob 
like that”
I “do you think it made a difference  the way you heard the diagnosis?”
R ’’yeah it was much worse, more of a shock, that’s really affected my life I think, cos 
you know, we weren’t expecting it really, I don’t smoke or am/thing, then he just said 
“you’ve got cancer do you want to talk to [Macmillan nurse] our Macmillan nurse?” 
and I got out of there and thought, wait a minute he’s just told me I’m dying.”
I “right”
R “ but it hadn’t sort of struck me or I hadn’t digested it  It was like well here it is
and you’ve got that murh to live and  I couldn’t talk to [Macmillan nurse] and I
just got out of there  that time has affected things I think.. .it being such a shock and
no-one knowing if I could get any treatment  they tell you different things”.
54 year old woman
188Many cancer diagnoses offer some hope of recovery and return to the “normal” 
previously functional self. This is playing the part of the sick role, as expressed in 
Talcott Parson’s seminal work (Parsons 1951) of the social rights and obligations of 
the sick. To comply with treatment and become well again-to take up a useful role in 
society in return for the support of society during illness. Patients with advanced lung 
cancer are unlikely to fulfil this obligation as it is likely to be an illness without 
recovery, which respondents expressed as a factor affecting qvality of life.
Lung cancer still seems to be surrounded by therapeutic nihilism, expressed at time of
diagnosis, which respondents cited as having an impact on quality of life:
P  “it iiict oil SOIindcd SO final.  knOw . H ?_T -rr*  cninp  n ff nnH Hif*  lifp jq
over  weii ihai’s a bit uuiair reaiiy, they were very nice at [ret iiospitaij and said
they would get a Macmillan nurse to see us. My sister in law lives in the states and 
when [wife] spoke to her, she went to see a friend who is a doc tor, I think he looked 
up something from the Internet because a few days later lots of information arrived 
about treatment and so forth, chemotherapy and radiotherapy and some experimental 
treatments, we knew then that we had to find some way of getting these treatments, to 
try them, that it wasn't the absolute end for us-that improved the outiook and by 
default, quality of life.”
I “in what way do think it improved your quality of life?
R “I think... .its about having something, anything really, some hope after all the 
doom and gloom (laughs)!”  62 year old man
The denial or displacement of the word cancer at diagnosis was cited by respondents 
as a negative part of the process:
“I knew something wasn’t right  it was a shadow on my x-ray, I’d had a cough for
about three months and my GP sent me for an x-ray, he said they found a shadow and 
I thought cancer straight away cos that’s what they call it.”
70 year old man
189“I saw lots of people.. .1 can’t remember who they all were, but I remember this 
doctor at [referring hospital] he told me about the growth that they saw on the scan. I 
was really shocked when the other doctor came round, I know now he was the cancer 
doctor, and said I could go to [cancer centre] if I wanted, for chemotherapy.. ..I 
thought, hang on that’s for cancer so I asked him, like, have I got cancer and he said it 
was cancer.. .no one had said it was cancer before.”  69 year old man
In the national study referred to at the start of Chapter 2 by Krishnasamy and Wilkie 
(1999) the language used to communicate diagnosis was one of the items examined in 
needs assessment in lung cancer patients. Although this study is now seven years old 
and pre-dates the majority of the Department of Health cancer initiatives, it is one of 
the few pieces of work involving lung cancer patients and there is nothing more recent 
that is comparable in the iiterature.
Krishnasamy and Wilkie (1999) found that only 58% of individuals (n=l 15) had been 
told they had cancer or lung cancer. The use of language in this study can be seen in 
Figure 5.7
Fig 5.7 From Krishnasamy & Wilkie 1999-use of language in the communication of 
NSCLC
Language used to 
describe illness
Number of patients using 
language
Number of doctors using 
language
Cancer 30 30
Lung Cancer 67 64
Specific Diagnosis 19 21
Malignancy 4 7
Shadow 4 2
Growth, lump, tumour 
mass
70 72
190These authors also report that in their study, 10% or respondents felt not at all 
prepared when asked if they had received information about treatment.
There is a reticence of those working outside of cancer settings to use the word 
cancer. Jackie Stacey (1997) quoted at the start of this chapter recalls her own story of 
the mid 90’s, of her surgeons telling her she will receive chemotherapy for her cyst. 
This is also the lived experience of the researcher. Upon approaching patients to take 
part in clinical chemotherapy trials, occasionally patients would not be aware that the 
disease they were being treated for was a cancer. However, after two years 
ethnographic research (unpublished) as a participant observer in thoracic surgical unit, 
the researcher found thi«? nrarticc of avoidance to be common.
The most common method of delivering bad news such as unsuccessful lung cancer or 
some diagnostic surgery, was a “hit and run” technique. This involved delivery of 
diagnosis in the anaesthetic recovery area before patients were fully awake and with 
poor recall. This avoided interaction with patients and even in this situation 
euphemisms were often used particularly the word “growth”. This was common in 
observed surgical practice over a two year period.
Ward rounds are part of the medical ceremony (Dingwall 1977) of surgical life, and 
an average surgical ward round of eight patients took approximately twelve minutes. 
This demonstrates the lack of social interaction in surgery and possibly other medical 
specialities in which pa dents are diagnosed and treated before they have access to an 
oncology service. Ward rounds from the oncology members of the same 
multidisciplinary team take over one hour to see six patients.
191The modernisation agenda in cancer has attempted to address this issue in terms of 
communication, but only very recently (NICE 2005) and only in clinical areas such as 
oncology, haematology and palliative care. This is one of the few measures that 
examines and intends to address the quality of the service provided, rather than the 
dominant factor which is to provide an increased quantity of service (Dingwell 2001) 
to meet set targets such as wait times. Such reforms do not address the underlying 
issue, one of fear of the professions to talk about cancer. Respondents have used 
words such as “embarrassment” and described closed body language that 
demonstrates the reluctance to discuss the subject “he just looked at his feet” or “he
just left”  Patient*; on w:*rHc c  r *   rp  f'ti  rn  q  c describe bine  bine beb.nvieur  ir-
“he was at the door” signifying the end of the consultation at diagnosis. This is 
closure on the terms of the health professional, and not the patient who may leave or 
be left without all information needs being met.
An articulate example of this is again given by Jackie Stacey ia her experience on a 
surgical ward as a cancer patient:
“shortly before I left hospital one of the more sociable nurses sits on a patients bed 
down the row from me and starts to chat about her work. What are her ambitions, one 
of the patients asks her. She would love to work in oncology, she replies. Suddenly 
she catches sight of me she, blushes with embarrassment. Una ware of the reason for 
this mood change the patient asks her what oncology is. The whole ward falls silent.
“it’s  ” she glances nervously in my direction, hesitates and never finishes her
sentence, she had better get on with her tasks she announces. Have I a disease so 
unspeakable I wonder to myself?”
Cancer is still an illness that even health care professionals try to avoid. A study by 
Jessica Comer (Comer & Wilson-Bamett 1993) showed that newly qualified nurses 
found the meaning of cancer to mean poor prognosis and associated with death. Much
192more recently the same issues have been raised in nursing and are being addressed 
through education (Stegmga et al 2005, Leary 2005) and work has been done in areas 
such a palliative surgery which supports the unprepared naturp of the practitioners 
working in this area in dealing with the emotional burden of this work (Galante et al 
2005) but little has changed when considering staff attitudes. Such negative attitudes 
have a negative effect on the quality of care.
Respondents spoke at length of the experience of diagnosis, pre diagnosis and in one
respondent’s case, re-diagnosis of lung cancer, some typifications can be made:
•Repetitive theme-not just at inventory stage 
•Often viewed as atrocity stories 
•Rest of ionmev is fomsspH tkrrmoh
The lens of diagnosis constructed from responses is shown in figure 5.8
193Figure 5.8 The lens of diagnosis in the respondent group.
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194Chanter 6 A
Quality of life
Suffering in the 
Context of Advanced 
Lung cancer 
And
The Worth of Treatment6 Suffering
Much theoretical work has been done in the last thirty years, which examines the 
concept of suffering. While suffering is associated with illness and is a facet of human 
nature, it has only recently been accorded any legitimacy within the health care 
literature and the professions (Cassell 2004, Morse and Johnson 1991), it is now 
recognised as an entity in cancer nursing practice as part of assessment and holistic 
care delivery (Houldin 2000).
In this chanter the majority of the rpcrwiHents n^rrctives end the nnnlysis of the 
accompanying data is presented  Althmmh th#» nnti*»«t jr»nrr»<»y o«ri  v/crk cf concer 
provoked the most typical and greatest number of responses in one core theme, the 
majority of the data can be grouped into context of suffering.
This data consists of respondent narratives and coded responses. Data collected ai 
time of interview and the majority of the EORTC QoL 30 data collected as part of the 
original study. This section therefore examines the physical, psychological, social and 
functional coded data. From the interviews these are root codes of:
•  Psychological well-being
•  Physical well-being
•  Relationships with significant others
•  Health behaviours
•  Spirituality
•  Changes in role/social function
196The EORTC QLQ 30+LC17 domains reflect this data:
The functional domains
Physical functioning 
Role function 
Emotional function 
Cognitive function 
Social function
Symptom scales
Nausea and vomiting 
Pain
Dyspnoea 
Insomnia 
Appetite loss 
Constipation 
Diarrhoea
LC+17 domains (specific lung cancer domains) 
Cough 
Haemoptysis 
Dyspnoea 
Sore mouth 
Dysphagia 
Hoarseness 
Peripheral neuropathy 
Pain in chest 
Hair loss 
Upset by hair lossFever 
Global quality of life
These data from the interview studies are compared to the EORTC QLQ 30 data, 
which strives to quantify quality of life and as, has been shown in chapter 2, does so 
largely from a functional perspective. Do these data support a quality of life as 
interpreted by respondents as one in which there is suffering?
What is suffering? It is as subiective a term as quality of life but unlike QcL there 
seems to have been little pressure from areas snob as tbp ncypbr»_rm™Wy movement 
to, in some way, measure suffering in the same way that quality of life is “measured”. 
Suffering as an entity or the relief of suffering is not seen as an achievable endpoint. 
This is puzzling as the apposition of the relief of suffering in medicine is entrenched 
through western history as the study of the classical schools. Much of the literature on 
suffering originates in disciplines such social science, medical sociology, 
anthropology and nursing. These disciplines hold an advantage in the examination of 
the lived experience of lung cancer patients, as they are not confined to the occasional 
limitations of deterministic or reductionist methods of study that require integer 
outcomes.
Science is capable of such action as it deals with generalisations, but medicine deals 
with individuals-this resonates back to the classical period, a conflict between the 
emphasis on theoretical knowledge and the actual experience of the doctor with this
198patient (Zaner 1988). Despite its purposeful individualistic approach, medicine is also 
trapped by technical rationality-practitioners are seen as technical problem solvers 
(Schon 1991). This means that physicians are caught in a dichotomy between the 
application of science to a population and the treatment of an individual and suffering 
is an individual experience.
The benchmark of the modem medical literature on suffering was the work produced 
by physician Eric J Cassell in 1982, who noted that medicine tends to focus on the 
body, whereas suffering is an experience of the whole person. After further work, he 
states in 1992 that is not possible to divide problems into physical, psychological and 
social aspects because suffering is an experience of the whole person as a state of 
distress induced by the threat of loss of intactness or disintegration no matter what the 
cause.
The preface to his work Eric Cassell, a physician, (Cassell 2004) explains this line of 
reasoning in an articulate manner:
“The test of a system of medicine should be its adequacy in the face of suffering: this 
book starts from the premise that modem medicine fails that test. In fact the central 
assumptions on which twentieth century medicine is founded provide no base for an 
understanding of suffering. For pain, difficulty breathing or other afflictions of the 
body, superbly yes, for suffering, no. Suffering must inevitably involve the person- 
bodies do not suffer-persons suffer.
Eric J Cassell
The Nature of Suffering and the Goals of Medicine 2004
199Suffering was further developed in the context of nursing/caring by Kahn and Steeves 
(1986) who proposed that a person experiences suffering when some crucial aspect of 
self, being or existence is threatened. The fact that advanced NSCLC is currently a 
life limiting disease would constitute a threat to the integrity of the person. In later 
work Kahn and Steeves (1995) developed the clinical relevance with the help of 
aphorisms from suffering-summarized with an understanding of suffering experienced 
by the whole person (Arman and Rehnsfeldt 2003).
Rodgers and Cowles (1997) examined suffering as a concept in the nursing literature 
and concluded the suffering is “an individualised, subjective and complex experience 
that involves the assignment of intensely negative meaning to an event or perceived 
threat”
Although suffering is a concept that is hidden by everyday English in everyday life as 
concepts such as pain, anxiety and fear, it is unlikely that these words alone will 
capture the meaning of suffering (Arman and Rehnsfeldt 2003). Suffering occurs in 
many life situations and has many levels of meaning. To alleviate suffering a person 
must be triggered by something so that the struggle for development takes place. The 
struggling act of suffering demands a compassionate other to confirm the suffering 
(Lindholm and Eriksson 1993) which might lead to meaning as a shared experience or 
as Rehnsfeldt proposes, in communion (Rehnsfeldt 1999).
200Authors such as Frankl (Frankl 1984) take a philosophical tone, which originates from 
the classical schools and also has spiritual undertones:
“We must never forget that we may also find meaning in life when confronted by a 
hopeless situation, when facing a fate that cannot be changed. For what then matters is 
to bear witness to the uniquely human potential at its best, which is to transform a 
personal tragedy into triumph, to turn one predicament into a human achievement. 
When we are no longer able to change a situation, we are challenged to change 
ourselves”
V. Frankl 1984
Frankl asserts, like Cassell, that the person rather than just the body, experiences 
suffering.
Medicine is where patients with lung cancer (or any other disease for that matter) turn 
to alleviate suffering. The ontology of medicine reflects physical embodiment with 
the emphasis on curing disease. Medicine not only pathologises quality of life by 
using functional scales to measure a subjective experience, it also pathologises 
suffering as it can only reply to such challenges with pathology which can be treated. 
If Cassell’s line of thinking is adopted, does medicine fail patients with lung cancer if 
it does not seek to alleviate their suffering?
2016.1 Illness and suffering-having cancer
There is a dearth of qualitative literature examining the lung cancer population and it 
has not proved possible to find qualitative literature that deals specifically with 
suffering in lung cancer. This is despite utilising the specialist search mechanisms 
employed in Chapter 2, specialist historical and archive searches performed by library 
professionals at University College London, The British Library and a search of the 
Steinberg Collection- a collection of nursing and related theses which dates back to 
the 1950’s.
There is however a omurina body of knowledge around suffering in me toutci 
population which gives perspective, particularly as some of this work is from 
palliative care. Medical sociologists and nurse researchers are examining the 
experience of cancer and the attendant experience of suffering.
Much of the literature on suffering in cancer appears to come from Scandinavia, a 
study by Hallorsdottir and Hamrin (1996) interviewed nine people in 
recovery/remission from cancer and found an overriding theme of “experiencing 
existential changes” which had the sub themes of uncertainty, vulnerability, isolation, 
discomfort and redefinition, A study by Kuppelomaki and Lauri (1998) examined 
suffering in patients in the palliative stages of cancer. They found evidence of 
Physical, psychological and social suffering-the psychological and social suffering 
was underpinned by the physical- the disease and the treatment of the disease.
202Annan and Rehnsfeldt (2003) explored suffering in patients with breast cancer 
(different stages/prognosis) and found that the early stages of the experience caused a 
sudden disruption and disintegration of the person with the evident awareness of death 
being significant to the individual. This experience caused the individual to suffer.
Suffering is a personal matter, unique to the individual experiencing it. Suffering has 
temporal quality for example Cassell (2004) states that fear always involves the future 
(for example a fear of v/h2t will happen rathci  Lhcm  what is happening) or ihai me 
lived past is projected into the future and suffering is onticiPaU.J which hi ium causes 
suffering in the present “one can suffer again the injuries of yesterday”  (Cassell 
2004). Persons also suffer when they have lost. When the relationships with others, 
the physical world, the future is lost, suffering occurs because the intactness of the 
person is lost.
A cancer diagnosis represents many of these facets. Uncertainty in the future, possible 
loss of future, loss of relationships with the physical world, social environment and 
loss of independence because of the work of negotiation of the illness and treatment 
calendar are just a few example of this. Cassell gives an excellent example in cancer 
of the facets of suffering in the individual
203A thirty five year old sculptor with cancer of the breast that has spread widely was 
treated by a competent physician.. .At every stage the disease and the treatment was a 
source of suffering to her... .She was constantly tortured by fears of what tomorrow 
would bring, each tomorrow worse than today heralding sickness, pain or disability- 
never as the beginning of better times. She felt isolated because she could not do the 
things other people could do, she feared her friends would stop visiting her and she 
feared she would die.”
This is an excellent illustration of the multifaceted nature of suffering of the person. 
This woman had severe physical pain and other physical symptoms that caused her to 
experience suffering. However she also suffered threats that were to her personal and 
social existence. She suffered the effects of the disease and the effects of the treatment 
that caused not only physical suffering but feelings of loss in terms of her appearance 
and her abilities. Her disease caused her to lose her means of living and the pride 
associated with it, along with her professional identity. Finally she also suffered from 
her own perception of a future that was anticipated with fear and loss.
Cassell (1998,2004) also points out the relevance of meaning. Chapter 2 referred to 
the meaning of certain issues in cancer, such as the word “cancer” the meaning of 
pain etc. An example was given in Chapter 5 to illustrate communication is repeated 
here to show “meaning”. This demonstrates the meaning ascribed to the word 
“shadow” by a 70 year old gentleman:
“I knew something wasn’t right  it was a shadow on my x-ray, I’d had a cough for
about three months and my GP sent me for an x-ray, he said they found a shadow and 
I thought cancer straight away cos that’s what they call it.”
70 year old man
204It is important to acknowledge the meaning ascribed to language-indeed it can be 
argued that this is the function of language. For the same word, event, object or 
relationship, a person may have simultaneously experience a cognitive meaning, an 
emotional or affective meaning, a bodily meaning and a transcended or spiritual 
meaning (Cassell 1985). Meaning in suffering is important because although unique 
to each individual it is a shared process-almost all humans suffer in their own way. 
Although a shared human experience the language of suffering is unique and personal 
to each individual (Rodgers and Cowles 1997).
XJ..-------
X xvuiiu.1 a   i iiol vicweii as the opposite ot health, but is mtegratea into Human 
iksson 2001). SuiTciing is compatible witn Health it the 
suffering is bearable (Arman and Rehnsfeldt 2003).
The ontology of health has three dimensions. Health as having/doing: The person is 
focussed on health problems and external matters such as health behaviours, disease 
and medicine. Health as being: The persons deeper needs and longings, these can be 
beyond articulation and strive for a balance or harmony, Health as becoming: is a 
process of reconciliation, the person reconciles themselves to the present situation as 
is able to face suffering and death. The person then strives for development, to 
become more whole (Fagerstrom and Bergbom 1998).
Ontological suffering in cancer (or any life/person threatening illness) is described in 
a similar way (Fredriksson 1998) Having suffering is experienced as sorrow, fear and
205alienation. Being suffering includes more intense feelings such as distrust, distrust, 
hopelessness and a lack of freedom. The becoming of suffering the existential 
perspectives are examined such a life and death.
Cassell argues that the grip of this is loosening (Cassell 2004) particularly in 
medicine. Medical ontology has been to view the patient as the unlucky recipient of a 
disease to be treated-in the strict ontology of medicine the disease is the focus of the 
attention-it would not matter which individual had it, the effect would be the same. In 
the observed practice of some members of the cancer multidisciplinary team the 
ontology is undermined with a prevailing attitude of a disease that is integrated into 
the life of the person. Many comments from members of each multiprofessional team 
across the cancer network demonstrated this via a degree of empathic response to the 
life situations of the patients, for example if the patients had young children. The 
observed confirmation of this was through the medical-technical roles of the 
pathologist, radiologist and surgeon whose speech deferred to the ontology cited by 
Cassell of the abstraction of a disease process.
Is it possible to control or alleviate suffering? Certainly that is often the professed 
aims of the healthcare professions. Suffering remains a complex issue and requires 
work by the person with cancer often faces suffering in terms of loss. This can be a 
cascade of loss such as threat to the person, failure of treatment and loss of body 
image (Houldin 2000). The reasons for suffering are variable and the nursing 
literature supports meeting the person in their suffering and moving with them as the 
compassionate other as they go through the experience (Byock 1994). Nurses seek to
206understand the suffering of the person with cancer by offering authentic presence and 
empathic caring (Houldin 2000). The impact of bearing witness to suffering often 
creates suffering in clinicians. This suffering may cause those professionals to 
maintain emotional distance and not make time available to patients or focus on the 
treatment or disease (Klagsbrun 1994). This in turn will change the perception of the 
person with cancer to that professional.
As indicated in the introduction to this Chapter, suffering has recently been accorded 
legitimacy in the literature. Over the last twenty years the concept of suffering has 
become more widely accepted and a thus a component of this work.
2076.2 The lived experience of advanced lung cancer in the context of suffering
The literature can offer little that is specific to the population of advanced non-small 
cell lung cancer in terms of suffering. Specific searches for NSCLC and suffering (of 
anything other than linked purely to physical parameters) yielded one paper (Benedict 
1989) which was utilised a basic Likert scale from “very much” to “none at all” 
arranged over five points. However the findings presented here are compared to the 
other literature which examines suffering in poor prognosis patients in addition to the 
other sources of data aforementioned.
The  responses from respondents were « response Jo cApIiun questions asked 
about quality of life. These narratives have been framed within the context of either 
the experience or alleviation of suffering. The responses themselves are also framed 
as narratives, with particular reference the having, being and becoming of suffering. 
The responses in comparison with the other data begin to give meaning to the 
experience.
2086.2.1  Psychological well-being
Psychological well-being was the most diverse and prominent root code, second only 
to patient experience from the interview studies. The range of coded responses is 
presented in Fig 6.1
Fig 6.1  Root code Psychological Well-being
---------------------------------------------------------
■
I  w
1  Ability to adjust to diagnosis/prognosis
2 Ability of significant others to adjust to diagnosis/prognosis
3 Suffering-Inability to adjust to diagnosis/prognosis
4 Suffering-Inability of significant others to adjust to diagnosis/prognosis
5 Feeling independent
6 Feeling Isolated (psychological)
7 Suicidal ideation
8 Emotional distress*
9 Labile mood/mood swings*
10 Depression*
11 Feeling fear of unknown (e.g. suffering “what happens when you die?)
12 Feeling well (psychological)
13 Feeling relief
14 Experiencing other mental health problems
15 Change in body image
16 Suffering caused by uncertainty (e.g. not being able to make plans)
17 Feeling guilty (smoking)
18 Feeling guilty (other)
20919 Feeling determined/not giving up
20 Feeling disbelief
21 Feeling Failure
22 Feeling Anger
*as defined by respondent
All of the respondents talked about the psychological impact of disease, particularly 
around diagnosis and patient experience. For this reason the responses of patient 
experience and psychology are not mutually exclusive.
A strong topic in the respondents’ narratives was the experience of living with 
uncertainty. This was typically viewed as a negative experience and a negative 
consequence of the journey. The uncertainty of living with illness has been explored 
in this work, but as this is such a prominent topic it is explored further here in the 
context of NCSLC-this supports the literature in other life threatening diseases.
Illness related uncertainty is highly complex and as a construct uncertainty has both a 
perceptive and cognitive component (Houldin 2000). Mischel (1990) developed a 
theoretical model of uncertainty in illness organised around four categories:
1, Antecedent factors, which precede and contribute to the perception of uncertainty, 
such as illness severity, personal beliefs and social support
2, Uncertainty and its personal appraisal as a threat or opportunity
3, Problem focussed and emotion-focussed coping
4, Adaptation
210These elements are all apparent in typical responses:
“..quality of my life... .its about doing the normal everyday things... .since I’ve had 
this... .the treatment’s not been too bad, I go to work and do all the normal things I 
used to do, but I can’t make plans anymore and that’s really difficult. I can’t say to my 
girl, “don’t rush your wedding plans, get married in the summer” like she wants to 
instead of rushing on account of me”  60 year old man
“when I’m doing things its OK, I feel OK, its when I’m on my own, my mind just 
starts... I suppose you cant help it really... .my mind just wanders off and I start 
thinking about things, you know the kids, E [husband] how are they going to get on
after I’m gone  Its hard when you don’t know when.. .how long”
54 year old woman
“I kept on at work, they said I could take the sick or retire on medical grounds but I’m 
only part time and I’d really miss it you know, its company and it steps me thinking 
about things”
R “how does it help?”
“seeing other people, they are a good bunch there [work] there is no point worrying 
about things, I cant do anything about it and I don’t know when I will get ill and have 
to stop”  64 year old woman
In common with the respondent quoted above, living with uncertainty and the 
suffering associated with this was linked with emotional distress or changes in affect:
“I get so angry at times, for no reason... .1 just fly off the handle... I never used to get 
so angry”  62 year old man
“I get so frustrated at times, I think its because you cant do anything about it, you 
don’t know what’s going to happen, what its going to be like”
54-year-old woman
The experience of uncertainty is personal, and has degree of significance to each 
person. The personal perception of uncertainty appears to play a major role in
211appraisal of and coping with the situation. To understand the situation it is necessary 
to place the illness in its biographical context-what life was like before the illness 
intruded, what hopes were lost or changed (Corbin and Strauss 1998). This can also 
be viewed in the context of the illness calendar as described in Chapter 5, the 
temporal nature and expectations of the person. It is not the cancer-the disease per se- 
that is feared, but what a cancer diagnosis represents, the multiple meanings of a 
future in which cancer diagnosis will dictate.
There does not seem to be a relationship between illness severity/progression and 
uncertainty (Hilton 1988, Mast 1995) Uncertainty in cancer is also a personal 
experience  Patients need to construct personal meaning of the illness to understand 
the event within their own lives, the appraisal of a situation as dangerous and the 
perception of a high level of uncertainty and thus vulnerability, results in greater 
disturbance in psychological and emotional well being (Wineman et al 1996, Houldin 
2000).
Because of the subjective experience of uncertainty, it is not possible to generalise 
from the literature which coping strategies effectively reduce the emotional distress 
caused by uncertainty. For the respondents, distraction was a technique mentioned by 
many:
“I needed people who needed me, you know, so many people were depending on me 
to do good jobs for them”  72 year old woman
“I had to go to work, so I didn’t allow my self time, I call it a luxury to be depressive 
because then you can just pack up and give up”  62 year old woman
212Some respondents focused on the experiences of others-helping others cope with 
treatment acts as a distraction and comparisons of those “worse off’
“For C it all seems so unfair. There is no sense to that of course, anything can happen 
at any time but.... its almost as if her life has been stolen....” 69 year old woman
Emotional distress is a recurring sub theme, and can be seen as labile mood,
depression, fear of unknown and suicidal ideation.
Two respondents talked about dealing with uncertainty and gaining control through 
suicidal ideation, some fear of the unknown at the end of their lives (in the embodied 
sense rather than purely the existential) both with sub themes of psychological 
isolation:
[This selection also demonstrates the ethical difficulties of interviewing those who are 
dying and have potential vulnerability. R=Researcher]
“well I often wonder what people are thinking, people like me. they probably do find 
ways of getting out”
R “hmmm”
“pulling the plug, it costs a lot”
R “Really?”
”yeah, you have to go abroad”
R ”you are very frank about it, it obviously concerns you quite a lot and you have 
given it a lot of thought”
“well yes, if you feel you can control it you know, and a way that is fair to everyone 
else, you just cant tell anyone else in the family  ”
R “yeah?”
213”  there’s no real dialogue about it. They have their problems facing up to that
issue. If I could talk to them maybe I could convince them that [inaudible] with dying 
in horrible circumstances, what are the alternatives? They could see it makes sense.”
R “Do you see the end of your life as being like that? From listening to you, and I 
know we are going a little off track here but it concerns me, you seem to have decided 
that the end of your life is going to be a really terrible experience”
“It could be if I loose all control, and obviously I am bound to loose control. If they 
said at the beginning that it’s the kind of illness where you are walking down the 
street and you just drop dead, so, no, if it was that it would be quite a relief actually”
R “right”
“If you could just, have a heart attack or something and then you’re gone and that 
would be better. Have you got something that induces a heart attack? [both laugh] but 
really, I am gonna need more drugs and control is gonna be taken away from me 
because of the drugs.  That’s the thing about quality of life, having control is a big 
nart of aualitv of life”  48 vear old man
A  i   y
[Interviewer further explored  fears around death and psychological distress-this 
respondent agreed to referral by the researcher to a local psychologist and handover 
of  some information to his local palliative care team]
or
“I cant see myself going out as a hero, I don’t know, jumping of off the white cliffs of 
Dover.. ..I did see that as the practical answer to a problem that’s facing me. That 
doesn’t mean I am suicidal or a danger to myself, it means the answer to a problem 
that is my head at the moment”  60 year old man
and
“.. .quality of life is going to deteriorate, and there must be some level at which, and 
we cant get into times cos doctors wont tell you, I cant ask my doctor to terminate 
everything today cos I’ve had enough, well I can but they wont take any notice”
R “hmmm  how do think quality of life will deteriorate?”
“ its going to be harder to make my own decisions....and then.. .having to rely on 
other people for everything”
64-year-old man
214This shows the having, being and becoming of suffering in cancer described by others 
and explored in the beginning of this chapter (Fredriksson 1998).
The becoming of suffering is seen, the work being done by the respondents narratives 
show how each respondent is working through their own experience.
Quality of life as a psychological construct
Respondents’ narratives use the term “quality of life” explicitly in the psychological 
themes. In other themes there was occasional usage of the phrase, however in the 
psychological theme and sub themes the term was used to describe issues around 
control of life choices, depression, mood changes, uncertainty and fear of the 
unknown:
“I don’t know.. .the more I try to cope with it all the worse my quality life seems”
48 year old man
Is quality of life a psychological construct? From these data it seems likely. The idea 
that quality of life is best understood as a psychological state has gained popularity 
over recent years-Rapley calls this “cultural common sense” (Rapley 2003). Chapter 2 
explored definitions-or lack of-when considering quality of life as an entity. As a 
psychological construct it makes much more sense. Cummins et al offer a theory of a 
biological, hard wired brain state, and Cummins (2001) provides a homeostatic model 
to support this. Cummins argues that since the seminal studies of Campbell et al
215(1976) the view that personal or subjective well-being is made up of affective or 
cognitive components has become accepted. This is referred to as subjective well­
being.
In the examination of six national samples, Crooker and Near (1998) concluded that 
the distinction between the affective and the cognitive is illusionary but Cummins 
group have continued using this dichotomy with interesting results.
The presumed cognitive element of subjective well being from Cummings suggests 
that personal evaluations of this dimension are generated via the internal computations 
of multiple comparisons. The net satisfaction from this is described as a positive 
linear function of the perceived differences between what one has versus
•  What one wants
•  What others have
•  The best one has had in the past
•  What one expected to  have hi the past
•  What one expects to have  in the future
•  What one deserves
•  What one needs
Although this can be interpreted in the context of suffering and is comparable to the 
narratives elicited from the respondents, it is not clear what kind of mathematical 
operation would be needed to validate this (i.e. function of x and y) to yield net 
satisfaction.
Some of Cummins work is confusing; a commentary given by Mark Rapley (2003) 
about the internal calculation of subjective well-being with its duel component state 
(cognitive and affective) confirms this. Whilst Cummins insists on an affect and
216cognitive component as separate, his biological (or indeed mathematical) theory relies 
on the combination of these distinct areas to yield subjective quality of  life (SQOL) 
(Cummins 1997).
Cummins et al (2005 in press) state that SQOL can be expressed as a normative 
empirical standard, in the western population mean SQOL lies between 70-80% and 
claim that measuring such values reflects biologically based human universals 
(Cummins 2001). This would mean that on average people are around 70-80% 
satisfied with their quality of life-but 70-80% of what? What does the remainder 
represent? These questions are not tackled. The reason for the inclusion of this work 
here is that it offers a psychological origin rather than functional. Although it is 
difficult to grasp in its entirety, some strong themes emerge, particularly in the 
internalisation and process of quality of life as a psychological phenomenon. This 
merely re-enforces the futility of measuring such a subjective experience.
Whilst the work of Cummins, Campbell and commentators propose to describe the 
biological components of subjective well being-that subjective well being is not 
principally dependent on circumstance as the American ideologists would purport, the 
shared variance between satisfaction reports of the highest coefficient cited-a value of 
0.65 (Bowling 1996, Cummins 2005 in press, personal communication with author) 
equates to a mere 42%-this does not support the studies of satisfaction as merely 
internal but a role for circumstance must exist.
217The difference could be explained by life events. Much of Cummins work is done at 
equilibrium without consideration to extremes of extrinsic factors. In light of this a 
relationship between these subjective and objective features must be considered. 
Figure 6.2. The respondents in the interview study did not “list” explicitly.
218Fig 6.2. The relationship between these subjective and objective features and extrinsic faclors including the possible plateau explanation for
Cummins work (2001)
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219The data given by the LLCG QoL study via the QLQ 30+LC 17 also re-enforces the 
subjective nature of quality of life in the psychological context. The content analysis 
of the narratives of 40 patients who have undergone platinum based treatment for 
advanced NSCLC has provided a rich insight into the experience, the suffering 
associated with the experience of the disease and the treatment, the experience of 
negotiating the illness and treatment calendar, the psychological perspective in this 
instance and yet from the QLQ 30+LC 17 data very little of this experience, of what 
the respondents considered quality of life, is reflected.
The scoring in the domains that could be associated with suffering caused bv 
uncertainty or other psychological factors i.e. the emotional or cognitive domains are 
not specifically given in any of the papers reviewed in the literature review and are 
certainly not examined in any detail. If these scores are endpoints, albeit secondary 
endpoints, to palliative chemotherapy trials why effectively are only two very broad 
aspects measured? Emotional and cognitive items of the QLQ 30 are firmly based in 
the functional domains and in the study by Rudd (Rudd et al 2005) the confidence in 
even these scores has dropped by the 12 week measurement (Figures 4.2 and 4.3).
The scoring from the LLCG study (Rudd et al 2005) did not show appreciable 
worsening in these domains but perhaps this is because the baseline was already at 
over 30% in both groups for the emotional domain and 14% GC arm and 12% for 
MIC arm in cognitive domain (baseline % of those scoring “quite a bit” or “very 
much”). This is surprising as the narratives are rich in such data. The sensitivity of the 
EORTC QLQ30+LC17 has been tested, but it is nomothetic.
221This re-enforces the initial review, authors such as Montezari et al (1996) who ask 
patients to nominate items for quality of life scales also find that family life, health 
and social life are cited as important and as yet not considered in any depth by trial 
groups.
2226.2.2  Physical well-being and the worth and work of treatment.
From the field notes made at MDT meetings across the cancer network (the joint 
cancer centre and three cancer units) the physical side effects of the chemotherapy 
regimens was cited in the decision making process, along with age but rarely 
performance status (indeed performance status was rarely recorded in the medical 
notes prior to chemotherapy). An observation of twenty such decisions yielded data as 
part of the internal peer review process. Functional/performance status was discussed 
only in two cases, as it was poor. Decisions were made on the basis of chronological 
age for example a typical response to the presentation of a 42 year old, a clinician 
remarked up how young the patient was and therefore il was important to try despite 
the poor performance status of the patient.
The most dominant factor from the field notes was the prevalence of predicting the 
impact of side effects of the drugs used and whether patients would tolerate these.
The interviews yield a surprising response.  It can be shown from Fig 6.3 that physical 
well-being is remarkably understated in this group of patients, with physical 
narratives making up only 10% of the total responses.  This could be for many 
reasons. The patient group was partly self-selected, 12 actively sought out treatment 
after being offered supportive care or older regimens in other unit/centres. These 
respondents had taken part in a chemotherapy trial, which has performance status and 
other inclusion/exclusion criteria (listed in Chapter 3). This study used the same 
criteria, principally that the respondents had survived the course of treatment.
223Despite this if the ECOG score of patients at time of interview is considered (13 had 
ECOG 0,15=1, 10=2 and 2 had and ECOG score of 3 and were in the terminal phase 
of their illness) this should be associated with considerable obvious physical and 
functional impairment. Why is this not reported by the respondent?
Fig 6.3 Root code Physical well-being
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Branch codes
1 Experiencing symptoms of NSCLC,
2 Experiencing symptoms not associated with NSCLC,
3 Experiencing side effects having a detrimental affect on QoL,
4 Experiencing side effects not having a detrimental effect on QoL,
5 Feeling well,
6 Experiencing improvements in symptoms,
7 Physical effort of treatment (eg fatigue)
The respondents did report the effects of both the chemotherapy and of the NSCLC, 
however, they were reported without emphasis. This could be because respondents 
were interviewed approximately one month after treatment, after the work of the 
treatment and much of the negotiation of the calendar has been completed.
224The typical responses involved minimising the effects of treatment. One respondent
who experienced grade 2 CTC nausea and vomiting which required admission
describes his experience:
. .1 mean.. .it was no-where near as bad as I thought  err.. .1 was sick a few times
but I’ve had worse hangovers...”  56 year old male
For many respondents the experience of chemotherapy was not as deleterious as the 
anticipation and fear of chemotherapy:
“at the start I was really wound up about it, I felt sick the first day I had to go, then 
you meet other people there and they have been going a bit longer than you-that helps 
a lot”  68 year old man
“T  thought, god you know, this is going to make me really ill, but I was surprised, I 
had the first one, I remember that, they give you this drip and then you go home and 
that was it-it would have been good to know exactly what it was like and I wouldn't 
have worried so much.”  54 year old woman
Four respondents cited the chemotherapy as responsible for the improvement in 
symptoms for example:
“I only had breath for six words.. .1 would say to my children those six words and 
they would say ‘What did you say dad?’ and I didn’t have enough breath to say those 
six words again and I would get irritable and spread out to everyone around me but 
that’s got a lot better”  48 year old man
Although respondents talked about side effect of treatment in terms of quality of life 
for example:
“I think the steroids had a much more impact on my quality of life than the 
chemotherapy, I am sensitive to them, I just COULD NOT sleep. I would get about 
three hours [sleep] a night, I watched a lot of News 24!”  62 year old man
or
225“the chemo did affect me-I just felt, I don’t know how to describe it really, just rough 
I suppose, tired and washed out. It just made doing things harder, but I was feeling 
down so that could have been the reason.. .its hard to say”  64 year old
woman
As many referred to existing co-morbidity such as arthritis or migraine:
“I have had migraine for years, I have more now but I do have them when I am under 
stress-I have been feeling stressed about it all”  62 year old woman
Physical domains are the predominant areas of assessment for the versions of the 
EORTC QLQ 30, both in terms of the main body of the questionnaire and also the LC 
17 lung cancer module (Appendix A).
How then do these functional measures compare with the lived experience of 
uiicLisuing clicinuiherapy? From me Study 1 1  data (Rudd et al 2005), patients 
undergoing platinum based chemotherapy do report physical effects of treatment and 
disease. The LLCG Study 11 group are reported in Chapter 4, where the raw data can 
be found for the EORTC QLQ 30+LC 17 (see Figures 4.2 and 4.3 i  n Chapter 4).
The LLCG Study 11 data is rich with physical and functional data. The authors’ state 
that the patients in the gemcitabine/carboplatin arm experienced less nausea, 
vomiting, constipation, alopecia and this regimen was associated with fewer hospital 
admissions. These data are derived from scoring systems (the Common Toxicity 
Criteria (CTC) expanded NCIC 1994 Version Appendix C) or a defined factor- 
hospital admission. The nomothetic nature of the CTC is absolute. Although self 
reported, a healthcare professional grades toxicity. Some scores are based on 
numerical/observed data e.g. episodes of vomiting in 24 hours or renal toxicity as
226measured by serum creatinine) others are much more subjective (e.g. lethargy) but all 
pertain to a physical sign or symptom.
Rudd et al (2005) also state that in addition to the observation that patients 
experienced less nausea, alopecia and other physical effects associated with toxicity 
Rudd et al (2005) observed “patients experienced better quality of life”. This 
statement refers to the overall findings of the QLQ 30 EORTC data but the word 
“experience” is an interesting choice. These data represent a group-the LLCG went 
into detail when collecting QLQ data-they used not only the QLQ 30+LC 17 but also 
daily diary cards (The fuii protocol for Study 1 1  is given in Appendix D) but can the
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the experience of cancer as subjective was supported by evidence. So what do Rudd et 
al (2005) and the previous studies of this design refer to when they refer to “better 
quality of life”?
The data from the LLCG QLQ 30 EORTC LC+17 study is comprehensive. A 
common feature of the EORTC based work in the literature is the limitations of the 
data-handling tool for the QLQ 30. Limitations are examined in Chapter 7 however 
need to be considered here as factor into interpretation. Baseline data with variance is 
available and is usually based on the two most negative responses (“quite a bit” or 
“very much”) aside from interpretation of these terms by respondents (how much is 
“quite a bit”?), the recorded score is percentage from baseline of those answering with 
these responses essentially determined from the raw score.
227Overall there is no appreciable decline between baseline scores and those at end of 
treatment (12 weeks). In the physical domain there is some improvement with mean 
raw score of 1.87 (n=l 89) in the GC arm at baseline and 1.82 (n=95) at 12 weeks. 
There are similar findings in the symptom specific scores. Pre treatment percentage of 
those reporting in the physical domains (i.e. the “quite a bit” or “very much” 
responses) 26% and at 12 weeks 32% which does represent an increase in those 
reporting worsening physical function. However as can be seen from the baseline 
mean scores, the attrition rate should be considered (GC group 189-95=94 non 
reporters an attrition of almost 50%). What happened to this group? Research groups 
such as the LLCG factor into studies for attrition as part of the sample size/power (see 
Appendix D) and some of this group mav simnlv have heen lost to follow ur> or 
decided not to take part in the study, however it is more likely that this attrition rate 
was due to death or ill health (respondents only filled in the questionnaire when 
coming to the cancer centre) and so these factors are inadequately captured.  This 
factor has been recognised by the group (Brown et al 2005) and others (Donaldson 
and Moinpour 2005). The interview study can contribute to this missing data in terms 
of experience. The method of interview was in respondents own home, this allowed 
poor performance (ECOG 2 and 3) respondents to take part.
Re-review of the literature in Chapter 2 reveals little mention of attrition rate 
(although decrease in survival is given and therefore implicit reasoning) and no paper 
mentioned the impact of attrition on QLQ scoring-despite the efforts to power such 
studies statistically.
228The symptom scales exhibit a drop in percentage of reporting (representing 
improvement in symptom specific symptom) for example cough GC arm pre 
treatment of the LLCG Study 11 reports a 46% response, which becomes 22% at six 
weeks and 19% 12 weeks.
It could be the apparent improvement in physical symptoms coupled with the steady 
physical domain scores from questions 1-5 account for the low reporting of physical 
symptoms by the respondents in the interview study.
The toxicity recorded in the subgroup compares with the LLCG study, but yst u^uiu 
there is minimal reporting of these physical symptoms in the respondents’ interviews. 
The greatest range occurred in haematoiogicai toxicity, which is defined by 
haematological parameters (i.e. bone marrow function) and is unlikely to produce 
physical symptoms unilaterally but can lead to detrimental health states such as 
infection or bleeding. The exception to this is anaemia and 22 respondents used words 
which described fatigue such as “washed out” ‘"tired” or “no energy”.  Data from the 
medical notes informs that 15 respondents required one or more transfusions during 
treatment.
During observation in the field, at MDT meetings and other arenas for clinical 
decision-making the physical consequences of offering the patient chemotherapy were 
the dominant arguments. In the decision making process observed, the reasons for not 
offering chemotherapy to patients was noted. The physical argument was the only one 
offered.  On occasion social reasons were given to support this decision (for example
229homelessness) or chronological (as opposed to biological) age, but the primary 
apparent decision was based on physical status or probable decline in physical status.
From the respondents perspective the experience of chemotherapy and the physical 
effects of the disease and treatment were generally referred to in retrospect:
“the chemo didn’t affect me as much as I thought, I think its important to try— Dr X 
was pretty straight I knew it was not gonna make the cancer go away but at least I was 
trying.. .for me and the kids.. .at least we gave it a go and I dunno if I would have felt 
bad if I hadn’t tried it”  62 year old male
“I felt tired a lot of the time, but I think that was partly due to the going backwards 
and forwards [to cancer centre] I suppose 1  just knew... .well its chemotherapy... .you 
know its going to be nara, mat s what puts people off it”
72-year-old female
“I put it off for a long time, I thought if its not going to get rid of the cancer.. .you 
know, what’s the point of going through all that... .1 put it off for a few weeks.. .1 was 
talking to B [wife] about it, she said yon might as well try it-I think I did for her 
really, otherwise its just... .well... .waiting to die I suppose”
60-year-old male
“I wanted the treatment very badly, despite what the doctors at [referring hospital] 
said about it not being a cure-how can they expect you not to do anything? Just write 
you off like that? You need some hope to hang onto”
54-year-old female
Chemotherapy was seen as hope in response to questioning about quality of life. It has 
been shown in earlier sections how authors such as Cassell (2004) and Houldin (2000) 
have expressed suffering in terms of existential plight and perceptions of a lost future. 
Intense unhappiness results from the loss of the future and its expected profile. Hope 
is necessary for successful life; it is in this dimension of existence that hope dwells 
(Cassell 2004).
230Macintyre (1979) is often quoted as a result of his work into hope
“Hope is in place precisely in the face of evil that tempts us to despair, and more 
especially that evil that belongs specifically to our own age and condition. The 
presupposition of hope is, therefore, a belief in a reality that transcends what is 
available as evidence”
Alisdair Macintyre  1979
Chemotherapy as a focus for hope was a recurring narrative as was chemotherapy not 
as an option or even a choice but a necessity. Hope is one of the most cherished ideas 
in western culture (Omer and Rosenberg 1997) and hope is seen as adaptive for 
coping (Lazarus and bolkman 1984).  l his is a controversial point, others do not agree 
that hope is always adaptive (and conversely that despair is always maladaptive) 
(Bennett and Bennett 1984).
The loss of hope is cited as a feature of some psychiatric disorders (Beck et al 1985) 
and for some is essential to maintaining a “fighting spirit” (Houldin 2000). This can 
be seen from some of the themes in the psychological responses-not giving up was 
cited as a factor in good quality of life.
231The cancer nursing literature supports the value and necessity of internal sources of 
hope, for most part irrespective of the course of disease (Ersek 1992 Ballard et al 
1997). Post-white et al (1996) describe five central themes influencing hope for 
cancer patients:
•  Finding meaning
•  Relying on inner resources
•  Affirming relationships
•  Living in the present
•  Anticipating survival
Post-white et al (1996) also found individual variability to define hope. In addition 
Ballard et ai (1997) found that patients with newiy diagnosed and recurrent disease 
did not differ in levels of hope, but differed in the type of hope expressed. Patients 
with recurrence and thus poor prognosis tended to express hope in terms of faith 
whereas the newly diagnosed expressed hope in terms of medical technology. In this 
study the respondents, although poor prognosis patients in terms of survival, express 
hope through medical technology in the form of drugs (chemotherapy). If Ballard’s 
interpretation is accurate, this may be because although the respondents were a poor 
prognosis group, they were also newly diagnosed.
In terms of patient outcomes, there is some evidence that hope can enhance 
adjustment to illness (Christman 1990, Ersek 1992, Omer and Rosenbaum 1997). 
Spencer et al (1997) suggest that the acknowledgement of despair over the lost 
possibilities of a life or future lost can activate the will and trigger hope. This is very
232much embedded in specialist cancer nursing practice and was observed in interactions 
between patients and the Clinical Nurse Specialist in lung cancer at the cancer centre 
as part of the researcher’s own reflection on practice as a Clinical Nurse Specialist.
As has been seen, nursing literature supports meeting the person in their suffering and 
moving with them as the compassionate other as they go through the experience 
(Byock 1994). Nurses seek to understand the suffering of the person with cancer by 
offering authentic presence and empathic caring (Houldin 2000). This accompanying 
on the journey of adaptation is recognised by the respondents.
“Its good to have someone you can just ring up and you don’t have to put on a show”
72-year-old woman
“You’ve got to keep coming back to [cancer centre] its so nice having someone there”
68-year-old woman 
The CNS’s and experienced medical staff dealt with and supported hope by 
employing the strategies observed by Morse and Dobemeck (1995). These are reality- 
based strategies for supporting hope:
•  A realistic assessment of threat
•  The envisioning of alternatives and the setting of goals
•  Preparing for negatives outcomes
•  A realistic assessment of personal and external conditions and resources
•  The solicitation of supportive relationships
•  The continuous evaluation for signs that re-enforce the selected goal
•  A determination to endure
233“Even though you always have to wait...its worth going to [cancer centre] I feel better 
going there because they always have something positive to say, I think its important 
to hope for the best sometimes”  56 year old man
Houldin (2000) also remarks that hope and despair are two sides of the same coin.
The coexistence of hope and despair is observed throughout the narratives and authors 
such as Kegan (1982) argue that one cannot exist without the other. As Spencer et al 
state-acknowledge the limits of hope, understand the associated emotions of despair 
and grief and rejoice in the discovery of new possibilities. This may seem trite; 
however hope is a process, a dynamic process that will change over time and 
circumstance. As Houldin states (2000) “For hope to be enduring and adaptive, as 
much as possible for each individual, it should be rooted in reality'. When hope is 
based on iiiuMom fuelled by false assurances it can c?iic#i mnciHerable aneuish”
Chemotherapy as work to be done
Chemotherapy was seen as a focus for hope, despite its meaning and fear. How did 
the respondents view the experience and reconcile medical factors (known poor 
response rate) to the hope given? In addition-despite recorded toxicity-what other 
features account the low prevalence in the physical theme?
Typical responses involved hope (as has been seen), fear, a view that there is no other 
realistic choice and influence of others. The nature of conversations around 
chemotherapy and quality of life reflect these and also the view that once the decision 
to have chemotherapy is made it becomes, perhaps simplistically, work to be done.
234“I had the chemo because I thought it might be a chance, I didn’t like the thought of it 
but all happened so quick I didn’t think about it, but what else could I have done?”
64-year-old man
“I knew I just had to get on with it, no choice in the matter... .1 was not about to just 
give up and die”  69 year woman
“I suppose  quality of life, it was a lot of work.. .very involved.. .going to see Dr
[oncologist], then for the blood tests and then the chemo then start all over again,
more blood tests and that  I did feel tired but who knows why that is.. .it could have
been the travelling.. .the transport used to go and pick up lots of other people so 
sometimes it took ages to get to [cancer centre]”
68-year-old woman
The respondents seem to “factor in” that chemotherapy would involve work, both 
physical work and psychological work. Doing work is part of negotiation of both the 
illness and treatment calendar (see Chapter 5) and as has also been discussed the 
social meaning of the word chemotherapy induced fear in respondents.
Respondents did not expect the experience of chemotherapy to be pleasant or even 
neutral-they described negative attributes to the meaning when told about 
chemotherapy as a treatment to advanced NSCLC. Some respondents even sought out 
chemotherapy despite this fear as the fear of losing control or having few options 
apart from death in narratives.
235The narratives inform the researcher of the experience of chemotherapy and the 
minimisation of the physical effects demonstrates several things:
•  Chemotherapy discussions occur, by necessity, at the pre treatment milestone, 
close to diagnosis and involve the loss of future and a social meaning of the 
word “chemotherapy” before professionalisation has begun.
•  Respondents expected chemotherapy to involve work and be difficult to cope 
with.
•  A temporal quality-the chemotherapy had been completed at interview and 
was viewed as work completed.
“.. .erm looking back.. .yeah the first one seemed to shrink it down and I think that 
gave me more time.. .Early on.. .see.. .quality of life.. .its not in your hands.. .early on 
the doctors told me I had 30% chance of seeing next Christmas, but I might nut reach 
this Christmas and the seed was planted in that split second, and that dragged me 
down for six months. He was telling me i‘u onty gui o i a   l i i L f i i m u .  .Y hy he s?.id '^ ^  
that way.. .1 don’t know....my quality of life was instantly affected and the chemo 
made me think I was....1 suppose.. .buying more time...”
48 year old man
236Abandonment-treatment as social interaction
As can been see from Section 6.2.3 below, the support of others during the cancer 
journey is a recurring topic. The support gained is from a variety of sources such as 
family and friends. It should also be noted that some respondents verbalised feelings 
of increased uncertainty or abandonment. This may reflect the temporal qualities of 
the joumey-respondents were interviewed on completion of treatment, were waiting 
for follow up and some were waiting for disease reassessment (i.e. response). From 
what has been shown it is not unreasonable to expect increased uncertainty at this 
point in the journey.
Schou and Hewison’s work (1999) examined the journey and these authors have 
researched the effect of treatment as a social interaction. This is reflected in Chapter 
5, the work of cancer. The work of negotiating the treatment calendar and attendance 
at the cancer centre ensures regular contact with health professionals and other 
patients. When treatment such as chemotherapy stops some respondents expressed 
feelings of abandonment:
“while you are going for the treatment, you are going to the hospital a lot... .and you
see all the people there  erm...the nurses and that  but now I’ve finished, what
happens now?”  56-year-old man
or a respondent in the final stages of her disease had care handed over to a local
community team:
“I’m not fit enough to go on the transport now, [oncologist] said I can go back if I 
need to, anytime, erm....it’s a bit odd thinking I wont be going there again.. .its nice
to think I can go back if I need it.....the new Macmillan nurse is lovely but its not the
same as people you know”.  54-year-old woman
Or
237“I’m a bit worried about what happens next, my next appointment is in a month... .and 
that’s... .that’s the next big thing to get through”
R “in what way?”
“because it’s the results....the x-ray, it might find something.. .and that’s it 
now... like... I’m on my own”  72 year old woman
Abandonment is beginning to be recognised along with survivorship issues in the 
literature. It is rarely acknowledged in practice although observation of practice and 
reflection of practice by the researcher demonstrates how team members would 
arrange follow up at units or in the community if not necessary at the cancer centre. 
There has been observation within this study of the professionalisation of the 
respondents but this has been within institutional context-respondents become adept at 
negotiation within a specific institution. Loss of this relationship implies that the 
process has to start again-not from the beginning as before, but respondents see it as 
having a negative effect. It involves repeating some of the work completed, increases 
uncertainty levels and occurs at an unstable point in the journey.
Some authors argue that issues around abandonment are generated from the “either- 
or” idea of palliative care-that patients are treated actively or are referred to palliative 
care services (Byock 2000) but not both. This leads to a clear end of treatment-referral 
to palliative care services boundary. Even if early referral to community palliative 
care takes place (standard practice in the cancer centre) respondents had little contact 
with community teams during treatment. Authors such as Daugherty (2004) are more 
provocative and issue a challenge to oncologists working with patients who have 
advanced cancers-that the oncologists themselves present obstacles to palliative care
238whilst patients are receiving active treatment, even with such a poor response rate as 
those with lung cancer. Daugherty (2004) views this as an ethical issue for medicine 
in the creation of obstacles access and adaptation to palliative care is diminished.
2396.2.3 Relationships with significant others
Fig 6.4 Rcot codes Relationships with significant
others
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Branch codes
1  Willingness of family/others to discuss diagnosis/prognosis
2 Reluctance of family/others to discuss diagnosis/prognosis
3 Concerns about fixture of family/children (also in psychological 16)
4 Experiencing difficult reactions from other (denial, exclusion from activities)
5 Refusal to discuss with others
6 Support from family/others
Supportive relationships helped respondents cope with the disease process, 
negotiation of the illness and treatment calendars and the distress associated with 
uncertainty. This has been shown in the literature (Mast 1995, Houldin 2000).
It has been shown how hope (Post-white et al 1996) is central to adaptation to 
difficult life situations and that hope-affirming relationships are a way of creating this. 
The observed practice of the CNS and senior medical staff affirmed the observations 
of Morse and Dobemeck (1995) discussed in the previous section.
240Is it finding these relationships with others who are closer than professionals that also 
facilitates hope?
Supportive relationships were given by all respondents as important coping factors. 
The depth and level of these reports varied a great deal but all respondents included at 
least one narrative, which illustrated support of others outside of an institution.
Twenty respondents also cited experiences of others close to them who did not wish 
to or could not engage in any acceptance of the respondent’s situations. This will be 
examined in the context of denial. Supportive relationships and societal role are 
discussed in section 6.2.6 Changes in role/social function.
Denial
Half the respondents cited denial or reluctance/unwillingness by those they considered 
close to them, to discuss issues around their illness as an experience in their journey. 
The intensity and number of narratives varied. One powerful example has been cited 
in Section 6.2.1 of the 48 year old man who wished to discuss issues around his own 
death with his close family:
”  there’s no real dialogue about it. They have their problems facing up to that
issue. If I could talk to them maybe I could convince them that [inaudible] with dying 
in horrible circumstances, what are the alternatives? They could see it makes sense.”
Denial is often cited as a coping mechanism (Ness and Ende 1994) and in a poor
prognosis group is more likely to be an adaptive mechanism (Lazarus 1983).
However, perhaps because of the phase of the treatment/illness calendar that the
respondents were in at time of interview, they were largely grounded in reality. The
241denial narratives dealt almost exclusively with significant others. Denial offers 
psychological protection when dealing with distressing information (Goldbeck 1997) 
and in cancer patients is eventually replaced with other coping mechanisms-perhaps 
this is why the respondents did not deny their situation.
Denial cited here by respondents takes the form of psychological protection but would 
become an issue if it became collusion. Observed and reflective practice of the lung 
cancer CNS role demonstrated an interesting set of interactions. During a four year 
period of this study the researcher was employed as both a lung research CNS and a 
CNS in thoracic surgery.
Patients did not disclose concerns for fear of upsetting their significant other and the 
significant other would use denial or reluctance to discuss with the patient and yet be 
able to articulate fears to the CNS-the CNS being the only one in receipt of both sets 
of fears (Fig 6.5). The CNS can then facilitate communication by giving permissions 
and sanctioning communication by using reflective/questioning techniques between 
all or selected parties.
242Fig 6.5 The dynamic of the relationship in alleviation of denial
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The CNS role is central tc the dissolution of situations that lead to collusion in 
particular, at a pace sensitive to the patient and others. Techniques such as open 
questioning and active listening facilitated this. As denial is a technique used to 
protect not only oneself but also close others, it is important that clinicians not only 
identify denial but also the motivation for it. The denial or reluctance of others caused 
suffering in the respondents who experienced it:
“I suppose its just too much.. .all at once, my husband drives me to distraction. The 
way... .but I know my illness has had a bad effect on him as he’s slowed down so
much: of course he’s 77  he needs so much help now and... GOD! Before my
illness he didn’t need this much attention.. .he just can’t cope and wont talk to me 
about it.. .he just goes off!”
76-year-old woman
243The relationships that respondents had with others who were close to them were 
threatened by the experience of advanced NSCLC and this in turn was cited as a 
factor in quality of life.
2446.2.4 Health behaviours
Fig 6.6 Root code Health Behaviours
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1  Giving up smoking
2 Smoking more/not giving up
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4 New belief in alternative or complementary treatment/practitioners
There were few references from respondents in terms of health beliefs. Considering 
previous work done by those such as Chappie (2004) and the associated guilt of 
tobacco use, this is surprising. Only one respondent out of forty had decided to try 
complementary health practices and lifestyle change in terms of diet.
The issue of tobacco could be due to the demographic of the group (2 lifetime non- 
smokers, 15 current smokers, 23 ex smokers), a desire not to discuss this subject area 
or as the trigger questions were quality of life ones, no association with the topic. This 
topic is further explored in context of social role and function in Section 6.2.6)
2456.2.5 Spirituality
6.7 Root code Sprituality
1 2   3  4
Branch code
1  Affirmation of religious belief
2 Interest in spirituality/non religious
3 Interest in the “afterlife”
4 Rejection of previous religious belief
Few references were made specifically about spiritual life in tiie context of quality of 
life. The narratives which included explicit spiritual references (as opposed to 
existential plight which is grouped with psychological themes) all referred to 
spirituality in the context of religion. One respondent rejected their previous religious 
belief system and one had affirmed religious belief.
2466.2.6 Changes in role/social function
Fig 6.8 Root code Changes in role/ocial 
function
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1  Changes in work pattern/giving up work
2 Changes in financial circumstances (positive)
3 Changes in financial circumstances (negative)
4 Changes in social activity/interaction (positive)
5 Changes in social activity/interaction (negative)
6 Changes in independence/mobility (negative)
7 Feeling isolated (Socially/ mobility)
8 Leading a normal life
9 Suffering not leading a normal life (social role)
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247The literature review for this study examined social role and meaning in a broad 
sense. The work of Talcott Parsons (1951), Graham Scambler (1991) and Robert 
Dingwall (2001) have all examined the meaning of illness in society, the social 
construction of illness and the meaning and impact of ill health.
It is interesting to note that many of the issues identified by authors such as these are 
present for the respondents in the interview study. Parsons “sick role” followed by 
“patient role” are reflected in the cancer illness and treatment calendars. The lay 
construction of illness cited by Parsons and interpreted by authors such as Dingwall 
(2001) is reflected in the “meaning” of words ascribed to actual things encountered 
(for example the meaning and lay interpretation of chemotherapy and its attribution to 
a negative experience and hard work or the meaning of the word shadow on an x ray 
and its interpretation to by the respondent as cancer).
Social role and the maintenance of social role was cited by respondents when asked 
about quality of life. Changes in social role and activity was generally a negative 
experience, for example a 69 year old woman with bone metastasis who could no 
longer drive:
“I think having a good quality of life is about having.. .about being able to do things. 
The biggest change that came to my life with the cancer was the fact that my mobility 
was very restricted”
69-year-old woman
248Role and social activity were used as coping techniques (such as distraction). In order 
to deal with uncertainty and regain control, respondents used the mundane as a focus 
for hope. The loss of the mundane and associated independence caused suffering both 
in terms of loss and in terms of distraction:
“I used to work for the council.. .maintenance work, you know? There was a big gang 
of us and we was always out and about. I used to moan to [wife] about getting up 
early in the morning.. .1 used to get up at five am but I wish I could do that now.”
56-year-old man
or
I think its important to have a normal life.
R “In what way?
’’Well, when I was diagnosed with this, I was like, well you know shattered, I gave up 
smoking years and years ago, I couldn’t believe it, but soon after, the next week I 
think, I went back to the site, and I have been working ever since. I get to sit in an 
office all day and the blokes are really good blokes you know, but I went straight back 
to work. I know some people would’ave taken to their bed but to be honest that would 
ave just killed me stone dead.
R “Do you think work helped you then?
“God yeah! I go to work, see me mates, we have a laugh, I am not thinking cancer, 
cancer, cancer all day like at hospital and it takes my mind off it all for a bit, its just 
normal and I am doing all right. We will be OK for money but I really don’t like the 
idea of giving up work.... Oh yeah, its not just the work, it’s the company I suppose, 
at work I am just another bloke on the site, not the bloke with cancer d’ya know what 
I mean?”
Some respondents felt physically well at diagnosis and even through treatment. This 
led to expression of “being a fraud” (72 year old woman) and guilt at being able to (or 
encouraged to) assume a sick role without feeling physically ill:
249“I didn’t know what to do with myself really you know? Dr [GP] signed me off sick 
like, from [workplace] for the chemo.. .but I felt alright, a bit of a fraud really”
59-year-old woman
This was despite recoded CTC grade 1  of lethargy due to treatment and treatment for 
anaemia by transfusion before the last cycle of chemotherapy (approximately one 
month prior to interview).
Guilt is now becoming a recognised issue in lung cancer, but as these findings show 
perhaps from a different viewpoint than the link with tobacco.
“I want to describe, not what it is really like to emigrate to the kingdom of the ill and 
to live there, but the punitive and sentimental fantasies concocted about the situation: 
My subject is not physical iiiness itself, but the uses of illness as a figure or metaphor. 
My point is illness is not a metaphor  Yet is hardly possible to take up residence in the 
lanri nf the ill unprejudiced by the lurid metaphors with which it has been huiuscapcu *
Susan Sontag 1977
Sontag’s work (Sontag 1977) was a reply to the growing construction of the 
metaphorical in cancer from the 1960’s. This can be seen today in the self heip 
literature for example the popular books of authors like Louise Hay which continue to 
grow in popularity. The metaphorical basis of cancer originates (like other 
metaphorical origins of disease) from the lack of knowledge of cause and therefore 
cure (Stacey 1997). Authors like Stacey (1997) and Sontag (1991) refer to the often 
insidious nature of many cancers. Whilst the epidemiological link between lung 
cancer and tobacco was established in the 1950’s by Doll and Hill (1953) NSCLC is 
often advanced at presentation and remains insidious. This lends lung cancer to 
metaphorical meaning:
250“ I keep wondering if I could have done anything to stop it, I gave up smoking twenty 
years ago-being self employed is stressful and wonder if that didn’t help”
52 year old man (ex smoker)
Guilt featured in few of the narratives and this expression of guilt with the life style 
choice of smoking has begun to be explored in the literature (Chappie et al 2004) but 
by comparatively few. Two responders were never-smokers and 23 declared 
themselves ex-smokers at time of diagnosis and interview. Although some 
respondents did mention regret of tobacco use, this was not a typical response. Guilt 
seemed to be associated more with the fraudulent nature of assuming the sick role 
under false pretence and therefore not fulfilling societal obligations. Perhaps this is 
the reason for less self-professed guilt.  However there is a paucity of literature in this 
area with wliiGi L u cumpaie uiese findings, it may be that the respondents do not view 
a link between smoking and guilt as a quality of life issue.
2516.3 Summary
Suffering is “immobile and quiet” (Eriksson 1997) but with the support of 
compassionate others the person can turn toward the development of suffering 
(Arman and Rehnsfeldt 2003). To ease suffering the person with lung cancer needs to 
be able to do this in a safe environment physically, emotionally, socially and 
spiritually.  This is shown graphically in Fig 6.9
Fig 6.9 The suffering struggle in ontological dimensions (after Arman and Rehnsfeldt 
2003)
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This gives meaning to quality of life in the experience of these patients.
252Chapter 7 
Conclusion7.1 Quality of life in patients receiving platinum based chemotherapy for advanced 
non-small cell lung cancer-the contribution of this thesis.
Five years has lapsed since the start of this study, the modernisation agenda has 
become entrenched into NHS cancer practice in the UK, the role of multiprofessional 
care is recognised by th<  Department of Health and yet the literature in advanced 
NSCLC reflects the literature of the late 1990’s. A return to the current (2005) 
literature in NSCLC reveals the continued dominance of trial data using HRQoL 
assessment tools such as the EORTC QLQ 30 and similar functional tools.
In many ways this is understandable. Despite its ideals of equitable good quality 
cancer care for all, the modernisation agenda has only increased the need for 
measurable outcomes-target waits, user involvement and performance are all factors, 
these outcomes are used as the measures of success, which both further entrench and 
even encourage the misuse of tools such as quality of life and HRQoL assessment 
measures.
In a target driven NHS the need for outcomes is influential, however within the 
academic writing reviewed herein, the conceptual work around quality of life 
constantly reiterates the controversial nature of these tools. Authors such as Ann 
Bowling, Mark Rapley and others who have spent a large part of their professional 
careers examining both global quality of life, life satisfaction and HRQoL have 
cautioned against the misuse of these tools, quality of life indicator tools are 
nomothetic and measure what they seek to measure-health related quality of life.
254This study sought to exr mine quality of life from the respondent’s perspective, to give 
meaning to and to articulate the experience of treatment for advanced NSCLC.
Quality of life is subjective and a wholly individual experience -should the sceptics 
win the day? Is it possible to construct a theory of quality of life in advanced NSCLC 
from the findings presented herein?
Accepting that each individual has his or her own quality of life experience is central 
to this. It is noi enough 10 construct a theory, as a general theory would have to be 
heavily qualified. Instead two main areas have become apparent:
•  In talking to patients who have undergone chemotherapy for advanced 
NSCLC lung cancer there are common themes, which they associate with 
quality of life
•  The HRQoL data of Study 11, whilst valid, reflects only a small component 
of what the respondents considered to he quality of life.
By comparing the data generated through the interviews and subsequent content 
analysis and coding, the observational work and the EORTC QLQ data from Study 11 
it has been possible to s*e concepts that are similar or dissimilar, and in many ways 
this has been exceeded. The work has also allowed comparison of how researchers in 
medicine view quality of life and how patients undergoing the experience of 
chemotherapy for advanced NSCLC view quality of life.
255It appears that the researchers who use HRQoL tools do not view an artificial image 
of quality of life, but they do view an incomplete one, a view that is taken directly 
from the medical ontological viewpoint. The data generated from respondents reflects 
the multidimensional nature of quality of life, particularly the concepts of the 
classicists “good life” of which HRQoL is a very limited part. This can be seen from 
the technical literature used to support the quality of life work in NSCLC and 
medicine in general. An apt illustration of this is the technical literature that has roots 
firmly in the (reductionist) Scandinavian school and social indicator movement and 
yet often draws on or quotes the classical school at the start of papers.
The quality of life data :i the NSCLC literature remains resolutely functional. Each of 
the tools used, despite individual differences, shares a functional perspective. So how 
can theories of quality of life for those experiencing platinum based chemotherapy for 
advanced NSCLC be generated? The same measures are being used without review as 
those used in the 1980’s-they are merely repackaged and revalidated along side 
existing measures. In addition very few poor performance status patients are given the 
opportunity to record HRQoL. HRQoL tends to be measured in the clinic and 
supposes that patients are fit enough to attend. The high attrition rate of HRQoL 
studies such as those in Study 11 (Rudd et al 2005) reflected this.  Note at howl2 
weeks from randomisation the attrition rate for QLQ 30+LC module has risen to 53% 
and 57% in each chemotherapy group. 12 weeks from randomisation is the 
approximate time at which respondents are interviewed. The interviews took place in 
the respondent’s home allowing capture of the poorer performances patients. In this 
way this work has confributed in capturing a varied group of performances status 
patients’ responses.
2567.2 Quality of life-The Scandinavian School versus the Classicists
A variety of themes have been generated from the content analysis and much of the 
findings are psycho social or experiential rather than the functional findings of the 
EORTC QLQ 30+LC 17 domains. Finding comparative data between the QLQ 30 
data and the thematic analysis is a challenge. This is partly due to the perception and 
meaning of quality of life in an academic and societal context.
“ The idea of quality of life as a measurable indicator of the great society’s 
achievements has, since it’s inception, been inseparable from ‘he notion of progress”
Mark Rapley 2003
The assertion of Rapley (Rapley 2003) reflects the growing trend of authors in quality 
of life research to reflect upon the concept of quality of life. This comment is an 
allusion to the dominance of the social indicator movement from which the 
functionally focused so-called “Scandinavian School” (Rapley 2003) originated and 
has been shown in Chapter 2.
The Scandinavian School concept of quality of life is based on the writings of authors 
such as Drenowski (1974), Erikson (1993) and the application of this work, 
particularly in cancer, by authors such as Niels Aaronson (Aaronson 1993).
Erikson and Uusitalo (1987) frame quality of life as the resoutces needed for the 
individuals welfare, such as money, physical energy, social support. Scandinavian 
thought focuses exclusively on objective indicators of living. This conceptualisation
257of quality of life fits with the desire to establish outcomes in Medicine, Nursing and 
Psycho-oncology (Holland 1998) and it is therefore unsurprising that this approach 
has gained authority.
It is apparent from the results presented in Chapter 4 that the dichotomy of quality of 
life as interpreted by each of the different theoretical schools is illustrated. The 
Scandinavian School which focuses on functionalism and is the predominant method 
of assessing quality of life in the context of clinical trials, and indeed, almost all of 
medicine as it adopts the medical ontology cited by Cassell (Cassell 2004) to a high 
degree.
A review of the quality of life literature in Non Small Cell lung Cancer demonstrates 
the dominance of such thinking. This is because the vast majority of literature 
examining quality of life in patients with advanced (non operable) NSCLC is 
originated from clinical trials funded by agencies such as the pharmaceutical industry 
or independent research groups. Scientific work needs measurable outcomes and this 
has contributed to the rise and dominance of the Scandinavian School and its 
associated philosophy.
The literature reviewed for this work, although rich in functional quality of life data, 
makes no reference to the social indicator movement in the clinical papers. Some 
background information is given in most papers on the post war WHO definition and 
President Lyndon Johnson’s speech in the 1964 (for example Aaranson et al 1988, 
1991,1993) but only as much as is given to Aristotelian (i.e. Classical) ideas in the 
introductions of the papers reviewed.
258This finding echo’s the work of Haura (Haura 2001) in which NSCLC trials were 
reviewed and only brief mention was given to quality of life as defined in any 
convention, despite the assumption of the authors, that chemotherapy for advanced 
NSCLC is palliative. In addition when Kong and Gandhi (1997) reviewed 265 papers 
reporting HRQoL assessment in clinical trials, only 21% reported any HRQoL 
validity data. This has aiso been seen in this study; very few studies reviewed provide 
definitions of QoL, sensitivity or validity data.
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influence or non-inclusion into the assessment of quality of life in people receiving 
chemotherapy for advanced NSCLC have been demonstrated in Chapter 2.  However 
the acceptance of the dominance of the functionalists and the Scandinavian School as 
a principal influence is only now being recognised as more medical sociologists 
examine the literature. The common theme of the Scandinavian School and its 
founders is that it applies quality of life as individual welfare needs with outcomes, 
but on a societal level- does this mean it is an appropriate concept to apply to the 
individual person dying of cancer?
Much of the literature, particularly that which views quality of life “measurement” 
with sceptism (for example Downie 1999, Hunt 1999) reiterates the subjective nature 
of quality of life. It is the individual nature of quality of life which is the flaw of much 
the work of the functional, social indicator and societal movement and this individual 
nature is now becoming recognised in the literature-it is not enough to simply:
259“ .. .represent social facts independently of personal evaluations and in contrast to 
subjective indicators which rely upon the individual perception and evaluation of 
social conditions” (Noll 2000).
The literature available in NSCLC quality of life is almost exclusively consists of data 
from clinical trials and therefore the functional Scandinavian School. The QoL 
literature from a sociological perspective is almost exclusively classical but not in the 
context of NSCLC. The generation of a theory of quality of life in patients receiving 
platinum based chemotherapy must therefore be embedded in both schools.
Quality of life as an acauemic concept is still young. Although the classical theorists 
and philosophers have discussed the idea of quality of life and the good life for 
centuries, as an academic area of study in the reductionist sense it is surrounded by 
“conceptual confusion” (Rapley 2003). This can also been seen in attempts to clarify 
the conceptual confusion of quality of life. The work of Mary Cooley (Cooley 1998) 
who has undertaken one of the few qualitative studies in advanced NSCLC goes some 
way to tackling this issue.
Conceptual clarity is an enduring problem in quality of life studies and is likely to be 
so until a consensus exists. The futility of reaching a consensus in such a subjective 
area has been debated and beyond the remit of this work. However this study has 
given insight into the experience of quality of life in advanced NSCLC, particularly in 
the context of chemotherapy and adds to current work by taking a mixed method (i.e. 
not exclusively HRQoL) approach.
260From the data generated in this study the respondents generated four core themes 
when quality of life was discussed. These themes are reflected in an extremely limited 
way by current HRQoL tools, if at all. This thesis adds to the body of knowledge by 
eliciting these themes.
The core themes from the respondents were:
•  The work of cancer
•  The lens of diagnosis
•  Suffering
•  The worth of treatment
These are summarised as follows and should be included when any debate where 
quality of life in patients with non small cell lung cancer is aired.
261The work of  cancer
This elicited most of the responses in the interview study. The amount of responses 
and the rapidity of saturation was the reason for interviewing outside the study group. 
The experience of being a patient and the work involved in having cancer was cited as 
a factor of quality of life. Respondents found that negotiating the illness and treatment 
calendars required effort, particularly the beginning of the journey, before they had 
learned the systems of the institution, which, once familiar with, they could have 
some control over.
Gaining access to health professionals at crisis points was also important to 
respondents. Gaining reassurance in the early stages, having a treatment broker 
(usually the Clinical Nurse Specialist) who dealt with the complexities of the 
treatment calendar and  ’ .ormalised (as opposed to pathologised) the distress of cancer.
Having access to treatment brokers such as CNS’s or medical staff was valued in 
terms of quality of life as the respondents perceived that staff made life easier for 
them, at a time of distress and alienation these professionals were seen as caring and 
having the respondents best interests as central to the care they provided. This has to 
be considered in the light of the atrocity stories revealed however which is discussed 
in the lens of diagnosis.
Taken in the context of the Milestones identified by the Department of Health (2001) 
there are clearly areas in which input from professionals and service improvements 
could be targeted to improve quality of life as described by the respondents. This is
262shown in Fig 7.0.  HRQoL does not capture this element of what respondents 
considered a major influence on quality of life. Patient experience is largely measured 
through patient satisfaction surveys, which are also limited in scope and, for many 
clinical environments, availability and specificity.
263Fig 7.0 The Lung Cancer Care Pathway (DoH 2001). The Ten Milestones. Influencing Quality of life factors at different points through practice- 
minimising work.
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Contrary to the findings of qualitative work in other cancers, the respondents did not 
narrate with a beginning-middle and end. The respondents typically returned to 
diagnosis throughout the narratives. They viewed the rest of the journey through the 
lens of diagnosis and compared experiences, particularly subsequent experiences with 
professionals, back to the time of diagnosis.
The narratives of diagnosis typically took the form of atrocity stories as examined in
>
Chapter 5. Not only were these experiences centred around the pre and peri diagnostic 
element of the journey, the professionals were imbued with characteristics that were 
negative (e.g. amoral, cold or incompetent). The respondents recounted these 
narratives, generally around first contact with healthcare for this episode.
Placing these stories in context is difficult. It could be argued that at such an emotive 
time, emotions such as mger would influence the respondent. This is hard to dispute 
and the nature of this study is to allow the respondents to tell their story. If this 
interaction did provoke anger, that is surely a valid experience.
However the respondents did not emote anger-more a sense of injustice, particularly 
those who were not offered or refused chemotherapy at the time of diagnosis or those 
who had to make repeated visits to their GP with explicit symptoms. Other 
expressions in the context of atrocity stories included the inconstancy or inaccuracy of 
information that caused anxiety, mismanagement of the treatment calendar (for 
example repeated visits to clinic for results which were not available) and coldness,insensitivity, embarrassment or a sense of being rushed when diagnosis was 
communicated.
The respondents recount how at diagnosis their experience is re-organised by the 
medical staff and how the medical staff set the agenda to fit in with first the illness 
and then the treatment calendar. The respondents organise the:* : illness narratives as a 
coping mechanism, which is then upset. This means that healthcare professionals do 
not consider large sections of what the respondents considered important to quality of 
life in the early illness calendar. The early phase or lens of diagnosis becomes the 
mechanism through wh  ;h subsequent encounters are viewed and can also been seen 
at the end of treatment when some respondents expressed abandonment.
HRQoL tools do not reflect this experience or facet of quality of life directly. In 
current practice this area is not examined and yet is considered a factor influencing 
quality of life by respondents.
266Suffering
Respondents expressed the suffering of cancer as cited previously by other authors in 
the narratives of quality of life. In particular the respondents expressed ways of 
dealing with suffering zs being influential in the quality of their lives.
Physical, psychological and social factors contributed to suffering, the meaning of 
cancer, the suffering of oss such as perceived loss of future, loss of social function, 
loss of societal role and loss or change in close relationships such as the denial of 
close others all contribute to the suffering experienced.
Physical suffering is reflected in the HRQoL assessment tools. The QLQ 30+LC 17 
gathers information about HRQoL in this group but as has been shown; the 
respondents focus few of the narratives on physical experience of treatment or even of 
lung cancer, in some cases despite recorded toxicity or symptoms. This implies that 
the QLQ 30+LC 17 is not reflecting quality of life in this instance but rather a small 
fraction of what is considered quality of life by the respondents. The QLQ 30+LC 17 
has domains which are  lesigned to assess quality of life in terms of role and 
psychology. The validity of these domains is not questioned here but the scope of 
these domains is. They are extremely limited. Psychological issues have a strong 
presence in the narratives and these are not reflected by the QLQ 30+LC 17.
Access to knowledgeable, reliable, credible and approachable healthcare professionals 
was cited by respondents as a factor in quality of life in the context of the alleviation 
of suffering. This was from different perspectives. Trust, attitude and credibility of
267professionals was important to respondents, particularly to those who had recounted 
atrocity stories. Accessibility and negotiation of the treatment calendar was also given 
as an influencing factor as was handling difficult situations such as reluctance by 
close others to discuss illness, treatment and prognosis.
Normalising and acknowledging the distress of cancer was also cited by respondent in 
the context of discussions in the psychosocial dimension of the work. 
Professionalisation of the respondents (gaining knowledge abc ut NSCLC and 
treatment, becoming familiar with the mechanisms of the institution) and the process 
of doing work contributed io quality of life in terms of coping with a difficult 
situation. The struggling act of suffering demands a compassionate other to confirm 
the suffering (Lindholm and Eriksson 1993) which might lead to meaning in 
communion (Rehnsfeld: 1999). The value of CNS as treatment broker and the 
compassionate other was integrated into the narratives, as was the value of the 
relationships in terms of honesty and trust with the senior medical staff. This value of 
honesty and trust as integral to the relationship with staff extended to the acceptance 
of truth telling when the news was bad.
The reasons for suffering are variable and the nursing literature supports meeting the 
person in their suffering and moving with them as the compassionate other as they go 
through the experience (Byock 1994). Nurses seek to understa nd the suffering of the 
person with cancer by offering authentic presence and empathic caring (Houldin 
2000) as discussed in C’napter 6. The impact of bearing witness to suffering often 
creates suffering in clinicians. This suffering may cause those professionals to 
maintain emotional distance and not make time available to patients or focus on the
268treatment or disease (KJagsbrun 1994). This in turn will change the perception of the 
person with cancer to that professional. This can be linked back to the lens of 
diagnosis in the context of atrocity stories, for example the use of words like 
embarrassment by respo ndents when describing the experience of diagnosis.
269The worth of treatment
The worth of treatment was the fourth theme derived from the comparative data. 
Respondents viewed the treatment as a focus for hope and as a social interaction, 
including professionalisation. The physical work of treatment was minimised by 
participants in the interview study despite observed and recorded toxicities during 
treatment.
Respondents generally expected chemotherapy to be hard work and had already 
completed the work at t me of interview. The issue of respondents minimising the 
physical effects of chemotherapy has been raised in the seminar series that has 
accompanied this work. The question of whether respondents minimised 
chemotherapy adverse effects for fear of discontinuation of treatment has been 
considered. Respondents were interviewed outside the original study group so as to 
gain a clinical independence from the researcher-the researcher had no clinical contact 
with the group interviewed apart from a researcher-respondent relationship. The 
researcher identified herself as such, only revealed a professional background if 
questioned and asserted independence from the MDT, this is also reflected in the 
participant information sheet (Appendix B). The other factor to consider is that 
respondents had completed chemotherapy at time of interview and so discontinuance 
was not a threat.  It was not standard practice in the centre to consider refractory 
treatment at the time of the interviews.
270Respondents may have not considered physical side effects, although experienced, to 
be associated with quality of life in this way. Respondents recounted how they 
expected chemotherapy to by physically difficult. Some respondents experienced 
better symptom control as a result of the chemotherapy and this is reflected in the 
LLCG QLQ 30+LC 17 data quite clearly. As twelve of the respondents were self 
selected and sought out a centre where treatment would be available, treatment in the 
context of hope and adaptation to the suffering of cancer seems a plausible 
explanation.
The worth uf treatment  n practice is measured only in terms of tumour response, 
which given the effectiveness of current regimens in terms of response seems 
simplistic. It is time to look at chemotherapy more widely as not only a possible 
treatment for NSCLC but also as a source of hope and adaptation at a time of 
suffering. For the respondents the expected effort and the attempt allowed time for the 
patient and family to adapt.
The four themes are shown in Fig 7.1 as what respondents considered facets of quality 
of life when receiving platinum based chemotherapy for advanced non small cell lung 
cancer.
271Fig 7.1 The comparative properties of quality of life in patients receiving platinum based chemotherapy for advanced NSCLC
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272These findings reflect the subjective nature of quality of life. The core themes have 
evolved to give insight into the experience of NSCLC from the conceptual arguments 
of psychological perspectives to applied clinical practice and the social indicator 
movement.
2737.3 Implications for practice
From these data, the themes that predominate as factors of quaiity of life for the 
respondents were largely psychological factors or experiences of being in the role of a 
patient.
The respondents identified psychological factors which are often pathologised such as 
labile mood, but can equally be argued to be part of the distress of cancer given its 
meaning in society. Living with uncertainty and loss is considered to be important in 
narratives associated w'-ih quality7  of life rather than physical functioning. The cancer 
journey and the negotiation of the illness and treatment calendar constituent a core 
theme of quality of life for these respondents.
This infers that considerable improvement in quality of life as defined by the 
respondents could be achieved through service improvement and the cancer 
modernisation agenda. Cancer treatment calendars and cancer care need to be 
integrated to achieve confluence and improve quality of life. The recognition of the 
importance of the key worker/treatment broker as a central role needs to be affirmed. 
The CNS as central to psychological support needs to be recognised. The importance 
of the source of atrocity stories also needs to be recognised and tackled to improve 
quality of life in patients receiving chemotherapy for advanced NSCLC. Timely and 
appropriate information and an opportunity to discuss the experience needs to be 
available. For these participants, the negative experience of chemotherapy was 
expected; the factor that impacted on their quality of life was the amount of disruption 
it caused and the support available. Implications for practice are shown in Fig 7.2
274Fig 7.2 The implications for practice-factors for consideration in practice
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Although the modernisation agenda has been an active part of cancer services in UK 
for five years, and covers the common cancers such as lung cancer, there has been 
little specific work for this group of patients and yet the provision of services is cited 
by respondents in this study as being important to quality of life.
2757.4 Limitations of the study
The literature in the are* of NSCLC is limited in terms of quality of life. The trial data 
is plentiful but functional. This was despite utilising the specialist search mechanisms 
employed in Chapter 2, specialist historical and archive searches performed by library 
professionals at University College London and the British Library. This was in 
addition to the conventional searches performed by the researcher as documented. A 
search of the Steinberg Collection, a collection of nursing and related theses held by 
the Royal College of Nursing library that dates back to the 1950’s revealed no thesis 
that had Inna ranrpr in rnp title or as a keyword. T.nog cancer remains a poorly funded 
area of research and despite awareness campaigns has made little progress in eliciting 
public support.
The lack of consensus at an academic level was both a limitation and an asset to the 
study. A limitation as the original aim was to test a hypothesis and essentially the 
sensitivity and use of the QLQ 30+LC 17 in this group. The lack of consensus means 
no “gold standard” can be ascertained and there is no benchmark at a level other than 
HRQoL. A respondent asked the researcher “How do you measure quality of life?” 
This limitation allowed the study to open up, to explore quality of life and the 
experience of chemotherapy at a much more global level and to examine its meaning 
in the context of the patient experience.
276The group of respondents were self-selected. Although convenience sampling was 
used to recruit, twelve c.f the respondents had sought chemotherapy after a second 
opinion at the cancer centre. In qualitative research the aim is ,o gain insight to the 
experience rather than produce a representative sample and results that can be 
generalised into the wider population and so this is more of a consideration than a 
limitation.
The authors’ inexperience of qualitative methodology can be considered a limitation 
to the study. Data was collected pre study however the formation of hypothesis and 
testing of hypothesis was the original aim of the study. This is why the format of the 
study and theses (i.e. inclusion of a literature review) has not been changed. However 
in terms of data collection and handling this lack of experience is likely to be an 
influencing factor. For example, a reason for performing the study was the observed 
reaction of respondents in the original trial studies to the QLQ 30+LC 17. The 
reactions of respondents on completing the questionnaire for the first time included 
levels of distress at the questions such as “Have you coughed up blood?” This would 
sometimes provoke a response question to the researcher of “will that happen to me?” 
This data was never recorded
The data generated from the QLQ 30+LC 17 should also be considered. From this 
HRQoL data in the original study by the LLCG there is no appreciable deterioration 
of global or domain HRQoL. In fact within some domains there is an improvement in 
HRQoL. It is necessary to be cautious of this data in so far as it too is incomplete. The 
attrition rate for the QLQ study was high, probably due to severe decrease in function
277and death of participants. This means that an incomplete picture of HRQoL is 
presented. This has been recognised by authors as discussed herein.
The sample size used for content analysis is large for this kind of study, although not 
exceptionally so. However redundancy of data is apparent-saturation was reached 
with fewer than the 40 participants. This repetition of data can be seen in the analysis 
or over analysis and further fragmentation of the transcripts. T iis is why principally 
the thick layer of data has been presented here.  Strauss and Corbin warn against 
falling into an “analytic rut” but this seems to have happened in this study. Data as 
language is invisible-in -his study the words are analysed but context may be iost, 
although memoing took place no conversation analysis was undertaken. This may be a 
limitation in so far as the work remains superficial.
The handling of data from respondents was done with a single reviewer (the 
researcher) and without the benefit of social science packages such as SPSS or 
NUD*ST. This is unlikely to be considered best practice in social science or 
anthropology as it is not given as a method in any recent literature, however it was 
standard practice in the past. The primary reason for this method of data manipulation 
was budgetary, the study was unfunded.
Direct comparisons of the data generated are challenging enough but the study also 
looses some of it power due to the lack of theoretical comparisons the researcher was 
able to accomplish. Theoretical comparisons are necessary particularly when direct 
comparison is not possible, to allow relationships to become apparent. This is a
278limitation to the study as the study becomes less rich for the lack of depth of 
theoretical comparisons herein.
The researcher’s reflection
After reading the thesis of others, particularly in the Steinberg Collection, I have 
noticed that many theses and books in the areas of medical sociology, nursing and 
anthropology are written in the first person. This thesis has grown from a direct 
comparative study, in tLj positivist tradition. I do not have the necessary background 
in philosophy and have been educated as a scientist (taught to value empiricism), what 
is required for tiiis work is conceptual ciaritv of auaiitv of lire.  T r is nor usual to write A  X  *   x
in the first person in academic science and therefore T  have not done so in the rest of 
this work. As the interviews and indeed the whole experience was part of my own 
personal and professional experience, it could have been integrated into the work as 
reflection. As I have not used reflection to a great degree apart from examining my 
own practice as a CNS, there is a possibility that something is lost from the work.
This might be considered a limitation.
My original notes from almost five years ago tell me my original aim was “to add 
richness-to understand the perception and experience in addition to quantative quality 
of life data”. Instead the richness of the experience of the respondents has become 
paramount with the quantative EORTC QLQ 30 data only a facet of what a person 
with incurable lung cancer considers quality of life. This work has however 
profoundly influenced my own practice in caring for lung cancer patients and patients 
undergoing thoracic surgery. I have led service redesign and created a patient centred 
service as a result of this work (Leary and Corrigan 2005)
279The work has also been influenced by two factors. Being a participant observer within 
the service to a degree has influenced my thinking (particularly the motivation for the 
study). The influences c..:e shown in Figure 7.3 below
Influences
Data was collected from a variety of sources for comparative use to describe of 
quality of life in NSCLC.
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280In addition another influence, particularly in interpretation, could have been my own 
cancer experience from March 2004 onwards. This could be a limitation but reliability 
through tabulation should have countered this.
2817.5 Areas for further study
This study generated huge amounts of data, which could be reviewed and re­
processed as an independent study. Each theme could also be studied in more depth 
by experienced researchers who are skilled in drawing theoretical comparisons.
Each area elicited by this study could be examined in depth and using different 
methods, for example conversation analysis. More work is needed around a workable 
consensus for quality of life in clinical settings (it is unlikely the patient experience 
would appear in the social indicator movement in the well population) and more work 
needs to be done in terms of concept analysis and clari (icaiion from a nursing and/or 
socioiogical/phiiosophical perspective.
More work is needed around specific themes elicited such as the atrocity stories and 
negative experiences in the early illness trajectory. The focus of technical rationality 
(that professional activity is problem solving by application of rigorous scientific 
method-Donald Schon 1991) needs to be challenged if this aspect of care is to be 
improved but there is little evidence to support the value of work other than the 
technical. It has been shown that problem solving for these respondents involved 
much more than technical rationality but it can be seen from the stories and the lens of 
diagnosis that this is where the experience is located.
The experience from a family or significant other perspective would also be a 
valuable study. There has been some work in the experience of families and 
caregivers in the palliative setting, but these are mostly in the 'ast days of life.
282Work with healthcare professionals would also be of interest. Areas such as the 
emotional labour involved in a therapeutic relationship with patients with advanced 
NSCLC, the perceptions of staff with respect to diagnosis and atrocity stories, the 
perceptions of staff and the quality of life of their patients, how staff deal with issues 
in the context of the modernisation agenda and the Department of Health reforms, 
staff workload in lung cancer and issues around trust, truth telling and the experience 
of care would be interesting topics for further study and offer valuable insight.
2837.6 Summary
This work has only begun to touch upon the conceptual confusion that surrounds 
quality of life, to draw upon some elements of the literature and compare these to the 
data generated by the study contained herein. This work does, however, contribute to 
the practice of caring for people undergoing platinum based chemotherapy for 
advanced non-small cell lung cancer. It does this by providing insight into the 
experience, by allowing the people undergoing the experience to speak and by 
drawing the attention of the practice community to the limitations of current methods 
of quality of life assessment and their possible, albeit unintentional, misuse. Any 
discussion of the quality of life in this group of patients should include the four core
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of diagnosis and the worth of treatment  from the patient’ s perspective.
The NHS Modernisation agenda covers many of these areas, certainly the patient 
experience but the flaw in the method of modernisation is that it remains target driven 
and yet from the interviews with respondents, quality is a important factor. It is 
difficult to quantify what patients want and need and therefore difficult to address 
these issues in a target driven culture. The two week wait stipulated in the Cancer 
Plan (DH 2000) between seeing a GP with the symptoms of ccncer and seeing a 
specialist are only of benefit if the GP recognises the symptoms of cancer in the first 
place. They are only of benefit if the hospital specialist the patient has gone to see is 
professionally current.
The issues around quality have yet to be addressed. For example is the MDT in reality 
a team or do those members who are the most vocal or those who hold the positional
284authority making the decisions? Are patients really involved in the decision making 
process? What mechanisms are in place to ensure a broad quality of service?  Are 
quality assurance mechanisms such as the peer review process nomothetic in the same 
way that HRQoL is?
The way forward in quality of life assessment in advanced NSLCL may be to move 
away from the functionally dominant scales and questionnaires. A return to 
fundamental measures of which quality of life questionnaires are derivative may be 
the answer here.
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psychological tools, for example the Hospital Anxiety and Depression (HAD) scale. 
Unlike the QLQ 30+LC 17, which are derived from factor analysis, HAD is based on 
clinical experience.  From these data it seems likely the quality of life is a 
psychological construct, and as was discussed in Chapter 6, Cummins argues that 
since the seminal studies of Campbell et al (1976) the view that personal or subjective 
well-being is made up of affective or cognitive components have become accepted. 
This is referred to as subjective well-being. Should we measure this instead? Should 
clinicians who wish to - xamine the effects of palliative chemotherapy use 
fundamental measures? Derivation often leads to systematic e*ror and this is never 
considered in the literature.
Quality of life is certainly an area, which has impact on of nursing practice. The 
contribution of the professions is highly valued in the context of quality of life as 
described by the respondents. The alleviation of suffering, whether physical,
285emotional, spiritual social or psychological is central to the meaning of nursing. At a 
recent meeting attended by the researcher (November 2005) on the management of 
thoracic cancers, an international panel of speakers addressed issues such as 
combination chemotherapy, the future of radiotherapy and even the best way to 
calculate the glomerular filtration rate for optimum chemotherapy dosage. There was 
no discussion of quality of life other than the presentation of trial data in a group 
receiving palliative treatment.
Despite the fact that this group of patients are receiving palliative treatment, the 
observation of fne MDT meetings, the auaiitv of life auestionraires and the lung 
cancer clinical community still fail to address the psychological, social, spiritual and 
emotional needs of this group. In short-the dominance of medical ontology in this 
field fails to address the suffering of this group which has direct reference to quality 
of life. This is shown in Fig 7.4
286Fig 7.4 QOL as an area of practice-good quality of life in the care of patients with non small cell lung cancer through alleviation of suffering
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287As many professional groups are well placed to alleviate suffering in this group and 
deal with many of the factors that are intrinsic to quality of life as defined by the 
respondents, the vision of multiprofessional care must be more than rhetoric.
Truth is rarely absolute, a fact recognised by one of the greatest scientists of the 20th 
century.
“What is not surrounded by uncertainty cannot be the truth”
Richard P Feynman 
In Michelle Feynman 2005
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work has evolved into gaining to a deeper understanding of the lived experience of a 
person undergoing treatment with platinum based chemotherapy for advanced non 
small cell lung cancer and from their perspective elicit what quality of life means.
288Appendix A 
EORTC QLQ 30 Version 3 with LC17 (LC13) 
Lung cancer module
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292Appendix B 
Study Patient Information SheetThe University College London Hospitals
CLINICAL HAEMATOLOGY AND CANCER SERVICES
Clinical Trials Unit
Oncology Research Office,   
 
MIC Vs GC Chemotherapy Quality of Life Study 
Patient Information Sheet
You are being invited to take part in a research project. You have a type of cancer called Non- 
Small Cell Lung Cancer and we are interested in how your treatment for this has affected your 
quality of life.
What will this involve?
In addition to any questionnaires you may have already completed, we would like to ask you 
some additional questions about how you feel about the chemotherapy you have had. There 
are no right or wrong answers and we would like you to be as frank as possible.
This would take no more than one hour and can be done at a time and place convenient to you.
Will this information be confidential?
Any information you give during this interview will be treated with the strictest confidence 
and wall not be revealed even to the medical team treating you. We hope this will allow you to 
be as open as possible about your experience of treatment.
If you decide that you would like anything discussed in the interview to be brought to the 
attention of the medical team caring for you please do let us know.
Do I have to take part?
It is up to you to decide if you would like to take part. If you decide not to take part it will not 
affect your care in any way.
What are the possible benefits of taking part?
It is unlikely that the study will benefit you directly but information you give may benefit 
others in the future.
This research is being conducted by Alison Leary, Research Nurse, at UCLH Trust.
Telephone 
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Common Toxicity CriteriaECOG
COMMON TOXICITY CRITERIA
0 1 2 3 4
Leukopenia vw cxitf
Gramiocytes.'&reas
Lymphocytes
,45
,20
,2.0
3.0-3*
1.5-1*
1.5-1*
29-2.9 
1.9-1.4 
1.0-14
19-1* 
0.5-C.9 
0.5-0.9
<1.0
<0.5
<0.5
Trrcrrbocyo-
oerea
RtxH? WNL 75.C - ncrrral 50.0-74.9 25 C - 49 9 <25.9
Anemia Hgb WNL 100-normal £0-19* 6.5-7.S <0.5
riemarThage
;Ciiniqa!i rone nvd. no tran^scn
gross. 1-2 mils 
transfusiaiveptsoae
gross 34 units 
vanskisiotv episode
massve. >4 .nits 
cans'Lscneprscde
"Weecn
rone ndd, no active Rx
Moderate, localized 
rieaaen requires active Rx
severe, systemic irfectcn 
requires active Rx. spec-y
site
We-tnreaEenrg, sepsis, 
specify si*
Fevern 
absence cf 
nfection
none 37.1 *-38.0-C 
98.7 ■-100.4- F
38.1 ' -400* C 
101.5 ' -104 0- F
>400* C !>104.0* FI ter 
less than 24 hours
>40*- C (1C4.0* R for 
>24 hrs or fever vtth 
hyposewon
• Fewer let? to be caused by dmg allergy should be coded as allergy.
•  Fewer due to infection is coded under infection only.
GO Creadnre WNL <!5xN 15-35xN 3.1-e.Oxhl >6.0 xN
Prtterura Ho change l-r or <8 3q% or <3® S
2-3rcr0.3 -1*3%cr
3-IOg.* 4+ or >1,0s% cr >" Owl nephrotic syncrcme
Hemauia neg maocrty gross, no ciots gross + dots requires transfusion
■sik <1.6 x N 1  5 - 2.5 x N 2£-5xN 5.1 - 10xN >10 X  I*
• Urinary tact infection should be coded under infection, not GO.
• Hematuria resulting from thrombocytopenia should be coded under hemorrhage, not GU.
a
Nausea new
able tc ear reascnade 
intake
.flake signticarxty 
decreased but can eat no agnficarc intake
Vcmrtxtg none 1  episode n 24 hours 2-5 episodes in 24 hours 8-lC episodes in 24 hours
>10 epsooes n 24 hrs or 
requiring parentera 
support
Diarrhea new increase of2-3 sroo&day 
over pre-fix
ncrease of 4-8 stoots'day. 
cr nccaimal stools. or 
Tnaerate orarncing
increase of 7-9 stoofecay 
or ncorswnce, cr severe 
cranping
increase of, 1C stodvsay 
or (possly fcloocy darrhea, 
or need nr parenteral 
supper
Storrjbas now
pairress ulcers, erythema, 
cr fno soreness
painful erythema, edema, 
cr uicers. but can ex
panful eryrema. ederra or 
users, and cannst ea;
requires Garersrai cr 
enteral succort
jver Bkiniw) WNL <" 5 x N 1.5-3.0 xN >3.0* N
iransamnase
iSGCT. SGP~I m sloxN 2c  5.9 x N 5.1- 25.0 x hi >200 xN
AkPhosor
5hudeofcdase WNL u25xN 25-59xN 5.1- 29.0 xN >20.G x N
L/ver-dr-ca
nc change
TO T!
caseSne
precoma hepaccccma
• Viral Hepatitis shotdd be coded as infection rather than Sver toxicity
ruHO'dry 1   new or no 
-------  |  change
asympax'iatic wf- 
abnormality in PFTs
cyspnea on significant 
exerbcn
dyspnea at neural level of 
adMty dyspnea at rest
• Pnetmonia is considered infection and not graded as pulmonary toxicity unless felt to be resultant from pulmonary changes directly induced by 
treatment
Caraiac
Cardiac
dysihytrmias
row asymptomatic. t-ansiert, 
requnno no therapy
recurrent cr persisted, no 
therapy required
requires treatment
reqjres montomg. cr 
hypotenscn cr venincuiar 
tacryoaroia crflbritaticn
Cardiac Cncaon new
asymptomatic decfine or 
ressrg ejecton bacdon by 
•ess Kan 29% of baseSrse 
value
asymptomatic decline of 
resting eecdart TacScn by 
more Sun 2C% of baseline 
vaue
miti CHF. responsive to 
therapy
severe or r»*3<stxy C“c
Cantac-
iscnema
now non-specific T-wa*e
flattering
asymptomatic. ST and 7 
wave changes suggesting 
schema
angina vKthouteviderce 4or 
rfatcHen
acute myocardial infarction
Canfao-
oencardiai now
asymptomatic eflusion no 
intervention rewired
pericarditis true, chest 
oam. £03 chanoesi
symccomaac effusion: 
drartaoe reoured
tamponade; drainage 
urgently reourec
Page 1 of 2
2962970 1 2 3 4
3ood
Eress-re Hypertension none or no 
change
asymptomatic transient 
increase by >20 rmiHg 
<D J or »  >fSQfieC if 
previously WNL No 
Seatmere recured
recurrent or persisted 
increase by >2S nm Ho 
-!D)or to>150rl00d 
previously WNL No 
treatment required
requires therapy hypertonsve crisis
Hypotension none or no 
change
changes reusing no 
therapy (inaudng transient 
orthostatchypotenBcr;
requires laid replacement 
or oner therapy but not 
nospitaizaeon
requires therapy and 
tosptaizabon, resaws 
within 48 hours o? stopemg 
the agent
recuses etersw arc 
hospMzatiai far >45 
hoijs after sapemg the 
agent
Sion
none or no 
change
ssabaednacularor 
pap.iaretupoo'icf 
eryrerrarjt is 
asyrictorTabc
scatsered maciiaror 
papuaren^tnnor
SS^SodatS'r^npars
genera zed syrrpttrratc 
macular. papJar or 
vesicular eruptcn
exfoliative cematibs o' 
liceraang dermadtis
Allergy
none
transient rash, ckug %*er 
<38* C. 100.4* F
i/tcana. drug fever; 
38*C, 100.4‘F mid 
cronchospasjr
serum sickness, 
trcnchcspasm req-rres 
parenteral rreos
arapfryiaxs
’Piebis none arm drostcpNebifcs, eg bos&a.zsxx' embays
uxaf
ncne pam
cain and swettog with 
damnation or phlKiss uceraoon plastic surgery rocatec
Aiopeca
nc'oss mdc har toss
pronounced or ta» har
■css
Wee*
S3*V K 95S <5.0% £.0-8.0% tQ.O-1881s
Sensory
neuro-
sensory
none or no 
change
m e paresthesias: -oss cf 
deep tendon reflates
trap or moderate objective 
sensory loss: moderate 
oarednesias
severe objective sensory 
loss cr paresthesias that 
irseriiee with n/aion
nejre-
vision
ncne or no 
change
symccotTHricsupaeailoss
rfvsicn bareness
M
neuro-
hearing
ncne or no 
change
asymptomatic, heamg ioss 
on auxmesry only Jimius
hearmg loss •serferng 
with function but ccrrect- 
abievrh hearing ard
dea4«ss, ratccrrectab*
j
R A
Moor
neuro-
notor
none or no 
change
subjeobve weakness: no 
ctgeebve finontp
mid objecrve weakness 
wshour significant 
anpasmentotfinctnr.
objec&e weakness w kt 
impsKnnent of ftrtdion paralysis
h
neurc-
consbpaDor.
none or no 
change m£d moderate snee Heus >96 hours
n Psych neuo-
mooa sc orange miid anxiety or depression
moderate anxiety or 
repression
severe anxiety cr 
depression sufadal wesson
Cfinicai nejrc-
O O rt!C a
none mdsomnorencecr
aptabcn
moderate scmrolence or 
agtatcn
severe sorroax*. 
agiiasor ccnftjscn, 
dsonentabcn or 
haiucnafccns
coma, seizures, toxic 
psychoss
najro-
CcfsbCIK II
ccne sight ircoominadon 
dysoadodonests
.roereen tremar dysmerra. 
stirred speech, '■ystagras tw C O T T C suf afloA td cereoe ar "etyoss
headache none m d
moderate cr severe out 
transient irreterbng and severs
'.fetabefe H^ergycemia <*18 118 - IcC ’61-250 251-500 >5D£ or ketoacidosis
Hyoooycemia >64 35-64 40-54 30-38
V V rfi. M.OXN t£-10xN 11 -5.0xN >5.1 xN
Hypercalcema <*c.e 10.6-11.5 11.6-115 128-135 *115
Hypccalcema >54 14-7.5 7.7 -7.0 8.9-61 -.6.0
hytxraonesema >14 1.4-12 1.1 -0.8 0.8-0.6 >0.5
Coaqutaricn Fibrincgen WNL 0.80- 0.75 xH 0.74-Q.50xN 0.49-015xN JLSxN
ProthfcnDnrime WNL 1.01-125 xN 1.28-1.50 xN 151-2.00 xN >2.00 xN
Partia
bTwrbonasantn* WNL 151-1.66 xN *?7-133xN 234-3.30xN >3.00 x N
'  derates ECOG specific criteria
Page 2 of 2
298Appendix D 
Protocol for Study 11 
London Lung Cancer GroupA*
LONDON LUNG CANCER GROUP
CRC & UCL CANCER TRIALS CENTRE
A Phase III Randomised Comparison of 
Gemcitabine/Carboplatin with Mitomycin,
Ifosfamide and Cisplatin in Non-Small Cell Lung Cancer 
(Study 11)
November  1998  version 2 
April  1999  version 3.1
June  1999 version 3.2
UCL
m k d ic a l
SCHOOLSTUDY CONTACTSPage CONTENTS
1 Introduction
4 Trial Objectives
5 Eligibility Criteria
6 Trial Design
6 Chemotherapy Treatment Plan
6 Administration of Regimens
7 Anti-emetics
7 Prophylactic Antibiotics
7 Concomitant Medication
7 Dispensing Procedures
7 Radiotherapy
8 Patient Evaluation
8 Clinical Evaluation
8 Quality of Life
8 Toxicity
8 Response
9 Follow-up after Chemotherapy
9 Criteria for discontinuing protocol treatment
9 Therapy after protocol treatment stopped
9 Follow-up after stopping protocol treatment
10 Investigations
10 Initial Investigations
10 Assessments during treatment
10 Assessments at follow-up
11 Dose Modifications
11 Consent, Ethical and Regulatory Considerations
11 Serious Adverse Event Reporting
12 Statistical Considerations
13 Randomisation
13 Data Management
14 References
15 Appendix 1 WHO Toxicity Scores
17 Appendix 2 WHO Response Criteria
18 Appendix 3 ECOG Performance Scale
19 Appendix 4 Cockcroft & Gault formula
20 Appendix 5 EORTC QLQ C30 + LC 17
23 Appendix 6 Daily Diary Card
24 Appendix 7 Staging
26 Appendix 8 Statistical Methodology
All clinicians wishing to enter patients on this study should be able to comply
with this protocolINTRODUCTION
Non-small cell lung cancer (NSCLC) is inoperable at presentation in more than 80% of cases and 
with the exception of a small  minority suitable for 'radical radiotherapy" the only realistic option 
for treatment aimed at prolonging survival is chemotherapy.
Several  drugs  have  useful  response  rates  of  20%  or  greater  and  combination  chemotherapy 
produces higher response rates. One of the most active and most widely used regimens employs 
mitomycin, ifosfamide and cisplatin (MIC). This regimen has been shown in randomised trials to 
improve survival  significantly  in  patients with  extensive  disease1. In  these  patients  the overall 
response rate to MIC was 31% (2% CR and 29%  PR)1.  In this study WHO toxicity scores were 
not  reported.  In  a  study which  compared  three  cisplatin  containing  regimens  in  patients  with 
stage Illb and  IV NSCLC and found  a  response rate of 40% with  MIC grades 3  and 4 toxicity 
were found for neutropenia in 21% and for thrombocytopenia in 10%.2
New drugs that have already shown both predinical and clinical activity with low toxicity should 
be strong  contenders for introduction as agents for initial  treatment of NSCLC.  In  this respect 
gemcitabine [G] is an interesting new agent which could have a major impact in the treatment of 
NSCLC and therefore warrants further clinical investigation.
Gemcitabine (diflurodeoxycytidine) an  analogue of cytosine arabinoside  (ara-C)  is  a  pyrimidine 
antimetabolite  whose  mechanism  of  action  has  been  well  characterised  and  is  reviewed 
elsewhere.3  On a predinical basis, gemcitabine is active in a variety of murine solid tumours and 
leukaemias, as well as several human tumour xenografts4.  Clinically, gemdtabine has undergone 
extensive testing and has activity in many cancers including NSCLC and SCLC.
Extensive  phase  II  single-agent  and  combination  studies  indicate  that  gemcitabine  possesses 
significant activity  in  NSCLC.  Single-agent studies from  around  the world  have  involved  nearly 
600 evaluable patients.  Anderson  et a!5 reported  on the results of four phase II triais in  Great 
Britain and Denmark with gemdtabine given by short IV infusions weekly times 3 every 4 weeks 
in doses ranging from 800 to  1,250 mg/m2 and involving 332 evaluable patients with advanced, 
inoperable  NSCLC  (54%  stage  IV).  Objective  responses were documented  in  20%  of patients, 
and toxic reactions were generally mild with WHO grade 3 or 4 neutropenia occurring in 25% of 
patients (dinical infections were rare), WHO grade 3 or 4 thrombocytopenia in2%, WHO grade 3 
or 4 elevations of hepatic transaminase levels in  12%, and transient rashes or lethargy in 20 to 
24%.  Negoro et al6 reported the results of two Japanese  phase II trials involving  74 evaluable 
patients with  NSCLC (41  with  stage IV disease)  using gemcitabine  in  doses of  1,000 to  1,250 
mg/m2 /week.  Objective responses were reported  in  20 patients, for an overall  response rate of 
27%. WHO grade 3 or 4 leukopenia was seen in <10% of patients.
Shepherd et al7 reported on a multinational trial involving 93 response-evaluable, chemotherapy- 
naive patients with inoperable NSCLC (60% stage IV), exduding large cell histology, treated with 
gemdtabine 1,250 mg/m2 /week times 3, with cydes repeated every 4 weeks. Objective 
responses were seen in 20% of patients, with principal toxic reactions consisting of WHO grade 3 
or 4 neutropenia in 6% of cycles and WHO grade 3 or 4 thrombocytopenia in <1% of cycles. 
Hepatotoxic reactions, manifesting as WHO grade 3 or 4 elevations in transaminase levels, 
occurred in <3% of cycles. Abratt et al8 from South Africa reported on 76 evaluable patients with 
locally advanced or metastatic NSCLC (41.7% with stage IV disease) who had not received 
previous chemotherapy. Gemdtabine was again given as a short IV infusion weekly times 3 and 
repeated at 4-week intervals in doses of 1,000 to 1,250 mg/m2 /week.  Objective responses were 
seen in 15 patients (induding 2 CRs), for an overall response rate of 20%. Toxic reactions were 
again minimal, with WHO grade 3 or 4 leukopenia occurring in 1% of cycles and WHO grade 3 or 
4 thrombocytopenia occurring in <0.1% of all cycles. Non-haematologic toxic reactions were 
generally mild and included peripheral oedema, asthenia, transient malaise, and elevations in 
hepatic transaminase levels.
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NSCLCGemcitabine may modify the ability of the cancer cell to repair platinum induced DNA lesions and 
thereby modify resistance to platinum. Several trials have evaluated gemcitabine in combination 
with  cisplatin  in  advanced  NSCLC.  Gemcitabine  was  administered  on  a  weekly  basis,  while 
cisplatin schedules varied.  One study administered gemcitabine weekly (days  1,  8 and  15) at  1 
g/m2  and  cisplatin  100  mg/m2  on  day  2 of each  28  day  cycle.9 This combination  produced  a 
dramatic increase in the overall  response rate to  54%.  Although 27% of patients experienced 
grade 4 thrombocytopenia, this was short lived and there were no clinical sequelae.
Carboplatin  [C]  is believed to share a  common  mechanism  of chemical  activation with cisplatin 
and it has advantages over cisplatin in terms of lower toxicity and being suitable for out-patient 
administration.  There  has  been  only  one  head-to-head  randomised  comparison  of  the  two 
agents. The European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer 
Working  Party  conducted  a  randomised  trial  comparing  cisplatin  120  mg/m2,  day  1  and 
carboplatin  325  mg/m2,  day  1  in combination  with  etoposide  100  mg/m2,  days  1,  2,  and  3  in 
advanced  non-small-cell  lung cancer (NSCLC)10.  228  patients were eligible for survival  and  202 
assessable for response. There were no significant differences in response rates or survival. The 
carboplatin  arm,  however,  produced  significantly  less  leucopenia,  nausea,  vomiting,  and 
diarrhoea than the cisplatin arm.
When  single-agent  carboplatin  was  compared  with  several  cisplatin-containing  combination 
regimens in an ECOG prospective randomized trial11, the single-agent carboplatin arm produced a 
lower objective response rate (9%) but significantly longer median  survival (p=0.008) than the 
other arms in the trial.
The mitomycin, vinblastine, and cisplatin (MVP) combination  is one of the most frequently used 
for NSCLC.  Data from the Royal  Marsden showed overall  response rate of 32% (95%CI 24-42); 
52% for stage Illb and 25% for stage IV. The median response duration was 6 months and the 
median survival 5 months12.
Paccagnella et al13 evaluated a combination similar to MVP, using carboplatin instead of cisplatin 
to  render  it  more  feasibie  in  an  outpatient  setting.  Inclusion  criteria  for  this  study  included: 
inoperable patients or patients relapsing after previous surgery, with  NSCLC. The chemotherapy 
regimen  included  carboplatin,  300  mg/m2  on  Day  1;  mitomycin,  8  mg/m2  on  Day  1;  and 
vinblastine, 4 mg/m2 on Days 1, 8, and  15 (on Day 15 vinblastine was delivered only in the first 
cycle) (MVC) every 3 weeks for at least 3 cydes. 70 patients entered the trial with only 4 patients 
requiring  hospitalisation  for  treatment  delivery,  the  remainder  being  treated  as  out-patients. 
Overall response rate was 38% (95% a  27-51%).  Median duration of response was 9.8 months 
(range, 2-27 months) and the median survival 9.5 months. In Stage III patients the RR was 42% 
and  in  Stage  IV patients  it was 34%. The results  using  carboplatin  were therefore at least as 
good as those expected from cisplatin in combination with vinblastine and  mitomycin. The back 
calculation of carboplatin  area  under the curve  (AUC)  with  Calvert's formula  showed a  median 
AUC value of 4 (range,  2-8).  Haematologic toxicity was the  major side effect;  Grades  3 and  4 
leukopenia  were  observed  in  34%  and  6%  of  patients,  respectively,  and  Grades  3  and  4 
thrombocytopenia in 25% and 4% of patients, respectively. Grade 2 infection occurred in 10% of 
patients, with only 1 case of sepsis; severe constipation and Grade 2 alopecia occurred in only 1 
patient; and no case of higher than Grade 1 nephrotoxicity was observed.  No pulmonary toxicity 
was observed.
Therefore,  because  of  its  nearly  equivalent  efficacy,  more  manageable  toxicity,  and  ease  of 
outpatient administration,  carboplatin  is a  more  attractive  platinum  analogue than  cisplatin for 
outpatient  treatment  of  NSCLC.  Furthermore,  an  improved  understanding  of  the 
pharmacokinetics  and  pharmacodynamics  of  carboplatin  strongly  suggests  that  its  efficacy  in 
NSCLC  may  have  been  underestimated  in  trials  that  used  body  surface  area  based  dosing. 
Several  investigators  have  found  that  carboplatin's  pharmacokinetics  (area  under  the  plasma 
concentration  time  curve  [AUC])  and  pharmacodynamics  (myelotoxicity)  are  more  closely 
associated with an individual  patient's glomerular filtration  rate (GFR) than with BSA.  Calvert et 
al14  have  proposed  the  use  of  a  simple  formula  in  which  the  dose  of  carboplatin  (in  total 
milligrams) is determined by multiplying the calculated creatinine clearance (an estimate of GFR)
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NSCLCplus  25  by  the  desired  carboplatin  AUC  (ie,  carboplatin  dose=AUC  x  [calculated  creatinine 
dearance+25]).  This  approach  would  be  expected  to  decrease  the  proportion  of  patients 
suffering severe toxic reactions when their dose based on BSA is much higher than it would be if 
based on  GFR.  Conversely,  there would  be a decrease in the proportion of patients receiving 
doses too low for therapeutic effect, because their carboplatin dose based on BSA is much lower 
than it would be if based on GFR.
A phase I study evaluated  a  combination  of gemcitabine and  carboplatin  in  13  chemotherapy- 
naive  patients  with  non-small  cell  lung  cancer  to  determine  the  maximum  tolerated  dose  of 
carboplatin  in  combination  with  gemcitabine.15  Gemcitabine  at  a  dose  of  1,000  mg/m2  was 
administered on days  1, 8, and  15 of a 28-day cycle and carboplatin was given as a 30 minute 
infusion  immediately  before  gemcitabine  on  day  1.  Carboplatin  dosing  was  escalated  and 
determined  using the Calvert formula,  and  three  patients were treated  at the  initial  predicted 
dose  of  area  under  the  curve  (AUC)  4  mg/mL/min.  Subsequently  the  carboplatin  dose  was 
escalated  to  a  predicted  AUC  5.2  mg/mL/min.  Pharmacokinetic  studies  were  performed 
measuring  gemcitabine  and  carboplatin  (total  platinum)  concentrations.  Responses  were 
assessed  following  two  cycles  of  treatment  and  patients  with  stable  disease  or  objective 
responses  proceeded  to  receive a  maximum  of six cycles.  Dose-limiting  myelosuppression  was 
identified at a  predicted carboplatin AUC 5.2  mg/mL/min, with two patients developing grade 4 
neutropenia and two patients grade 4 thrombocytopenia. However, these grade 4 toxicities were 
not associated with any serious sequelae.  In this preliminary study, four partial responses were 
observed  and  the  median  length  of  survival  for  all  patients  was  45  weeks.  The  authors 
commented that symptomatic toxicities were rare and outpatient treatment was easy.
These preliminary data suggest a response rate and survival from this combination comparable to 
that obtained  with  MIC.  We  propose to  examine  the  role  of gemcitabine  in  combination  with 
carboplatin (GC) in NSCLC. We plan a randomised comparison with MIC which is the combination 
that has been used most widely for treatment of NSCLC in patients with inoperable stage Illb - 
IV NSCLC. The aims will be to determine whether GC can achieve a  response rate and survival 
advantage comparable to or better than that conferred by MIC but with less tnxicity and greater 
quality of iiic duvdiilage.
The  four  weekly  schedule  involving  treatment  on  three  occasions  per  four  week  cycle  is  less 
convenient for comparison with  MIC which  is a three weekly regimen,  and the different timing 
considerably complicates  comparison  of quality  of  life.  Gemcitabine  has  most frequently  been 
used at a doses of 1000 mg/m2  on days 1, 8 and  15 of  a four weekly cycle, ie a dose intensity 
750 mg/m2 /week. To maintain a comparable dose intensity using gemcitabine on days 1 and 8 of 
a three weekly cycle a  dose of 1200  mg/m2  is appropriate.  A regimen  using gemcitabine  1250 
mg/m2 and carboplatin AUC 6 based on measured EDTA clearance has been used in  19 patients 
with advanced lung cancer. A total of 62 cycles have been administered with a maximum number 
of 6 cycles per patient. Grade 4 thrombocytopenia was observed following 8% of cycles and the 
regimen  was  generally  well  tolerated.  (Dr  Sederholm,  Sweden,  personal  communication). 
Because  experience  with  this  regimen  is  limited  the  design  of  the  study  incorporates  early 
stopping rules based on response and toxicity data after the first 40 patients have been treated 
with GC.
Ideally any measure of QOL should  be 'self-reported' and  multi-dimensional, encompassing the 
domains of psychological,  social  and  physical functioning  as well  as disease  related  symptoms 
and relating toxicities. The EORTC QLQ-C30 with additional lung cancer module (LC17) has been 
well  validated  and  appears  to  achieve  these  requirements.  Daily  diary  cards  are  better  than 
interval  questionnaires  at  demonstrating  daily  fluctuations  and  these  are  particularly  relevant 
when  comparing  chemotherapy  regimens  given  at  similar  intervals  and  over  the  same  total 
period. The LLCG diary card has been validated for use in SCLC16 and  has been used  in several 
previous studies, eg 17, and will therefore be used in addition.
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NSCLC2.0 TRIAL OBJECTIVES
2.1  To compare survival following GC and MIC.
2.2  To determine the response rate to GC x 4 courses in patients with  NSCLC  and compare  it with
MIC x 4 courses.
2.3  To compare toxicities of GC and MIC.
2.4  To compare QOL in patients with NSCLC receiving GC and MIC. The  dimensions which  will  be
assessed are: physical (including lung cancer symptoms and treatment side effects), social and 
cognitive functioning, as well as global quality of life.
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NSCLC3.0 ENTRY CRITERIA
3.1  ELIGIBILITY CRITERIA
3.1.1  Histologic or cytologic proof of non-small cell carcinoma of the lung.
3.1.2  Stage Illb or IV disease (See appendix 7).
3.1.3  Measurable or evaluable disease.
3.1.4  Renal function adequate for chemotherapy: ie, EDTA clearance greater than 60 ml/min.
In cases where EDTA is not possible, measured creatinine clearance or calculated (Cockcroft 
formula) should be greater than 50 ml/min
3.1.5  Age 18 or over.
3.1.6  If female and of child bearing potential using adequate contraception for the duration of 
chemotherapy.
3.1.7  Willing to give written informed consent.
3.2  CRITERIA OF INELIGIBILITY
Patients will not he eligible for entry into the trial under any one of the foiiowing conditions:
3.2.1  Prior treatment with radiotherapy or chemotherapy.
3.2.2  A life expectancy of less than 8 weeks.
3.2.3  A history of prior malignant tumour, unless the patient has been without evidence of disease for 
at least 3 years or the tumour was a non-melanoma skin tumour.
3.2.4  White cell count less than 3,000/ mm^.
3.2.5  Platelet count less than 100,000/ mm^.
3.2.6  Haemoglobin less than 10.0 g/ dL
3.2.7  A medical condition that excludes the use of chemotherapy.
3.2.8  Symptomatic brain metastases.
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NSCLC4.0 TRIAL DESIGN
4.1  OVERALL DESIGN
A multicentre randomised, phase III, open label, study to compare 4 cycles of GC with 4 cycles of 
MIC with respect to response rate, survival and QOL.
4.2  CHEMOTHERAPY TREATMENT PLAN
4.2.1  GC -  3 weekly regimen
Gemcitabine 1200mg/m2 IV Day 1 and 8
Carboplatin (AUC 5). Dose in mg calculated according to formula:
Dose = Target area under curve  x (Creatinine clearance  + 25)  IV dayl.
*NB: where possible, EDTA should be used to calculate GFR as it is most accurate 
measure of renal clearance.  [Measured (creatinine) clearance gives closer approximation to 
EDTA.  Calculated (Cockcroft) underestimates by about 10%].
Thus, the formula for dose of Carboplatin is:
5 (EDTA/creatinine clearance + 25) mo  OR  6 (calculated (Cockcroft) clearance + 25) ma
4.2.2  MIC -  3 weekly regimen
Mitomycin 6 mg/ m2 IV Day 1 
Ifosfamide 3 g/m2 IV Day 1 
Cisplatin 50 mg/m2 IV Day 1
4.3  ADMINISTRATION OF REGIMENS
GC  -   Gemdtabine and Carboplatin 
Day 1  Gemdtabine 1200mg/m2 IV in 250 ml N saline over 30 minutes 
♦Carboplatin mg=AUC 5 IV in 500 ml dextrose over 30 minutes 
Day 8  Gemdtabine 1200mg/m2IV in 250 ml N saline over 30 minutes 
MIC -  Mitomyan, Ifosfamide and Cisplatin 
Day 1  Mitomycin 6 mg/m2 iv bolus into fast running drip
Ifosfamide 3 g/ m2 in 1 L N saline over 3 hours and Mesna 1.5 g/ m2 
Frusemide 40 mg po
Cisplatin 50 mg/m2 in 500 ml N saline over 1  hour
Mesna 1.5 g/ m2 in 1 L N saline with 20 mmol K CI over 4 hours.
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NSCLC4.4  ANTI-EMETICS
Suggested anti-emetics:
•  Granisetron  3  mg  iv  and  dexamethasone  8  mg  iv  before  each  chemotherapy  except
gemcitabine day 8 for which metoclopramide 20mg iv should be adequate.
•  Metoclopramide 20 mg 8 hourly pm after.
•  This may be varied according to local practice and patient needs.
4.5  PROPHYLACTIC ANTIBIOTICS
All  patients will receive prophylactic trimethoprim (or locally preferred equivalent) from day 8 to 
day 21 of each cycle to minimise the risk of neutropenic sepsis and respiratory infection.
4.5  CONCOMITANT MEDICATION
Other medication,  including steroids,  may be adminstered at the discretion of the clinician. The 
commonest indication for steroids would be as part of standard anti-emetic regimen.
4.7  DISPENSING PROCEDURES
Dispensing procedures will follow usual local pharmacy practice.
4.8  RADIOTHERAPY
If palliative radiotherapy is considered necessary before chemotherapy has been completed this 
will  be  considered  evidence  of  progressive  disease  and  the  patient  will  not  receive  further 
chemotherapy.
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NSCLC4.9  PATIENT EVALUATION
4.9.1  CLINICAL EVALUATION
•  Patients will be evaluated for response at the start of each cycle of chemotherapy by chest 
radiograph.
•  In cases in which disease is measurable or evaluable only by CT scan of the thorax this will 
be repeated after each second cycle.
•  Patients will also be assessed at 3 week intervals by history, physical examination, chest 
radiograph and laboratory tests as indicated in Section 5.2. Scans will be repeated if clinically 
indicated.
•  Toxicity to chemotherapy will be asssessed after each treatment, ie, toxicity scores at each 
cycle should relate to the previous course
4.9.2  QUALITY OF LIFE
•  The EORTC QLQ-C30 with additional lung cancer questions (LC17) (Appendix 5) will be 
completed by all patients after consent but before knowledge of randomisation to prevent 
any influence of treatment allocation on baseline information.
•  The EORTC QLQ-C30 + LC17 will also be completed before each cycle of chemotherapy and 
at the first two follow-up visits.
•  Each questionnaire refers to how the patient has felt over the past week. The questionnaire 
should be given out and collected at each visit, preferably by the same person and then 
returned to the trials office on completion. The forms will be completed by the patient 
without conferring.
•  The daily diary cards (DDC) will be completed on a baseline day to represent pre-treatment 
levels and then every evening from the first day of chemotherapy until 3 weeks after the last 
course.
4.9.3  TOXICITY
Toxicity will be assessed according to NCIC Common Toxicity Criteria. (Appendix 1)
4.9.4  RESPONSE
Response will be assessed according to WHO criteria (Appendix 2) 
Survival time is the interval between date of randomization and death.
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NSCLC4.10  PATIENT FOLLOW-UP AFTER CHEMOTHERAPY
Patients should be seen every 4 weeks for the first year and thereafter at 8 weekly intervals. At 
these  visits  the  date  and  site(s)  of  progressive  disease  and  any  further treatment  should  be 
recorded on follow-up forms.
4.11  CRITERIA FOR DISCONTINUING PROTOCOL TREATMENT
Once patients are randomised they remain part of the study until death.
•  Protocol treatment may, however, be stopped in the following instances:
•  Tumour progression
•  Unacceptable toxicity
•  Intercurrent illness which, in the clinician's opinion would require discontinuation of protocol 
therapy.
•  If subsequent histological / cytological review is contrary to the original diagnosis.
•  Patient wish.
4.12  THERAPY AFTER PROTOCOL TREATMENT HAS STOPPED
Subsequent therapy after discontinuation of protocol treatment will be left to the discretion of the 
clinician.
4.13  FOLLOW-UP AFTER STOPPING PROTOCOL TREATMENT
After stopping  protocol treatment,  all  patients should be followed  up in the usual way -  see section 
4.10.
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5.1  INITIAL INVESTIGATIONS
•  History and physical examination
•  Weight, height, surface area and record of performance status (ECOG scale as in Appendix 3)
•  Haemoglobin, white blood cell count, differential count and platelet count
•  Creatinine, blood urea, electrolytes
•  AST/ALT, alkaline phosphatase, bilirubin, calcium
•  Assessment of renal function in accordance with local practice but preferably bv EDTA
•  Chest X ray PA
•  CT or US abdomen
•  CT brain scan if clinically indicated
•  Isotope bone scan if clinically indicated.
EORTC-QLQ C30 + LC 17
5.2  ASSESSMENTS TO BE FOLLOWED  DURING TREATMENT
Prior to each cycle:
•  Weight
•  ECOG performance status
•  Full blood count and differential
•  Biochemistry
•  Chest xray (PA)
•  Scans (where clinically indicated)
•  Toxidty since last visit
•  EORTC QLQ-C30 + LC17
•  Daily Diary Card
•  Assessment of renal function as indicated
5.3  ASSESSMENTS AT FOLLOW-UP
•  Full blood count and differential
•  Biochemistry
•  Chest xray (PA)
•  Scans (where clinically indicated)
•  EORTC QLQ-C30 + LC17
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NSCLC6.0  DOSE MODIFICATIONS
D ose redu ctions are b a sed  on p re-trea tm en t blood te s ts  a n d /o r ren al function.
6.1  ALL DRUGS ON PRE-TREATMENT COUNTS
WBC x 109/l Platelets x 109/l
> 3 And > 100 Full dose
1.5 -  2.99 Or 50 - 99,9 75% dose
< 1.5 Or < 50 Delay 1 week
6.2  GEMCITABINE (Day 8) DOSE MODIFICATION
Day 8 Total WBC 
(x 10 9i  1)
Day 8 Platelets 
(with no evidence of 
bleeding) (x 10 9/ 1)
Gemdtabine
> 2.0 And >50 Full dose
< 2 Or <50 omit gemdtabine
6.3  CISPLATIN AND GEMCITABINE DOSE MODIFICATION FOR RENAL FUNCTION
Calculated Creatinine 
Clearance (m l/ min)
Cisplatin dose Gemdtabine
dose
> 60 100% 100%
40-60 50% 50%
< 40 Omit Omit
(NB: fo r an y seriou s u n expected drug reaction s during trea tm en t w ith 
G em dtabine/C arbopiatin, p lea se com plete a Seriou s A dverse E vent form - see 7.0J
7.0  INFORMED CONSENT AND ETHICAL CONSIDERATIONS
Written  informed consent will  be obtained  according to the local  institutional ethical  committee 
requirements.  Due to  differing  requirements,  a  standard  consent form  for the trial  will  not  be 
provided.  Multi-Centre  Research  Ethics  Committee  approval  will  be  applied  for.  It  will  be  the 
responsibility of the local participating investigators to obtain the necessary Local Research Ethics 
Committee  approval.  A  DDX  certificate  for  the  trial  has  been  obtained  as  Carboplatin  is  not 
licensed for use in  non-small cell  lung cancer.  The DDX  is also conditional on all serious 
unexpected adverse reactions being reported promptly to the Committee on Safety of 
medicines,  and  all  centres  must  take  the  appropriate  steps  to  ensure  that  this 
reporting mechanism is in place.
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The aim is to recruit 387 patients.  The basis for this is as follows.  We hope that GC may be less 
toxic with better QOL but we need to be reasonably confident that it will not be less effective in 
terms of survival.  Therefore patient numbers have been calculated to allow reasonable exclusion 
of a clinically significant survival decrement with GC.  With MIC in stage Illb-IV disease one year 
survival is 28% 1.
With the entry of 387 patients there would be only a 20% chance that the 95% Cl on the hazard 
ratio at the end of the trial would indude survival differences of 10% or greater in favour of MIC 
at 1 year (see reference  18 or Appendix 8 calculated with a=0.05, b=0.20, d - the difference in 
log hazard ratio - =0.298).  Thus, with 387 patients entered, and the two treatments being really 
equivalent, we are likely (with an 80% chance) to be able to condude at the end of the trial that 
there are not more than 10 percentage points difference in survival in favour of MIC.
The  statistical  methodology  for  these  results  is  given  in  detail  in  a  paper  submitted  for 
publication. 19   See also Appendix 8.  The method in outline consists of examining the confidence 
limits on the hazard ratio from a survival comparison (usually at the end of the trial), and setting 
the sample size sufficiently large that the lower confidence limit on the hazard  ratio gives a  % 
survival  difference  which  is  less than  some  pre-chosen  value,  at  a  particular time  of interest. 
Thus at the end of the trial, when the survival comparison is performed and confidence limits are 
calculated on the hazard  ratio, the numbers entered will  have been sufficiently large to ensure 
that the lower confidence limit exdudes a survival difference of more than x%, where x has been 
specified in advance (eg in this trial x=10%).
The  trial  will  continue  to  completion  only  if  response  rate  and  toxicity  of  GC  in  the  first  40 
patients receiving GC are regarded as acceptable. Criteria for acceptability will be:
1.  With MIC the response rate in this group of patients is 34% (95%CI 26-42) (MIC2 Cullen, 
persona! communication).  So if the true response rate is 26% then the chances of seeing 5 or 
fewer responses  in  the first 40  (GC)  patients  is just less than  5%  (exact probability  =  3.2%). 
Therefore  if  there  are  5  responses  or  fewer  in  the  first  40  (GC)  patients  the  study  will  be 
terminated.
2.  In the MIC2 trial  the proportion of courses 2,  3 and 4 delayed was 8.6%  (95%CI  5.7- 
12.2%)  mainly  due  to  haematological  toxicity  and  infection  (Cullen  et  al).  Some  increase  in 
haematological toxicity would be acceptable if GC had other advantages,  however.  Hence, the 
lower end of the 95% Cl for the proportion of courses delayed (ie courses 2,  3 and 4) due to 
haematological toxicity or infection shall not exceed 20%, (around twice that expected with MIC). 
In  the  MIC2  trial  60%  of  courses  2,  3  and  4  were  actually  administered,  others  not  being 
adminstered because of progressive disease,  patient refusal  or other reasons.  If patients were 
eligible for 60%  of courses  2,  3  and  4 of GC,  the total  number of courses  2-4  in  40  patients 
would be 72.  Hence, the proportion of courses 2-4 delayed because of toxicity should not exceed 
29% (95%Q 20 - 40%).
The planned study size would have only a modest chance of detecting anything less than a major 
survival advantage for GC over MIC if that existed.  If analysis of the data were to suggest the 
possibility of a survival advantage for GC which had not reached statistical significance because 
of inadequate  numbers consideration  would  be given  to extending  the study to a  total  of 631 
patients which would confer 80% power to detect a 10% survival difference significant at the 5% 
level (2-sided test).
For the  EORTC  QLQ  results,  the  main  comparisons  will  be  at 6  weeks,  ie  after two  cycles,  3 
weeks after the last cycle of chemotherapy (whenever that is for the individual patient) and at 6 
months from randomisation.  These time points have been chosen as representative of rapidity of 
relief of symptoms of cancer and  initial  tolerance of chemotherapy,  an  assessment of relief of 
symptoms and  tolerance at the end of treatment,  and  an  assessment of durability of relief of 
symptoms of cancer.  On the  DDC scores of 1-4 are obtained for each symptom  (1  well - 4 ill)
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NSCLCdaily. These are analysed  by comparing the  proportion  of patients whose  replies fall  into each 
category over the period of observation  using  non-para metric methods.  Graphical  presentations 
demonstrate the time course of adverse effects of chemotherapy.
Assuming that approximately 40% of patients fail to complete sufficient QoL assessments to be 
evaluable  and  that adequate data  are obtained  from  232  patients,  QoL comparisons will  have 
approximately 90% power to detect a difference between treatment groups of 20% or greater, 
eg difference between  15% and 35%, in the proportion of patients crossing a threshold score on 
a QoL measure.
9.0  RANDOMISATION METHOD
Patients are enrolled after completion of pre-treatment evaluation. They are stratified according 
to study centre, stage, ie Illb or IV, and according to ECOG performance status. The purpose of 
stratification  is  to  balance  the  groups  by  these  prognostic  factors.  Computer  generated 
randomisation using the minimization technique will be administered by the London Lung Cancer 
Group Trials Office.
Trial forms will  be returned to the London  Lung Cancer Group trials centre for computerisation 
and statistical analysis.
10.0  DATA MANAGEMENT
10.1  DOCUMENTATION - Study forms
Eligibility checklist - to be checked and then faxed or phoned to the Trials 
Office.
Chemotherapy - complete all details on form with each course of 
chemotherapy AND for every delay.
Post chemotherapy - complete all details after final course of chemotherapy 
and radiotherapy (if given).
Follow up - complete all details on form every month after the 
completion of  chemotherapy for 1 year, and every two 
months thereafter.
Quality of Life - complete EORTC QLQ-C30 and LC-17 before patients' 
knowledge of treatment allocation, before each cycle of 
chemotherapy and at first two follow-up visits.
- daily diary cards to be completed by patients and 
collected at each visit from randomisation until 3 weeks 
after the last course of chemotherapy
Final Form - on death of patient
Serious Adverse Event - complete form for all cases of serious unexpected 
adverse reactions during Gemcitabine/Carboplatin 
treatment
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NSCLCAPPENDIX 1
NCIC CTC expanded Common Toxicity Criteria
(revised 1994)
Grade 0 1 2 3 4
Allergy none transient rash, fever 
< 38° c
urticaria, fever >38°c 
mild bronchospasm
serum sickness, 
bronchospasm, req. 
parenteral 
medication
anaphylaxis
Fever felt to be caused by drug allergy should be coded as allergy.  Non allergic drug fever (eg: as from biologies) 
should be coded under 'flu like symptoms.  If fever is due to infection, code infection only
Other none mild moderate severe life threatening
Cardiac
Dysrhythmias none
asymptomatic, 
transient, req. no 
therapy
recurrent or 
persistent, no 
therapy req.
req. therapy
req. monitoring; or 
hypotension; or 
venticular 
tachycardia,; or 
fibrillation
Oedema none 1 + or dependent in 
evening only
2 + or dependent 
throughout day
3+ 4+, generalized 
anasarca
Other (indudes sinus 
tachycardia & 
palpitations)
none mild moderate severe life threatening
Flu like symptoms
Arthralgia none mild moderate severe
diaphoreses none miki moderate severe
Fever in absence of 
infection 
(indudes drug fever) none 37.1-38.° c 38.1-40.0° c
> 40.0° c 
for < 24 hours
_ _ _ _ _ _   __  _   _ _ _ _
> 40.0° c 
for > 24 hours or 
fever accompanied 
by hypotension
Fever felt to be caused by drug allergy should be coded as allergy.  Non allergic drug fever (eg: as from biologies) 
should be coded under 'flu like symptoms.  If fever is due to infection, code infection only
Lethargy none
mild -  fall of 1 level 
in perf. status
moderate -  fell of 2 
levels of perf. status
severe - fell of 3 
levels in perf. status
Myalgia none mild moderate severe
Rigors/chills none mild or brief pronounced and/or 
prolonged cyanosis -
Other none mild moderate severe life threatening
Gastrointestinal
Diarrhoea none increase of 2-3 
stools/day
increase of 4-6 
stools/day
increase of 7-9 
stools/day
increase of> 10 
stools/day
Nausea none able to eat 
reasonable intake
intake significantly 
decreased, but can 
eat
no significant intake -
Vomiting none 1 episode in 24 hrs 2-5 episodes in 24 
hrs
6-10 episodes in 24 
hrs
>10 episodes in 24 
hrs or requiring 
parenteral support
Stomatitis/oral none
painless ulcers, 
erythema or mild 
soreness
painful erythema, 
oedema or ulcers but 
can eat
painful erythema, 
oedema or ulcers and 
cannot eat
mucosal necrosis 
and/or req. 
parenteral or enteral 
support. Dehydration
Anorexia none mild moderate severe dehydration
Other none mild moderate severe life-threatening
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Grade 0 1 2 3 4
Haematology
Hb WNL 10 - Normal 8.0-9.9 6.5-7.9 <6.5
WBC S; 4.0 3.0 - 3.9 2.0 - 2.9 1.0 - 1.9 <1.0
Plats WNL 75.0 - Normal 50.0 - 74.9 25 - 49.9 <25.0
Neuts >  2.0 1.5 - 1.9 1.0 - 1.4 0.5 - 0.9 <0.5
Hepatic
Aik Phos none < 2.5 x N 2.6 - 5.0 x N 5.1 - 20.0 x N > 20.0 x N
ALT/AST none < 2.5 x N 2.6 - 5.0 x N 5.1-20.0 xN > 20.0 x N
Bilirubin none < 1.5 xN 1.5- 3.0 xN > 3.0 x N
Liver- dinical
no change from 
baseline pre-coma hepatic coma
LDH normal < 2.5 x N 2.6 -  5.0 x N 5.1 -  20.0 x N > 20.0 x N
Other none mild moderate severe life threatening
viral hepatitis should be coded as infection rather than liver toxicity
Infection
none mild, no active moderate, localized 
infect, req. active, trt.
severe, systemic 
infect., req. parenteral 
trt., specify site
life threatening sepsis 
specify site
febrile neutropenia none present
Fever felt to be caused by drug allergy shouk 
should be coded undrer Flu like s
be coded as allergy.  Non allergic drug fever (eg: as from biologies) 
ymptoms.  If fever is due to infection, code infection only
Neurological
Sensory none or no change
mild paresthesia, loss 
of deep tendon 
reflexes (ind. 
tingling)
M ild or moderate 
objective sensory 
loss; moderate 
parasthesia
sensory loss or 
parasthesias that 
interfere with 
function
-
Constipation none or no change mild moderate severe ileus > % hours
Renal (CTC Genitourinary Group)
Haematuria negative micro, only gross, no dots gross + dots req. transfusion
Creatinine WNL < 1.5 x N 1.5- 3.0 xN 3.1-6.0 xN >6.0 x N
Skin
Alopeda no loss mild hair loss pronounced or total 
head hair loss total body hair loss -
Skin Changes none hyperpigmentation atrophy subcut. fibrosis ulceration or necrosis
Desquamation none dry desquamation moist desquamation confluent moist 
desquamation
-
Rash/Itch 
(not due to allergy. 
Indudes recall 
reaction)
none or no change
scattered macular or 
papular eruption or 
erythema that is 
asymptomatic
scattered macular or 
papular eruption or 
erythema with 
pruritOs or other 
asodated symptoms
generalized 
symptomatic 
macular, papular, or 
vesicular eruption
exfoliative dermitis or 
ulcerating dermatitis
Other none mild moderate severe life threatening
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RESPONSE CRITERIA (WHO)
Complete response (CR): total disappearance of all known disease for at least 4 weeks.
Partial response (PR): at least 50% reduction in the sum of products of diameters of measured lesions 
and no new disease, maintained at least 4 weeks.
Stable disease (SD): partial response cannot be established and neither can a 25% increase in tumour 
size be demonstrated.
Progressive disease (PD): greater than 25% increase in tumour size or the appearance of any new lesion.
Evaluable but not measurable disease will be assessed as PR if there is substantial improvement but not 
complete resolution of all known disease.
17 of30
june 1999
NSCLCAPPENDIX 3
PERFORMANCE SCALE  (ECOG)
GRADE
0  - Fully active, able to carry on all predisease performance without restriction (Kamofsky 90-100).
1  -  Restricted in physically strenuous activity but ambulatory and able to carry out work of a light
or sedentary nature, e.g. light house work, office work (Karnofsky 70-80).
2  - Ambulatory and capable of all self-care but unable to carry out any work activities.  Up and
about more than 50% of waking hours (Kamofsky 50-60).
3  - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
(Kamofsky 30-40).
4  -  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair 
(Karnofsky 10-20).
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COCKCROFT & GAULT FORMULA
If creatinine measured in umol/l:
Males:  1.23  x  (140 -aae^  x  weiahtfkcri
serum creatinine (pmol/l)
Females:  1.05  x  (140 -aae^  x  weiahtfkcT)
serum creatinine (|jmol/l)
If creatinine measured in ma/%
Males:  (140 - aoe^  x  wt (ka)
72  x  serum creatinine
Females:  (140 - aae)  x  wt (ka)  x  0.85
72 x serum creatinine
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EORTC QLQ-C30 (version 3)
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DAILY DIARY CARP
PLEASE a n sw er THE FOLLOWING QUESTIONS.  week I  WEEK 2  WEEK)
WRITE DOWN THE NUMBER OF VOUR ANSWER
IN THE APPROPRIATE BOX OPPOSITE THIS PAGE.
Mm TW m WM T W FH Sm Sm Mm T - Wai Thm Fh Sm Sun Mm Tw i w*a T W Fri SM SM Mm Tim W*4 Thw Fri Sm Sim
010 TOO FEEL SICK TODAY?
1  Not *1 «il  2. OaauonWhr 
3.  A lot  4.  AN lha lim a
DID YOU VOMIT TOOAV?
1. Noi at all  2. Onca 
3. Tvnca  4. Mora man twoa
HOW GOOD HAS YOUR APPETITE SEEN TOO  AY >
V Good  2  Fan 
3. Poor  4  Bad
K M  MUCH PAIN HAVE YOU KAO TOOAV?
I. Nona  2. A litBa 
3. (1jh« a lot  4. A lot
mow ru n  vn».i « | c *  LAST WC-WT?
1   Varywtll  2.  O utlaw ed 
3  Badly  4.  Not a t *1
KCW HAffY HAVE YOU SEEN TOOAV?
1.  Happy  Z Fairly haopy 
X  unhappy  4. Vary unhapov
HOW ARK YOU FECLMG g e n c h a l iy ’
V W ati  2.  Fair 
1  Poor  4  Vary poor
WHAT 010 YOU 0 0  TOOAY?
1  Stayed m bad  2. Got up —  did nothing 
3.  Light wprk/Houaework  4. Fully activa
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TNM AND STAGING DEFINITIONS
STAGING
Stage T N M
Occult X 0 0
0 IS 0 0
la 1 0 0
lb 2 0 0
lla 1 1 0
lib 2 1 0
3 0 0
Ilia 3 1 0
1-3 2 0
lllb Any 3 0
4 Any 0
IV Any Any 1
Ref: Mountain CF - "Revisions in the international system for 
staging lung cancer", Chest 1997, vol:111 (6) P: 1710-1717.
DEFINITIONS 
Primary tumour (T)
TX  Tumour proven by the presence of malignant cells in bronchopulmonary secretions but not 
visualized by roentgenography or bronchoscopy, or any tumour that cannot be assessed in 
retreatment staging.
TO  No evidence of primary tumour.
US  Carcinoma in situ.
contd.
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NSCLCT1  A tumour that is 3.0 cm or less in greatest dimension, surrounded by lung or visceral pleura, and 
without evidence of invasion proximal to a lobar bronchus at bronchoscopy*
T2  A tumour more than 3.0 cm in greatest dimension, or a tumour of any size that either
invades the visceral  pleura or has associated atelectasis or obstructive pneumonitis  extending to 
the hilar region.  At bronchoscopy, the proximal extent of demonstrable tumour must be within a 
lobar bronchus or at least 2.0 cm distal to the carina.  Any associated atelectasis or obstructive 
pneumonitis must involve less than an entire lung.
T3  A tumour of any size with direct extension into the chest wall (including superior sulcus tumours), 
diaphragm  or  the  mediastinal  pleura  or  pericardium  without  involving  the  heart,  great  vessels, 
trachea,  oesophagus, or vertebral  body,  or a tumour in the main  bronchus within  2.0 cm of the 
carina without involving the carina.
T4  A tumour of any size with invasion of the mediastinum or involving heart, great vessels, trachea, 
oesophagus, vertebral body, or carina or with presence of malignant pleural effusion.**
Nodal Involvement (N)
NO  No demonstrable metastasis o regional lymph nodes.
N1  Metastasis to  lymph  nodes  in  the  peribronchial  or the  ipsilateral hilar  region,  or  both,  including
direct extension.
N2  Metastasis to ipsilateral mediastinal lymph nodes and subcarinal lymph nodes.
N3  Metastasis to contralateral  mediastinal lymph  nodes, contralateral hilar lymph  nodes,  or ipsilateral
or contralateral scalene or supraclavicular lymph nodes.
Distant Metastasis (M)
M O  No known distant metastasis.
Ml  Distant metastasis present -  specify site(s)
* The uncommon  superficial tumour of any size whose invasive component is limited to the bronchial wall and that may extend 
proximal to the main bronchus is classified as Tl.
**  Most pleural effusions associated with  lung  cancer are due to tumour.  There are  however, some few  patients in  whom 
cytopathologic examination of pleural fluid (on more than one specimen) is negative for tumor and the fluid is nonbloody and is 
not an exudate.  When these elements and clinical judgment dictate that the effusion is not related to the tumour, the cases 
should be staged Tl, T2 or 13, with effusion being excluded as a staging element.
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'NON-INFERIORITY TRIALS' -  METHODOLOGY AND EXAMPLES
Background
It  is  becoming  more  common  to  design  clinical  trials  where  a  new  treatment  is  hoped  to  be  equally 
effective as the standard treatment but with  less toxicity;  so called ’000-1015600111/  or ’equivalence’ trials. 
Statistical methods for calculating sample sizes for such trials have been developed where response is the 
endpoint1  There is no comparable method for such trials where survival is the endpoint.  Actuarial survival 
times  are  continuous  data  and  therefore  contain  more  information  than  response  data  which  are 
categorical  in  nature.  Therefore  the  analysis  is  more  efficient  and  less  patients  are  required.  For 
conventional  (positive) trials, where the aim  is to show a benefit for the new treatment,  methods have 
been developed for both types of data2,3 and the numbers required are considerably less when survival is 
the  endpoint  A  new  method  is  presented  which  enables these calculations to  be  performed for  non- 
inferiority trials, with a similar reduction in required numbers.
Methodology
The method follows a generally similar line of reasoning to that employed by Makuch and Simon1 , and wi!! 
now be described in detail.
Suppose the two treatments give rise to survival  rates  Pi and  P2 at some chosen time point.  Suppose 
further that the ratio of the hazards (i.e. risks of death) in die two groups does not change with time and is 
0:1.  Then  0=loge(Pi)/loge(P2).  The  hazard  ratio  is  approximately  log-normally  distributed4,  so  let 
loge(e)=C.
For a  particular trial for each event (failure or death) we can calculate the expected number of events, 
given that the two treatments are equivalent, and compare it with that actually observed.  These can then 
be summed over the whole trial to produce total observed and expected numbers of events in each group. 
Suppose these totals are Oi and Ei respectively.  C , can then be estimated for the particular trial as (Or 
Ei)/V - see reference 5, where V is the variance of OrEi.  Let this estimate be denoted r\.  Denote the 
standard error of C  by a.  Thus a can also be estimated as 1/Vv (see below).  (Note that (OrEi)2 /V is the 
log-rank statistic, which has a x2 distribution).
Of course t\ is also related to Pi and P2 by
ti = loge(0) = loge{loge(Pi)/loge(P2)}  [1]
Based upon the patients studied r\ is the best estimate of the log hazard, which represents the treatment 
efficacy.  This observed efficacy is subject to random fluctuation however.  Thus when the sample sizes are 
small, even a small value for ti is consistent with a large true difference in hazards (large 0 and thus large 
Q.  An approximate upper 100(l-a)% confidence limit for the true log hazard,  is ti+z^o, where  is the 
upper a tail point of the standard normal distribution (eg, Z o.os = 1.645).
This confidence statement can be written 
Pr(£ > ri+Za-o) = a  [2]
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confidence level a, togkher with the true log hazard ratio, £, and the corresponding sample sizes (which 
affect V and thus a).  For infinite sample sizes the observed log hazard n is an exact estimate of the true 
log hazard £, since V approaches «, and a approaches 0.  In calculating the confidence limit at the end of 
the study, one can approximate a to estimate the unknown true log hazard, C, as follows:
Arguing conditionally on the set of patients at risk before each  event and  letting  < j> i denote the  ratio of 
patients at risk in the two groups before event i (i=l,...,d where the total number of events is d), then2
d
d
V  =  I   Oi/(l+d>i)  [3]
i = 1
(and a = 1/Vv, see above).
The confidence limit is a random variable, since it involves Pi and P2.  It is reasonable therefore to set the 
sample sizes sufficiently large so that, with a  high  probability (1-p), the confidence limit will  not exceed 
some value 8. This can be written
PrOi+Za-o > 8) = p  [4]
So that
Pr [ OrO/o > (s-Q/o -  ] = P  [5]
Which implies
(5-O/a -Za  =   Zp  [6]
where Z p represents the upper p tail point of the standard normal distribution (eg, zo.^ = 0.84).  If there is 
no difference in treatment efficacy then  0, and if the numbers in the two arms of the trial are equal then 
we can make the simplifying assumption that <j>j=l (i=l,...,d).
Then V=d/4, and thus o = 2/Vd, so that, from [6]:
d = 4{(za+Zp)/5}2  [7]
This  last  equation  specifies  the  required  number  of  events  (in  both  arms  together)  to  ensure  with 
probability (1-p) that the upper 100(l-a)% confidence limit for the true log hazard ratio does not exceed 8. 
For planning purposes 8 is estimated as follows:
Suppose  the  survival  in  the  standard  arm  of  the  trial  is  known  from  previous  studies  etc.  to  be 
approximately Ps.  A new trial with less toxicity or complications will be considered acceptable if it can be 
demonstrated with 100(l-a)% confidence that it is at worst x% inferior to the standard treatment.  Then
8 = loge{loge(Ps)/loge(Ps-[x/100])}  [8]
Having  estimated  the  number  of events,  d,  the  total  number  of  patients  required  in  the  trial  can  be 
estimated by2
n = d/(l-Ps)  [9]
assuming again equal numbers in the two groups.
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SCLC:
It is assumed that PE gives a 20% one year survival (Ps=.20) and we want the 95% confidence limit on the 
hazard at the end of the trial to exclude the possibility that GC is more than 10% worse at one year.  We 
are content to accept a 20% chance of falsely concluding that GC does confer a 10% or more reduction in 
survival at 1 year.
Thus z ^  1.645, Zp=.84.  From [8] 6 = .358, and therefore from [7], d=193.  From [9] n=241.
So the trial requires the entry of 241 patients.
NSCLC:
It is assumed that MIC gives a 28% one year survival (Ps=.28) and we want the 95% confidence limit on 
the hazard at the end of the trial to exclude the possibility that GC is more than  10% worse at one year. 
We are content to accept a 20% chance of falsely concluding that GC does confer a 10% or more reduction 
in survival at 1 year.
Thus za=1.645, Zp=.84.  From [8] 8 = .298, and therefore from [7], d=279.  From [9] n=387.
So the trial requires the entry of 387 patients.
Simulations
To check the accuracy of the formula a series of simulations were carried out.  A value was chosen for p, 
and the value for the total number of patients required in the trial (n) was derived from [7].  Survival was 
assumed to follow a negative exponential distribution, with parameter chosen to give the required % at the 
time  under consideration  (eg 20%  surviving  at  1  year).  Random  samples were  then  drawn  from  this 
distribution  for  each  arm  of the trial,  to a  total  number,  n.  Survival  times greater than  1  year were 
censored at 1 year.  The log hazard was calculated for the survival comparison of the two groups and a 1- 
sided upper 100-(l-a)% confidence limit was calculated for the log hazard, as described above.  As above, 
let x be the % below the standard which is still considered acceptable for the new treatment.  For different 
values of Ps and x (and therefore 8) this process was  repeated  1,000,000 times,  and the  proportion  of 
times that the upper 100-(l-a)% confidence limit exceeded 8 was recorded.  This was compared with the 
chosen value of p.
For the two values used for the lung trials, namely Ps=.2 and Ps=.28 (with x=10%), the proportions were 
.205 and  .202  respectively.  This is very dose to the theoretical  p of .20.  The values estimated for the 
variance, V, were also very dose to those actually seen.
Additional comments
The trial-size estimates for the lung trials are somewhat conservative.  Equation  [9] which estimates the 
total number of patients required from the number of events required, assumes that times are censored at 
the chosen time of 1 year.  However, patients continue to die with this disease after 1 year, with only a 
very small proportion of patients surviving more than 2 years.  Thus the total number of patients required 
is in fact very dose to the total number of events required, arid an estimate of 203 patients in total, for the 
SCLC case, is probably more accurate.  This depends to some extent on the time point at which the trial is 
analyzed.  The estimate of 203 assumes that patients are entered over a period of about 3 years, and the 
trial is analyzed about 1 year after the last patient is recruited.  This figure is derived by noting that survival 
in SCLC is about 2% at 2 years6.  Thus if analysed 1 year after the entry of the last patient two-thirds of
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NSCLCthe  patients  entered  will  be  at  or  beyond  2  years,  and  have  a  survival  rate  of about  2%,  while the 
remaining one-third will vary between 2% and 20%,  perhaps averaging about 11%.  Thus the average 
survival at the time of analysis will be approximately 5%.  The total number to be entered will therefore be 
d (100/95) = 203.
Under similar assumptions, with a  2-year survival estimate of 5%7 for NSCLC, an estimate of about 302 
patients required in total is reasonable for the NSCLC case.
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Scales of performance status referred to in the text
•  ECOG
•  WHO (simplified ECOG)
•  Kamofsky Performance Status
331ECOG PERFORMANCE STATUS*
Grade ECOG
io
; Fully active, able to carry on all pre-disease performance without restriction
i Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed 
or chair
5 Dead
•  As published in Am. J. Clin. Oncol.:
Oken,  M.M.,  Creech, R.H.,  Tormey, D.C., Horton, J., Davis,  T.E.,  McFadden, E.T., 
Carbone,  P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology 
Group. Am J Clin Oncol 5:649-655,  1982.
332WHO Performance Status (simplified ECOG score)
0  Asymptomatic
1   Symptomatic, fully ambulatory
2  Symptomatic in bed <50% day
3  Symptomatic in bed >50% day
4  Bedridden
5  DeadKamofsky Performance Status 
100  Normal, no complaints, no evidence of disease
90  Able to carry on normal activity: minor symptoms of disease
80  Normal activity with effort: some symptoms of disease
70  Cares for self: unable to carry on normal activity or active work
60  Requires occasional assistance but is able to care for needs
50  Requires considerable assistance and frequent medical care
40  Disabled: requires special care and assistance
30  Severely disabled: hospitalization is indicated, death not imminent 
20  Very sick, hospitalization necessary: active treatment necessary
10  Moribund, fatal processes progressing rapidly
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